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Introduction: Type 2 diabetes mellitus (T2DM) is a global health problem and its 
complications are a significant cause of morbidity and mortality worldwide. T2DM is the 
common type of diabetes and it affects mainly adults. Insulin resistance is considered as a 
main factor contributing to T2DM. Different substances are implicated in development of 
insulin resistance, among them vitamin D, resistin and homocysteine which can interrupt the 
insulin signalling pathway leading to insulin resistance. Elevated levels of homocysteine have 
been observed in patients with T2DM and metabolic syndrome, while resistin (a hormone) 
was suggested to play a role in the pathogenesis of T2DM. Increased levels of resistin have 
been linked with adiposity/inflammation and insulin resistance in T2DM patients. Vitamin D 
deficiency is another global problem and elevated levels of blood glucose and vitamin D 
deficiency have been linked to complications associated with T2DM. Recently studies 
conducted in ethnic groups in Asia and Europe suggest that vitamin D deficiency, resistin and 
homocysteine may also be implicated in the pathogenesis of T2DM. However, limited 
numbers of studies were from African subjects and none investigated vitamin D, resistin and 
homocysteine together in association with T2DM. T2DM is a common disease in Sudan and 
it causes considerable morbidity and mortality. Few studies have been conducted in Sudan to 
explain the increase in prevalence of diabetes but no studies looked at the role of 
homocysteine, resistin and vitamin D. Methyl tetrahydrofolate reductase (MTHFR) is an 
enzyme that contribute to the formation of methionine from homocysteine and it has taken all 
these attention because the present of the genetic mutation which led to 
hyperhomocysteinemia.   
Objective: The aim of this study was to investigate possible associations between 
homocysteine, resistin and vitamin D with T2DM in a representative study population from 
Sudan. In addition, associations between the Methyl tetrahydrofolate reductase (MTHFR) 
gene polymorphisms (C677T and A1298C) with homocysteine levels and with T2DM, as 
well as, the prevalence of VDR gene polymorphism (T56058C) in patients with T2DM and 
their healthy controls were investigated. 
Material and Methods: This is a case-control hospital-based study conducted at the Diabetes 
clinic with samples obtained from the Military hospital, Omdurman, Sudan. Two hundred 
patients with T2DM were consecutively enrolled during 2013-2014. The included patients 
were known to have T2DM for a minimum of one year and were under-regular follow-up at 
the diabetes clinic. Patients with chronic illness (especially heart and kidney diseases) and 
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other types of diabetes (including type 1 diabetes) were excluded. The control group (n=195) 
consisted of healthy individuals with no family history of diabetes. A questionnaire was used 
to acquire demographic data (age, gender), anthropometric measurements (weight/height and 
waist circumference), basic biochemical tests (HbA1c, fasting blood glucose (BG), lipid 
profile) and blood pressure (systolic/diastolic). Plasma levels of resistin and homocysteine 
were measured using ELISA-based methods, while total Vitamin D (D2/D3) levels were 
measured using an UHPLC method. The gene variants MTHFR C677T, MTHFR A1298C 
and VDR T56058C were typed using real time PCR methods. Associations between plasma 
levels of resistin, homocysteine and total vitamin D with T2DM, and their associations with 
different variables (age, gender, BMI, HbA1c, fasting blood glucose, lipid profile) were 
statistically analysed. This was in addition to the associations between the MTHFR gene 
polymorphisms and homocysteine levels, and the associations between VDR gene 
polymorphism and T2DM. 
Results: Resistin levels were significantly higher in the healthy controls compared to patients 
with T2DM (p<0.0001). Levels were significantly higher in healthy males compared to 
healthy females (p=0.007) as well as in males in the study population in general compared to 
females in the study population (p=0.002). However, no significant difference in resistin 
levels was found between male and female in individuals with T2DM (p=0.09). My results 
showed also that healthy controls had significantly higher resistin levels compared to patients 
with T2DM in groups with BMI>25 and BMI<25 (p=0.03, for both comparisons). In addition, 
the results also showed significantly higher levels of resistin in male healthy controls 
compared with male patients with T2DM in groups with BMI>25 and BMI<25 (p<0.001 and 
p=0.007, respectively), and there was no significant difference in resistin levels between 
female healthy controls and female patients with T2DM in groups with BMI>25 and BMI<25 
((p=0.45 and p=0.16, respectively). Resistin levels were significantly higher in patients with 
T2DM not using vitamin D supplementation compared with those using it (p=0.0039). There 
is a positive correlation between resistin levels and 2hBG and HbA1c% in the study 
population (all participants) (r=0.121; p=0.035 and r= 0.237p<0.0001, respectively) and also 
with FBG, BMI (log), homocysteine levels in individuals with T2DM (r=0.188; p=0.008; 
r=0.140; p=0.048 and r=0.335; p<0.0001, respectively), while there is a negative correlation 
between resistin levels and vitamin D in patients with T2DM (r= -0.261; p<0.0001). 
Homocysteine levels were significantly higher in patients with T2DM compared to healthy 
controls (p<0.0001). In addition, its levels were significantly higher in females compared 
with males (p<0.0001) and there was a positive correlation between plasma homocysteine 
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levels and HbA1c% (r=0.298; p<0.0001) and 2hBG (r=0.361; p<0.001) in all participants. 
The percentage of patients carrying the MTHFR C677T genotypes CC, TT and CT is 85.5%, 
0.5% and 14.0% respectively, while among healthy controls it is 88.7%, 0.0% and 11.3%. 
There is no significant difference in the genotype (CC, CT and TT) and allele (C and T) 
frequencies between patients and healthy controls (χ2= 0.909, p=0.340; χ2= 0.660, p=417; χ2= 
N/A, p=N/A for CC, CT and TT genotypes, respectively; and χ2= 1.110, p=0.292 for the C 
and T alleles, the % of patients carrying the MTHFR A1298C genotypes AA, CC and AC is 
65.0%, 6.0% and 29.0% respectively, while among healthy controls it is 65.1%, 5.1% and 
29.8%. There is no statistically significant difference in the genotype (AA, CC and AC) and 
allele (A and C) frequencies between patients and healthy controls (χ2=0.001 p=0.098; χ2= 
0.26, p=0.87; χ2= 0.143, p=0.71 for the AA, CC and AC genotypes, respectively; and χ2= 
1.031, p=0.86 for the A and T alleles). Our results showed that the levels of homocysteine are 
significance higher in patients with T2DM carrying the three genotypes, 677CT, 1298AC and 
1298CC, and carrying the heterozygous haplotype C677T/A1298C compared to the healthy 
controls carrying the same genotypes/haplotype.  
Vitamin D levels was significantly higher in patients with T2DM compared to healthy 
controls (p<0.0001), and its levels have negative correlation with FBG in patients with 
T2DM (r= -0.177; p=0.013). The % of patients carrying the VDR T56058C genotypes CC, 
TC and TT is 36.5%, 46% and 17.5% respectively, while among healthy controls it is 28.7%, 
52.8% and 18.5%. There are no significant differences in the VDR T56058C genotype (CC, 
TC and TT) and allele (C and T) frequencies between the patients and their healthy controls 
(χ2= 2.719, p=0.099; χ2= 1.838, p=0.175; χ2= 0.062, p=0.803 for CC, TC and TT genotypes; 
and χ2= 2.084, p=0.149 for the C and T allele, respectively). 
Conclusion: Previous studies have suggested a role for Vitamin D deficiency and elevated 
levels of plasma resistin and homocysteine levels in the pathogenesis of insulin resistance and 
T2DM. Our results confirmed previously reported high levels of homocysteine in patients 
with T2DM. A positive correlation was observed between homocysteine and FBG, HbA1c 
and resistin, as well as a positive correlation between resistin and FBG and HbA1c, and a 
negative correlation between vitamin D and resistin, homocysteine and FBG levels in patients 
with T2DM.  The negative association between vitamin D and resistin/blood glucose levels 
suggest that vitamin D might have an impact on resistin levels in patients with T2DM and 
improved insulin action/blood glucose levels and T2DM. Taken together, our results suggest 
a possible role for vitamin D, resistin and homocysteine in the development of insulin 
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1. Introduction  
1.1. Background  
 
Diabetes is a global health problem and the World Health Organisation (WHO) estimates the 
number of diabetics to be around 171 million and it is expected that the number will increase 
to reach 360 million by 2030 (Shaw et al., 2010). Type 2 diabetes melitus (T2DM) is a 
polygenic disease associated with defects either in insulin secretion or its action on the target 
tissues (Abdelgadir et al., 2002). In general, 80% of individuals with T2DM die from 
thrombosis and 75% from cardiovascular diseases (Carr et al., 2001). In Sudan, a relatively 
poor country with a multi-ethnic population, T2DM is a major health problem. The 
prevalence of diabetes (in general) is estimated to be around 3.4%, 75% of the diabetics 
having T2DM, and the disease is a leading cause of morbidity and mortality.Adipose tissue 
has the ability to produce and secrete different types of the adipokines (Abdelgadir et al., 
2013) among them resistin, which was shown to be linked with insulin resistance and 
adiposity (Rajkovic et al., 2014). Furthermore, several studies reported a positive relation 
between resistin concentrations and inflammation in diabetes and its complications (El-Tahir 
et al., 2016; Burnett et al., 2006 and Osawa et al., 2005). Recently, it was reported that 
resistin is a main factor in the pathogenesis of insulin resistance and T2DM via obesity 
(Kusminski et al., 2005). A study from Sudan found that about 40% of patients with T2DM 
were prone to be obese, and obese subjects were found to exhibit high levels of adipokines 
(Elmahadi et al., 1991). 
Homocysteine is an amino acid that contains a sulphur hydral group (-SH). It is produced 
during the metabolism of methionine. Methyl tetrahydrofolate reductase (MTHFR) is an 
enzyme that catalyses the conversion of 5, 10-methylene-tetrahydrofolate to 5-methyl-
tetrahydrofolate (Frosst et al., 1995). It is an important reaction in the conversion of 
homocysteine to methionine (Toffoli et al., 2003). The MTHFR gene is found on 
chromosome 1 at 1p36.6 (Qutinen et al., 1998). A genetic polymorphism in the MTHFR gene 
can affect the enzymatic activity leading to an increase in the level of homocysteine in the 
b l o o d  ( K l u i j t m a n s  e t  a l . , 1996). Increased levels of homocysteine (Hcy) in the blood is a 
condition known as hyperhomocysteinemia, which is considered as an independent risk
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factor for atherosclerosis in both diabetic and non-diabetic patients (Glueck et al., 1995 and 
Perry et al., 1995). Several studies investigated the possible association between levels of 
homocysteine in plasma and T2DM but results were inconsistent (Masuda et al., 2008; 
Huang et al., 2006 and Shaikh et al., 2012). Wouters et al found that there is no significant 
association between homocysteine levels and glycaemic control in females. On the other 
hand, there is a significant association between homocysteine levels and glycaemic control in 
males, suggesting a role for difference in sex hormones, as estrogen inhibits the progression 
of atherosclerosis (Wouters et al., 1995). 
Vitamin D can be produced by the skin as a result of exposure to sunlight or obtained from 
food (Basit, 2013). Vitamin D receptor (VDR) has been shown to be expressed by several 
tissues involved in glucose metabolism (e.g. muscles and pancreatic beta cells) (Bischoff et 
al., 2001 and Johnson et al., 1994). To produce the hormonally active form 1,25 dihydroxy 
vitamin D3 (1, 25 (OH) 2 D3), vitamin D3 (D3) undergoes two hydroxylation steps, one in the 
liver (on C2) and the second in the kidney (on C25). The biological actions of vitamin D in 
the body are mediated by VDR (Tuoresmaki et al., 2014). Genetic polymorphisms in the 
VDR gene may affect vitamin D actions, and might be associated with diseases like cancer, 
metabolic syndrome and T2DM (Rezende et al., 2007). The main form of vitamin D that 
reflects its status is 25-hydroxyvitamin D (25-(OH) D). Low levels of 25-(OH) D have been 
reported in obese subjects and in patients with diabetes (Scragg, 2008).  
Studies suggested that a deficiency of vitamin D can contribute to the impairment of secretion 
of insulin leading to glucose intolerance in humans and animal models (Mathieu et al., 2005). 
Vitamin D deficiency can impair insulin secretion by direct effect on the beta cells (β-cells) 
of the pancreas. The effects of the active form of vitamin D (1, 25 (OH) 2 D3) on the tissues 
occurs after the concentration exceeds the optimal level (10-10 mol/l) needed for maintenance 
of calcium and phosphate levels (Mathieu et al., 2005).  
In a healthy study population, Vilarrasa et al showed no significant association between 
resistin levels and plasma vitamin D concentration (Vilarrasa et al., 2010) while El-Tahir et 
al observed a negative correlation between resistin levels and vitamin D levels in patients 
with T2DM (El-Tahir et al., 2016). High levels of homocysteine in the blood promoted 
insulin resistance via induce production of resistin hormone and finally lead to T2DM. (Li et 
al., 2008).  
T2DM is a common disease in Sudan and it causes several complications. To my knowledge 
no studies have explored the interaction between resistin, vitamin D and homocysteine in 
Sudanese individuals with diabetes. In the present study, we investigated possible 
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associations between resistin, homocysteine, and vitamin D levels with T2DM; this is in 
addition to their associations with different variables (BMI, blood glucose levels, HbA1c% 
and lipid profile). We also investigated possible associations between vitamin D receptor 
(VDR) and MTHFR gene polymorphisms and T2DM; and possible association between 
MTHFR gene mutations and hyperhomocysteinemia. 
1.2. Diabetes Mellitus  
Diabetes is not a single disease entity but a group of metabolic illnesses that exhibit high 
glucose levels in the blood (hyperglycaemia) due to defects in secretion and/or action of 
insulin (Maori et al., 2012). Continued elevation of blood glucose is the characteristic sign of 
diabetes and hyperglycaemia can cause long-term damage and dysfunction of different 
organs including the eyes, bloods vessels, nerves kidney and heart.  Diabetes can develop 
through different processes, ranging from autoimmune destruction of the beta cells (β-cells) 
of pancreas (that lead to absolute deficiency of insulin) to abnormalities which can lead to 
resistance of insulin action (Gillett, 2009).  
1.2.1. Pathophysiology 
The basic concept of the pathophysiology of diabetes is based on our understanding of 
metabolism of carbohydrate, lipid and protein and action of insulin. After food (containing 
carbohydrate, sugars and starch) ingestion and digestion, monosaccharides are absorbed and 
enter the bloodstream (Bjorck et al., 1994).  In the liver, they are converted to glucose.  Blood 
glucose stimulates β-cells of the pancreas to secrete insulin which in-turn facilitates uptake of 
glucose by muscle and adipose tissues (Shulman, 2000). In general, when blood glucose 
levels increase, this leads to stimulation of insulin secretion from the β-cells of the pancreas 
and subsequent increase in cellular utilization of glucose which leads to a decrease in blood 
glucose levels and lower insulin secretion.   
Insulin resistance and T2DM can be associated with significant alteration in the release of 
insulin from the pancreas. In case of hyperglycaemia there is decrease in insulin production 
and subsequently reduced entry of glucose to tissues. Moreover, hyperglycemia occurs also 
when there is no proper response of target tissue to insulin. On the other hand, hypoglycemia 
happens when there is overproduction and secretion of insulin and entry of glucose to tissues 
resulting in lowered blood glucose (Brunzell et al., 1976).  
Counter regulatory hormones, especially adrenaline and glucagon, work against insulin action 
and prevent hypoglycemia by increasing blood glucose levels via stimulating production of 
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glucose from non-carbohydrate sources (gluconeogenesis) and liver glycogen breakdown 
(Meley  et al., 2006).  
1.2.2. Complications  
Complications of diabetes could affect different parts of the body. Several dangerous health 
problems increase in patients with diabetes. Cardiovascular diseases are the major 
complication of diabetes (Shah et al., 2015). In addition, several parts and organs of the body 
are affected by diabetes including the eye (retinopathy), kidney (nephropathy) and nerves 
(neuropathy), and feet. Foot complication is due to vascular as well as neurological problems 
(Aalto, 1997). Diabetic complications can finally lead to complete disability, reduced quality 
of life, and death.   
1.2.3. Diagnosis 
Diabetes is easy to diagnose especially if the patient has classic symptoms of high blood 
glucose level and has a random blood glucose (RBG) levels of 200 mg/l (11.1mmol/l) or 
higher. Oral glucose tolerance test (OGTT) can be used to confirm the diagnosis of diabetes. 
To do the OGTT, patients come to the clinic after over-night fasting for at least 8 hours. In 
diabetic patients, fasting blood glucose is initially higher than 7.0 mmol/l (126mg/dl) and 
raises to concentrations greater than 11.1 mmol/l (200mg/dl) after 2 hours following glucose 
load (Alberti et al., 1998). In general, fasting blood glucose (FBG) test is considered suitable 
for to diabetes because of its low cost and convenience. Nevertheless, it is not accurate as it 
may miss some cases of diabetes or prediabetes. OGTT test is highly sensitive compared to 
the FBG test in diagnosing prediabetes, but it is less convenient to administer. Random blood 
glucose (RBG) is used for a person who has already been diagnosed with diabetes and it is 
not suitable for prediabetes subjects. A second test is performed on a different day to confirm 
that this person has diabetes (Alberti et al., 1998). 
According to the WHO, the diagnostic criteria for diabetes include: fasting plasma glucose ≥ 
7.0mmol/l (126mg/dl) or 2-h plasma glucose ≥ 11.1mmol/l (200mg/dl) (Report of a WHO 
Consultation, 1999). Glucose Tolerance Test (GTT) is conducted to confirm the diagnosis of 
diabetes. Fasting blood glucose is initially higher than 7.0 mmol/l (126mg/dl) in diabetic 
patients and rises to concentrations greater than 11.0 mmol/l (200mg/dl) after 2 hours glucose 
load (Alberti et al., 1998; Report of a WHO Consultation, 1999). 
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1.2.4. Types of diabetes mellitus 
WHO published the first classification of diabetes which was widely accepted (WHO, 1980). 
Diabetic patients are classified into two major groups according to their clinical symptoms: 
insulin dependent diabetes mellitus (IDDM) (type1 diabetes mellitus) and non-insulin 
dependent diabetes mellitus (NIDDM) (type 2 diabetes mellitus) (T2DM) (WHO, 1985). 
There are other types of diabetes including gestational diabetes. This classification, “insulin-
dependent diabetes mellitus” and “non-insulin-dependent diabetes mellitus” was based on the 
treatment rather than pathogenesis. Stogdale recommended using the term "Type 1” because 
it describes a pancreatic islet β-cell destruction and Type 2 which is a result of a defect in 
insulin secretion/action (Stogdale, 1986). This classification was agreed upon after several 
attempts from the National Diabetes Data Group (WHO, 1980). Signs and symptoms used in 
the diagnosis of diabetes include polyuria, polydipsia and polyphagia. The emergence of 
these symptoms is usually accompanied by the appearance of other signs such as weakness, 
fatigue and weight loss.  
1.2.4.1. Type 1 Diabetes (T1DM) 
T1DM constitutes around 5-10% of all diabetic cases. Its incidence is on the increase 
worldwide. T1DM is associated with destruction of β-cells of the pancreas requiring the need 
for insulin injection to prevent patients from developing ketoacidosis, coma and death (WHO, 
1999). Vascular complications are considered as the main factors contributing to morbidity 
and mortality associated with T1DM (Daneman, 2006).  
1.2.4.2. Type 2 Diabetes (T2DM) 
T2DM is considered as the most common type of diabetes. In T2DM, the β-cells of the 
pancreas are unable to produce enough insulin or there is resistance to insulin action on the 
target tissue leading to diabetes and its complications. The more dangerous complications in 
T2DM include heart attack and stroke. All serious complications occur when diabetes is left 
undiagnosed or uncontrolled. Serious complications include blindness, foot and leg 
amputation due to damage to the nerves and blood vessels, and renal failure requiring dialysis 
or transplantation (Pasinetti, 2011). DePaula showed that there is long-term damage in the 
body, especially to the heart and circulatory system which occur mainly in the pre-diabetic 




1.2.5. Type 2 Diabetes in Sudan 
Diabetes mellitus is a major health problem in Sudan (Awadalla, et al., 2018). A recent study 
from an urban area in the north part of Sudan showed a 19.1% prevalence for T2DM 
(Elmadhoun et al., 2016) with a significant increase in the prevalence of T2DM and 
prediabetes over the last years (Eltom et al., 2018). Among Sudanese population with 
diabetes, 24.5% of them are obese and 39.9% are overweight (Ali et al., 2017). Obesity and 
central obesity were more prevalent in Sudanese females (Ahmed et al. 2017). It has been 
suggested that lifestyle factors including intake high amount of sugar and low physical 
activity led to obesity and diabetes, and reduced physical activity is common among women 
compared with men (El-Sayed et al., 2018 & Khalil et al., 2017).  The prevalence rate of 
uncontrolled T2DM was higher among Sudanese individuals with T2DM (Noor, et al., 2017). 
Diabetic complications are common among Sudanese patients and were observed in those 
with poor glycaemic control. Poor glycaemic control (HbA1c>7%), high cholesterol (76.2%), 
triglyceride (27.5%), LDL (48.8%) and low HDL (33.8%) and long-term complications (like 
peripheral neuropathy, visual impairment, diabetic foot, and myocardial infarction) were seen 
in Sudanese diabetics (Almobarak, et al., 2018). In Sudanese population, longer duration of 
diabetes and poor control of blood glucose have been contributed in increase prevalence of 
complications in T2DM (Awadalla et al., 2017). Omer et al. 2018 showed that uncontrolled 
T2DM is more prevalent among unmarried individuals and those adding sugar to the drinks 
(Omar et al., 2018). Two thirds of the North Sudan population with diabetes had low levels of 
HDL, while that over one quarter have elevated cholesterol and triglyceride. Coronary heart 
disease (CHD) is a common complication among Sudanese patients, and it is characterised by 
an increased level of triglycerides in the blood, especially non-fasting triglyceridemia and 
decreased the levels of HDL in the blood (Awadalla et al., 2018). About 34% of smokers are 
individuals with T2DM and an association between smoking and ischemic heart disease 
(IHD), high triglyceride and HbA1c was observed.  It was suggested to the health authorities 
in Sudan should call on Sudanese to quit smoking (Awadalla et al., 2018). Foot ulcer is one 
of the diabetic complications with a prevalence of 18.1% in a representative group from the 
Sudanese community and, its risk increased with duration of diabetes >10 years (Almobarak, 
et al., 2017). Retinopathy is one of the major complications in Sudanese patients with T2DM 
with high prevalence among patients attending Makkah Eye hospital in Khartoum (Elwali, et 
al., 2017). To avoid these complications urgent strategies are needed to monitor and treat 
hypertension and optimize diabetes control in individuals with diabetes (Elwali, et al., 2017). 
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Patients attending private clinics had a higher income and cost of diabetes control than those 
attending public clinics. However, both groups had similar proportion of poor glycaemic 
control, which reflects the insufficient care given to diabetic patients, mainly due to deficient 
resources and inefficient utilization of what is scarcely available (Elrayah-Eliadarous, et al., 
2010). To reduce the financial burden and adverse social effects of diabetes on diabetics and 
their families in Sudan, an awareness program should be adopted to protect the population 
from diabetes (Elrayah-Eliadarous, et al., 2017). 
1.3. Insulin and regulation of blood glucose   
1.3.1. Glucose    
Blood glucose is the sugar that is carried by the bloodstream to all tissues in the body to 
supply energy. In healthy humans, the levels of blood glucose must be kept within a tight 
range between 4 and 7 mmol/l. When its level exceeds the normal levels, this is a 
pathological condition known as hyperglycaemia. On the other hand, when the levels become 
under the normal range, it is also considered a pathological condition known as 
hypoglycaemia. Several factors are involved in controlling the blood levels within normal 
range. To perform its function, insulin binds to specific cellular receptors that facilitate 
glucose entry into the cells. Induction of secretion of insulin from the β-cells of the pancreas 
leads to a decrease in the level of glucose in the blood and by facilitating the entry of glucose 
into cells.  Lower glucose levels then result in a decrease in the secretion of insulin. If insulin 
production and secretion are altered by disease, blood glucose dynamics will also change. If 
insulin production is decreased, glucose entry into cells will be inhibited, resulting in 
hyperglycemia. The same effect will happen if the secreted insulin is not taken up and used  
properly by the target tissues (Brunzell et al., 1976). If the levels of insulin exceed the normal 
levels due to either overproduction of insulin from the pancreas or overdose of the treatment 
this leads to hypoglycemia (American Diabetes Association, 2005). Counterregulatory 
hormones, principally adrenaline and glucagon, prevent the falling of blood glucose levels to 
extreme levels by working against the effect of insulin action during hypoglycaemia and 
induce gluconeogenesis and glycogen breakdown.   
Following a meal, the amount of glucose obtained from carbohydrates after digestion and 
absorption often exceeds the cellular need for glucose. Excess glucose is stored in the liver 
and muscle in the form of glycogen (Fery et al., 2001) as well as in the form of fat in adipose 
tissues (Bulow et al., 1999; Fig 1.1). Glycogen is a reservoir for glucose and energy. When 
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needed, the stored glucagon in the liver is converted into glucose via glycogenolysis leading 
to elevation of blood glucose levels and providing the needed organic energy sources (Liu et 
al., 2011). In addition, the liver has the ability to produce glucose from non-carbohydrate 
sources (lactate, glycerol and amino acids) via the gluconeogenesis pathway (Liu et al., 2011). 
Therefore, glycogenolysis and gluconeogenesis both serve to increase blood glucose levels. 
Thus, the pancreas is a main organ to control glycaemia because it produces hormones 
(insulin and glucagon) that control glucose metabolism in the liver (Adkins et al., 2003).  
Patients with diabetes usually have an imbalance in secretion of these hormones 
(Fig1.1).
 
Fig 1.1 distribution of glucose after a meal: 
in the anabolic pathways, glucose can be stored either in the form of glycogen (in liver and muscle) 
 or in the form of TAG (in the adipose tissue). While in the catabolic pathways, glucose is degraded,  
either to lactate in kidney and muscle (by anaerobic pathway) or to CO2 and H2O in brain (by the 
aerobic pathway), to produce energy as a form of ATP. The diagram is taken from this website 
(www.medbio.info).  
1.3.2. Effect of insulin on metabolic pathways 
Insulin was discovered in 1923 by Banting and Macleod and it was shown to restore blood 
glucose in patients with T1DM (Raju, 1998). Human insulin is an anabolic hormone 
composed of two polypeptide chains. The A-chain contains 21 amino acids and B-chain 
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contains 30 amino acids, and the two chains are linked together by a disulphide bridge 
(Fig1.2). It is secreted from the β-cells of the Islets of Langerhans in the pancreas. It is 
responsible for the regulation of carbohydrate, lipid and protein metabolisms. The main 
function of insulin is the stimulation or inhibition of several genes that produce proteins that 
affect various metabolic pathways. Insulin regulates the uptake of glucose from the blood into 
muscle, and adipose tissue as well as regulates the metabolism of glucose in the liver. 
Therefore, it was suggested that a deficiency of insulin or reduced sensitivity of its receptor 
play essential roles in all types of diabetes (American Diabetes Association, 2014).  
 
                  Fig 1.2 The structure of the active form of insulin:  
             its composed of two chains (A and B) Linked together by Disulphide Bridges  
             between cysteine amino acids. Figure was taken from DeWitt and Hirsch, (2003) 
1.3.3. Insulin secretion  
In the normal pancreas there are around one million Islets of Langerhans, each of them have 
endocrine cells, 60-80% of which are β-cells that are responsible for insulin secretion 
(Marchetti et al., 2008). The pathophysiology of diabetes mellitus includes defect in insulin 
secretion and/or action. Secretion of insulin starts when blood glucose levels increase and 
enters the β-cells in the pancreas by way of a glucose transporter 2 (GLUT2). In cells, 
glucose is phosphorylated by glucokinase and is broken down to produce adenosine 
triphosphate (ATP). One of the main functions of the ATP is to close potassium channels and 
depolarize the cell. Depolarisation leads to an opening of the calcium channels and insulin 
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secretion (Mahler et al., 1999; Fig 1.3). Although glucose is considered the main factor 
responsible for insulin secretion, other factors, including other hormones, neurotransmitters, 
drugs and nutrients, also contribute to insulin secretion.  Insulin is needed by adipocytes and 
muscle cells to allow glucose entry, as well as glucose oxidation (Shulman, 2000). 
 
           Fig 1.3 Glucose uptake and insulin secretion:    
          A rise in blood glucose levels triggers secretion of insulin from b Islet cells. The process starts 
          by the uptake of glucose by the GLUT2 transporter. Following entry, glucose is phosphorylated 
          and broken down to produce ATP. As a result, ATP depolarises the cell leading to calcium 
          channel opening and insulin secretion. The figure was reproduced from Henquin, (2009).            
1.3.4. Insulin action 
To perform its function, insulin binds to its receptor and stimulates intracellular signalling 
cascades to downstream effectors of insulin’s metabolic and mitogenic effects (Fig 1.4). 
Insulin regulates glucose homeostasis at many sites. Insulin activates the formation of 
glucose transporter 4 (GLUT 4) in muscle and adipose tissues, glycogen synthase in the liver 
and muscle tissues and inhibits glycogen phosphorylase in the liver and muscle tissues and 
also inhibits gluconeogenesis enzymes in liver (Pessin et al., 2000; Fig 1.4).  Insulin 
stimulates the conversion of glucose to fat by producing triacylglycerol (TAG) (lipogenesis) 
in liver and adipose tissues, and at the same time inhibits release of fatty acids from TAG 
(lipolysis) in muscle and adipose tissues. Accordingly, several metabolic pathways are 
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affected in patients with T2DM due to the impairment of insulin secretion/action leading to 
metabolic abnormalities like hyperglycaemia and dyslipidaemia. Increased levels of blood 
glucose and fats lead to the disruption of insulin secretion and /or action and finally cause 
tissue damage.  
 
  Fig 1.4  Insulin and glucose uptake by tissues:  
Insulin receptor consists of 2 alpha and 2 beta subunits linked by disulphide bridges. Activation of the 
  phosphatidylinositol -3'-kinase (PI3K) pathway stimulates translocation of glucose transporter 4  
  (GLUT-4) to the cell surface. This leads to glucose uptake by muscle and adipose tissue, in addition 
 to stimulation of protein synthesis, glycogenesis and lipid synthesis. Activation of the Mitogen- 
  activated protein kinases (MAPKs) pathway induces cellular proliferation and growth as well as  
  regulation of gene expression in insulin response tissues. The diagram is reproduced from Osman et   
   al., (2000). 
1.3.5. Action and secretion of insulin in patients with T2DM 
When normal levels of insulin render it unable to perform its function (action) in tissues such 
as liver, muscle and adipose tissue, this stimulate β-cell to secrete more insulin to compensate  
for this defect leading to hyperinsulinemia. Insulin resistance and defect in β-cell function 
lead to insulin deficiency and hyperglycaemia, and therefore development of T2DM (Fig 1.5). 
A reduction in β-cell mass and function in patients with T2DM has been demonstrated by 
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several studies (Butler et al., 2003; Del Guerra et al., 2005; Marchetti et al., 2004; Rahier et 
al., 1983; Sakuraba et al., 2002; and  Yoon et al., 2003). 
 
Fig 1.5 Causes of T2DM: Insulin resistance and dysfunction in the beta cell.  
High blood glucose stimulates insulin secretion. Insulin activates all anabolic pathways such as  
glycogen synthesis in liver and muscle and lipogenesis (synthesis of TAG) in Adipose tissue, as well 
 as stimulates glucose uptake by muscle and adipose tissue, on the other hand inhibiting production of  
glucose (gluconeogenesis) in the liver; these processes lead to reduced blood glucose and therefore 
 reduction in insulin secretion. T2DM occurs when the target tissues do not respond properly to 
secreted insulin (insulin resistance) and dysfunction in the beta cells which leads to reduced insulin 
secretion. The diagram is reproduced from Cerf, (2013)  
13 
 
1.4. Insulin signal transduction  
After the discovery of insulin and its role in the regulation of metabolic pathways, scientists 
concentrated on studying the mechanism of insulin action in target tissues (Fig 1.6). 
 
Fig 1.6 Insulin signalling pathway, its regulation and metabolic effects  
Insulin binds with its receptor in a target tissue at the α-subunit and this leads to the phosphorylation 
of the β-subunit and activation of IRS protein. The signal from insulin is then transferred from 
molecule to another (in cascade) to its action such as protein synthesis, glucose production 
(gluconeogenesis), glycogenesis (production of glycogen), glucose uptake (GLUT4) and cell growth. 
The figure is taken from Chakraborty et al., (2011). 
1.4.1. The insulin receptor 
 Insulin receptor consists of two alpha (2α) and two beta (2β) subunits. The α subunit is 
 located outside the cell where it binds to insulin while the β subunit is immersed in the 
 membrane and extends inside the cell. The insulin receptor is a family of ligand- 
 activated receptor tyrosine kinases (RTK) and  receptors of  growth factors (Ullrich et al., 
 1985). The intracellular end of the receptor contains a kinase enzyme which is activated 
 when insulin binds to its receptor. This activation leads to autophosphorylation of specific 
 tyrosine residues on each β subunit (Jacobs et al., 1980). Phosphorylation of the β subunit 
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 activates some enzymes and inactivates others. The insulin receptor plays an important role 
 in the metabolic actions of insulin in target   tissues. It was shown in murine models that 
 disruption of the insulin receptor gene (Insr) leads to inhibition of its functions (Joshi et al., 
 1996). Studies have shown that mice with homozygous Insr null allele rapidly develop 
 diabetic ketoacidosis after birth and die within few days after birth (Accili et al., 1996; 
 Joshi et al., 1996). In addition, hyperglycamia and hyperinsulinemia were shown to be 
 accompanied by elevated levels of fatty acids and fatty liver. Experiments on disrupted 
 Insr gene using murine models enabled scientists to know the details about the metabolic 
 role of insulin and its receptor in different insulin-responsive tissues. Following a 
 carbohydrate rich meal, the majority of glucose is taken-up by muscle cells as facilitated 
 by insulin. Insulin resistance (restricted up-take of glucose) was observed in the early 
 stage of the T2DM (Bruning et al., 1998). 
1.4.2. Signalling downstream of the insulin receptor 
Following binding of insulin to its receptor, the insulin receptor can phosphorylate a number 
of proteins named insulin receptor substrate (IRS). IRS acts as an intermediate product in 
cascades between the tyrosine kinase and the phosphatidylinositol 3-kinase (PI 3-kinase) in 
the mitogen-activated protein kinase (MAPK) pathways. The role of the IRS is to transfer the 
signal of insulin to the PI 3-kinase and MAPK. (Fig 1.4) 
1.4.2.1. Insulin Receptor substrate (IRS) proteins 
IRS is a protein of molecular weight of 131 k Da. There are two types of IRS (IRS -1 and 
IRS-2) encoded by two genes IRS-1 and IRS-2. They work as signalling adapter proteins (Sun 
et al., 1991). IRS contains phosphotyrosine-binding (PTB) domains and N-terminal 
pleckstrin-homology (PH) and about 40 potential tyrosine phosphorylation sites that can bind 
effector molecules containing Src-homology 2 (SH2) domains (Copps and White, 2012). 
IRS-1 and IRS-2 play important and overlapping roles in the regulation of blood glucose. 
knockdown of  IRS-1 in mice led to insulin resistance and retardation of growth because of 
the resistance of Insulin-like growth factor 1 (IGF1)  (Araki et al., 1994; Tamemoto et al., 
1994), as well as increased serum TAG (due to impaired lipolysis) and hypertension (Abe et 
al.,  1998). Also removal of the IRS-2 of the mice led them to develop T2DM Due to the 
reduction in pancreatic ß-cell mass and failure to compensate for hepatic insulin resistance 
(Kubota et al., 2000; Withers et al., 1998) and are also dyslipidaemic and hypertensive 
(Kubota et al., 2003). Knockdown of IRS-2 from mice led to altered growth has been 
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observed in a few tissues such as certain neuronal cells (Withers et al., 1998). IRS-1 plays an 
important role in transmitting the insulin receptor signals to the intracellur pathways PI3K / 
Akt and Erk MAP kinase pathways. Knock-out of both IRS-1 and IRS-2 from mice 
hepatocytes led to insulin resistance, glucose intolerance and fatty liver (Taniguchi et al., 
2005). There are other IRS proteins (IRS3 and IRS4) but they have limited roles in insulin 
signal transduction.  
1.4.2.2. Phosphatidylinositol 3-kinase (PI3K)  
Phosphatidylinositol 3-kinase (PI3K) is an enzyme that has two units, a catalytic subunit and 
a regulatory subunit. It interacts with specific phosphotyrosine motifs of the insulin receptor 
substrates (IRS) through the SH2 domains on the regulatory subunit enabling recruitment of 
PI3K to the cell membrane and release of the catalytic subunit from the regulatory subunit 
(Yu et al., 1998). Following release of the catalytic subunit of PI3K, it mediates conversion 
of phosphatidylinositol-4, 5- bisphosphate (PIP2) to phosphatidylinositol-3, 4, 5-triphosphate 
(PIP3) (Whitman et al., 1988). PIP3 interacts with proteins of PH domains, resulting in their 
activation at the cell membrane (Fig.1.6). Studies showed that inhibitors of PI3K hinder many 
metabolic actions of insulin including stimulation of glucose transport, glycogen and lipid 
synthesis, and fat cell differentiation (Kanai, 1993; Cheatham, 1994; Clarke, 1994). 
Improvement in insulin sensitivity was observed in mice with knockdown of the regulatory 
unit of PI3K (Terauchi et al., 1999; Ueki, et al., 2002), rescuing the diabetic phenotype and 
reductions in insulin receptor and IRS (Mauvais-Jarvis et al., 2002). On the other hand, 
knocking-down the catalytic subunit induces glucose intolerance and elevated insulin levels 
(Brachmann et al., 2005). These findings suggest that insulin sensitivity is maintained by 
balancing the two subunits, p85 regulatory and p110 catalytic subunits. 
1.4.2.3. AKT/Protein Kinase B (PKB) 
PIP3 has several targets, including among others, Phosphoinositide-dependent kinase-1 
(PDK1), AKT (also known as protein kinase B (PKB) and some atypical forms of protein 
kinase C (PKC)) and cAMP-dependent, cGMP-dependent protein kinase C (AGC). AKT 
interacts with PIP3 via the PH domain and the activation of insulin to AKT requires 
phosphorylation at Thr308 (phosphorylated by PDK1) and Ser473 (phosphorylated by a 
mammalian target of rapamycin 2-mTORC2) (Alessi et al., 1996 and 1997; Ali and Sabatini, 
2005; Hresko and Mueckler, 2005; Sarbassov et al., 2005). Upon activation of AKT, it can 
mediate several of the PI3K mediated insulin metabolic actions via phosphorylation of many 
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substrates. AKT was shown to phosphorylate and deactivate glycogen synthase kinase 3 
(GSK3) resulting in the promotion of glycogen synthesis (Shepherd et al., 1995). AKT was 
shown also to phosphorylate members of the forkhead (FOX) class of transcription factors 
(TFs) resulting in the prevent on of these TFs from activating genes encoding enzymes 
involved in gluconeogenesis (Zhang et al., 2006). In addition, AKT enhances insulin-
stimulated glucose uptake by phosphorylating and inhibiting a Rab-GTPase-activating 
protein (Sano et al., 2003), triggering the activation of Rab small GTPases and therefore 
translocation of the glucose transporter GLUT4 to the cell membrane (Fig 1.6). AKT has 
three different forms encoded by three different genes (AKT1, 2 and 3). Studies showed that 
knocking-out AKT1 and AKT3 genes had no effect on glucose homeostasis (Cho et al., 
2001), unlike AKT2 gene (expressed in pancreatic ß-cells and skeletal muscle) (Easton et al., 
2005) knock-out which impaired insulin-stimulated glucose uptake by tissues (e.g. muscles) 
and inhibition of glucose production by liver (Cho et al., 2001). AKT2 gene knock-out mice 
are also glucose intolerant and are hyperinsulinaemic and hypertriglyceridaemic with 
reduction in pancreatic ß-cell and adipose tissue masses (Garofalo et al., 2003). In addition to 
the above, AKT2 (unlike AKT1 and AKT3) was found to localise together with GLUT4-
containing vesicles and it phosphorylates proteins involved in transport of these vesicles 
(Calera et al., 1998; Yamada et al., 2005).  
1.4.2.4. mTOR signalling pathway 
The mammalian target of rapamycin (mTOR) has two components, mTORC1 and mTORC2. 
They are downstream components of the insulin signalling pathway. As mentioned above, 
mTORC2 is responsible for phosphorylation of AKT Ser473 (Ali and Sabatini, 2005; Hresko 
and Mueckler, 2005; Sarbassov et al., 2005b) and is also involved in the actin cytoskeleton 
organisation (Jacinto et al., 2004; Sarbassov et al., 2004), while mTORC1 is activated by 
insulin signalling via AKT (Manning and Cantley, 2003; Tee et al., 2003). mTORC1 
regulates cell growth by modulating biological processes like translation, ribosome 
biogenesis and nutrient metabolism (Wullschleger et al., 2006). In addition, activation of 
mTORC1 signalling and its p70 ribosomal S6 kinase (S6K1) was shown to inhibit insulin 
signalling through IRS proteins (negative feedback).  
1.4.3. Attenuation of the insulin signalling cascade  
Insulin signalling can be regulated by different mechanisms (Fig 1.6). Protein tyrosine 
phosphatase-1B (PTP1B) expression was shown to reverse the autophosphorylation of the 
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insulin receptor and elevated expression of PTP1B was observed in insulin-resistant humans 
and PTPB1 knockout mice have increased insulin sensitivity (Elchebly et al., 1999). The 
tyrosine kinase activity of the insulin receptor was shown to be inhibited by beta-subunit 
threonine/serine phosphorylation. In addition, serine phosphorylation on IRS proteins was 
shown to oppose tyrosine phosphorylation and activation of IRS proteins. The actions of 
insulin, as well as others including free fatty acids, cytokines, factors that induce cell stress, 
and amino acids (through mTORC1), can result in activation of serine kinases like protein 
kinase C (PKC), suppressors of cytokine signalling (SOCS) proteins and S6K1. This could 
also act as a negative regulatory mechanism for the insulin signalling pathway. Finally, 
phosphatases, PTEN (phosphatase and tensin homologue on chromosome 10) and SHIP2 
(SH2-domaincontaining inositol 5-phosphate-2) can reverse the conversion of PIP2 to PIP3.  
1.5. Mechanisms of insulin resistance and pancreatic β-cell 
dysfunction 
1.5.1. Obesity  
Obesity is a medical condition associated with excess fat deposition, not only around the 
body but also in the tissues. This has a negative affect on the health leading to decreased life 
expectancy (Haslam et al., 2005). Individuals are considered obese when the body mass 
index (BMI) exceeds 30 Kg/m2, overweight when the (BMI) range is between 25-29.99  
Kg/m2 and normal when the (BMI) range is between 18-25  Kg/m2 (Flegal et al., 2002) Table 
1.1., Fig1.9. In addition, obesity increases the probability of infections in patients with T2DM 
and heart disease and certain types of cancer (Haslam et al., 2005). The major health risk of 
obesity depends on the distribution of fat around the body and excess fat located in the central 
abdominal area of the body is called upper body obesity (apple-shape) Fig 1.9. This type of 
obesity is a risk factor for cardiovascular diseases, insulin resistance, and diabetes (Ibrahim, 
2010). Several studies in humans have reported that expression of resistin increases in 
adipose tissue (Degawa-Yamauchi et al., 2003) particularly in those with abdominal obesity 
(McTernan, 2002). 
1.5.2. Adipocyte dysfunction 
The fat, derived from the excess food intake more than the body needs, in the body is stored 
in the adipocytes inside adipose tissue in the form of triglycerides (TAG), mostly in a single 
large lipid droplet.  When energy needed, TAG, diglycerides (DAG) and monoglycerides 
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(MAG) are hydrolysed by adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL) 
(Fig 1.7), and monoglyceride lipase respectively (lipolysis) to produce glycerol and three 
fatty acids, the free fatty acid can be oxidised by mitochondria in other tissues to generate 
energy, while the glycerol are transferred to the liver to convert it to glucose by 
gluconeogenesis pathway. Increased adipose tissue mass due to obesity are associated with 
insulin resistance. In this scenario, the capacity of adipocytes to store excess lipids becomes 
saturated, resulting in lipid deposition in non-adipose tissue such as muscle, liver, and 
pancreas. Furthermore, obesity can cause aberrant secretion of adipokines, the collective term 
for the large number of hormones, cytokines, and growth factors secreted by adipose tissue to 
influence whole-body energy balance and nutrient metabolism. 
 
 
Fig 1.7 Lipolysis. 
It is activated by HSL enzyme which its stimulated by epinephrine and cAMP. First epinephrine binds 
with beta-adrenergic receptors on the cell membrane of the fat cell and therefore generate cAMP 
inside the cell, which  in-turn activated the protein kinase which it  phosphorlates and activates 
HSL.The diagram is provided from Jocken and Black, (2008). 
1.5.3. Ectopic accumulation of lipids 
Increased free fatty acids in the blood (as seen in obesity) lead to the accumulation of large 
amounts of lipid (in the form of TAG) in liver causing fatty liver or hepatic steatosis and in 
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muscle causes muscle steatosis. When activated free fatty acid increases than the capacity of 
the fatty acid oxidation (the process of breaking down fatty acids to produce energy) the 
excess of these fatty acids can be used to build up monoglycerides (MAG) and diacylglycerol 
(DAG). Lipid intermediates are then thought to induce serine phosphorylation on IRS 
proteins through the activation of serine kinases such as PKC isoforms, I kappa B kinase 
(IKK), and JNK (Gao et al., 2004; Itani et al., 2002). Insulin resistance in humans and  
animal models has been shown to correlate with  fat content within cells (muscle cells) (Pan 
et al., 1997; Perseghin et al., 1999; Phillips et al., 1996; Storlien et al., 1991) and lipid 
content in hepatocytes (liver cells) (Kotronen et al., 2008; Ryysy et al., 2000; Seppala-
Lindroos et al., 2002). However, it remains controversial whether lipid accumulation in 
muscle and liver causes whole-body insulin resistance, or whether it is in fact merely a 
marker for insulin resistance. The lipogenic effects of insulin may cause, or at least 
exacerbate, lipid accumulation in ectopic tissues in states of hyperinsulinaemia (Savage et al., 
2007). 
High circulating fatty acids can also impact negatively on pancreatic β-function. Elevated 
fatty acid concentrations have been shown to increase basal insulin release and decrease 
glucose-stimulated insulin secretion in vitro (Sako and Grill, 1990), in rats (Mason et al., 
1999), and in humans (Paolisso et al., 1995). Fatty acids have also been shown to inhibit 
insulin gene expression in vitro (Kelpe et al., 2003). Fatty acids in concert with high glucose 
also promote β-cell death (El-Assaad et al., 2003). Many mechanisms have been suggested to 
mediate this effect including production of lipid intermediates and oxidative stress. More 
recently it has been shown that fatty acids can induce markers of (Endoplasmic reticulum) ER 
stress and changes in ER morphology, leading to β-cell death (Laybutt et al., 2007). There is 
strong evidence that the detrimental effects of fatty acids on β-cell function only occur in the 
presence of elevated glucose, which directs fatty acid partitioning away from oxidation and 
towards storage (Prentki and Corkey, 1996). 
1.5.4. Insulin Resistance  
Insulin resistance is a pathological condition in which cells fail to respond properly to insulin, 
thus blood glucose fails to enter the cells resulting in high blood glucose (hyperglycaemia). If 
not treated this may result in the development of T2DM. Several other factors can also 
contribute to the development of insulin resistance including obesity, resistin, homocysteine 




Adipose tissue has the ability to produce and secrete different types of adipokines. Several 
adipokines are known to be involved in the regulation of the action of insulin e.g. adiponectin 
and various inflammatory factors (interleukins, cytokines and tumor necrosis factors), leptins, 
retinol binding protein (RBP) and resistin.  Several studies in experimental models identified 
genetic mutations in the leptin gene and its receptor gene that were associated with obesity 
and diabetes (Chen et al., 1996; Lee et al., 1996; Tartaglia et al., 1995; Zhang et al., 1994). 
Leptin was shown to have several functions that include, hepatic insulin sensitivity and 
glucose production (Cohen et al., 1996), regulation of food intake (Stephens et al., 1995), and 
inhibiting fatty acid synthesis and stimulating fatty acid oxidation resulting in triglyceride 
accumulation in peripheral tissues (Minokoshi et al., 2002; Prieur et al., 2008). Resistin, 
another adipokine produced by adipose tissues in animals, was shown to reduce glucose 
uptake by skeletal muscle cells (Moon et al., 2003). It was suggested that insulin resistance 
and obesity in diabetic mouse can be attributed to the existence of resistin (Jamaluddin et al., 
2012). As will be described in detail in another section of this thesis, the role of resistin in 
obesity associated with T2DM in humans is unclear.  
1.6. Resistin 
1.6.1. Introduction   
In humans, resistin is mainly secreted from immune cells (macrophages and monocytes), 
while in rodents (Mice), it is secreted by adipocytes (in adipose tissues). Adipose tissue, the 
main site for lipid storage, has been shown to function as an endocrine and secretory organ by 
secreting hormones e.g. adipokines (Kershaw and Flier, 2004). Adipokines compris a variety 
types of cytokines, chemokines, and hormone-like factors which participate in the regulation 
of physiological and pathological processes like catabolism and anabolism of metabolic fuel, 
immunity, and inflammation (Wellen et al., 2005). In mice, resistin is derived of the adipose 
tissues (as a cytokine) and there is a lot of controversy about its physiologic role in obesity 
and T2DM (Lazar, 2007). Resistin was proposed as a potential link between obesity and 
diabetes (Janke et al., 2002) and studies showed that resistin could interfere with insulin 
signalling and glucose tolerance (Steppan et al., 2001). Obesity has been shown to contribute 
to insulin resistance which is considered a risk factor for development of (T2DM) (Kahn and 
Flier, 2000). Administration of a recombinant resistin to the obese Mice impaired glucose 
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tolerance, while suppressing resistin action by neutralizing resistin leads to improvement in 
insulin sensitivity and blood glucose in the obese Mice (Savage et al., 2001). 
In addition, resistin was shown to inhibit entry of glucose to muscle cells (Moon et al., 2003). 
Jamaluddin et al, observed that insulin resistance and obesity in diabetic mice was attributed 
to resistin (Jamaluddin et al., 2012). In humans, the role of resistin in obesity associated with 
T2DM is unclear. Experiments in murine models showed marked increase in levels of resistin 
in both genetic and diet-induced obesity and these levels correlated with impaired glucose 
tolerance and insulin action (Nagaev and Smith, 2001). In addition, Thiazolidinedione 
treatment was shown to inhibit resistin gene expression and enhanced blood glucose uptake 
and insulin sensitivity in mice (Sentinelli et al., 2002). It was suggested that resistin 
antagonizes insulin action and disrupts one or more component in insulin signalling pathways 
leading to insulin resistance. As stated previously, resistin plays an important role in insulin 
resistance and T2DM in the murine models, but the role of resistin in human obesity and 
diabetes is controversial. Resistin might have different roles in humans and mice. Resistin 
gene expression in adipocytes from overweight individuals has been reported to be absent 
(Nagaev and Smith, 2001) and there are controveries regarding the role of resistin in obesity 
and insulin sensitivity (Savage et al., 2001; Rajala et al., 2003; Ribon et al., 1998 and Ribon 
and Saltiel, 1997). Studies showed that the expression of human resistin mRNA is very low 
in human adipocytes (Savage et al., 2001).   
The association between human resistin and T2DM has not been clarified as well (Engert et 
al., 2002). A recently study found a resistin gene promoter -420 G/G genotype to be 
associated with T2DM (Osawa et al., 2004). Higher serum levels of resistin were shown also 
to be associated with this genotype (homozygosity -420 G/G). Therefore, they suggested that 
this mutation -420 G/G might be associated with elevated resistin levels contributing to 
insulin resistance and T2DM in human (Osawa et al, 2005). 
The association between elevated levels of resistin and T2DM in humans is very 
controversial (Cho et al., 2004). Lee et al reported that there is no association between 
resistin levels and obesity or T2DM (Lee et al., 2003). McTernan et al and Youn et al 
observed that serum resistin levels were higher in patients with T2DM, but are not associated 
with obesity (McTernan et al., 2003 and Youn et al., 2004). Fujinami et al and Azuma et al 
showed elevated levels of resistin in T2DM and in obese individuals (Fujinami et al., 2004 
and Azuma et al., 2003). 
In humans, resistin is mainly secreted by immune cells (monocytes/macrophages) and rarely 
by adipose tissue (Patel et al., 2003). On the other hand, in mice resistin is expressed mainly 
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by adipose tissue (Steppan et al., 2001). Macrophages infiltrating into adipose tissues could 
account for insulin resistance in obese mice. A study from Japan by Osawa et al. investigated 
the relation between human resistin and T2DM, and showed that the resistin promoter -420 
genotype was associated with monocyte resistin mRNA expression and serum resistin levels. 
In addition, the study found that patients with T2DM had higher serum resistin levels as 
compared to their controls (Osawa et al., 2005). Resistin expression was higher in patients 
with type 2 diabetes mellitus and dyslipidaemia and less in the control group. Resistin 
probably plays a role in the pathogenesis of hepatic insulin resistance and aggravates 
pathologic changes in the liver of patients with NAFLD (Gierej et al., 2017). Recently, a 
study has been reported on subjects with non-functional adrenal incidentaloma; they found 
not only significantly decreased serum adiponectin levels but also increased leptin, resistin 
levels as well as dislipidemia, hypertension and high insulin resistance index. All of which 
could affect insulin resistance and cardiovascular risk factors. The underlying mechanisms of 
these findings are unknown, hence further studies needed (Akkus et al., 2018).  
1.6.2.  Structure and forms of Resistin 
The resistin gene, referred to “Retn”, encodes the resistin peptide (Steppan et al., 2001). 
Resistin is found in two forms either high-molecular mass (HMM) which is the predominant 
form and contains a hexamer subunit, and low-molecular mass (LMM), which is monomeric 
and unable to form intertrimer disulphide bonds; this is considered the active form (Patel et 
al., 2004).  The resistin has a molecular weigh of approximately 12.5 kDa proteins that 
consist of 108 amino acids in human and 114 amino acids in Mouse and rat (Lazar, 2007). 
The gene that encodes human resistin is located on chromosome 19 whereas the Mouse 
resistin gene is located on chromosome 8 (Ghosh et al., 2003). Mouse and human resistin 
share 46.7% similarity at the genomic DNA level, 64.4% sequence homology at the mRNA 
level, and 59% identity at the amino acid level. The mature segments are 55% amino acid (aa) 
identical between mice and human (Steppan et al., 2001) and 72% aa identical between 
mouse and Rat (Del Arco et al., 2003). Resistin  also contains 11 cysteine (cys) amino acids 
residues 10 of which are involved in intramolecular disulfide bonding, the last one being (cys 
26) which participates in dimer structure formation (Juan et al., 2003). The resistin 
polypeptide consists of three domains, N- terminal which has 17 amino acids which 
represents, signal sequence, C-terminal is highly constant region, and variable region that lie 
in between N- terminal and C- terminal (Adeghat, 2004). There are three types of RELMs: 
Resistin-like molecule α-1 (RELM-α-1 ) (Found in Inflammatory Zone (FIZZ 1) is a secreted 
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protein that is present mainly in adipose tissue and found in the inflammatory zone in murine 
allergic pulmonary inflammation (Holcomb, 2000). RELM-β (FIZZ 2). It is secreted only in 
the gastrointestinal tract from goblet and epithelial cells, and it is markedly expressed in 
tumors, suggesting a possible role in proliferation. RELMs-γ the most recently discovered 
member of the RELM family is found in hematopoietic tissue, indicating cytokine- like 
functions (Gerstmayer et al., 2003). 
1.6.3. Resistin and Obesity  
Obesity is a growing global health problem. It is associated with insulin metabolic syndrome, 
resistance, dyslipidaemia, and T2DM (Steppan and Lazar, 2002). Several factors were shown 
to be involved including hormones, cytokines, growth factors and adipokines. The later was 
shown to be involved in controlling insulin sensitivity linked to the pathophysiology of 
obesity (Steppan et al., 2001; Kim et al., 2001 and Holcomb et al., 2000). Resistin is 
proposed as a link between obesity and T2DM and may affect insulin signaling leading to 
insulin resistance (Steppan et al., 2001; Sentinelli et al., 2002 and Asano et al., 2010). In 
vitro studies using adipocytes cell lines showed that neutralization of resistin with resistin 
antiserum was shown to lead to decreased insulin resistance and increase in glucose uptake 
by tissues (Steppan and Lazar, 2002). Increase in levels resistin were observed in high fed 
mice (Steppan and Lazar, 2002). Similar findings were observed in genetic models of obesity 
(ob/ob mouse) (Rajala et al., 2004). The previous studies are in murine models, and the role 
of resistin in the pathophysiology of insulin resistance and T2DM is not clear. Several studies 
showed high levels of resistin mRNA expression in adipose tissue from obese diabetic 
subjects (McTernan et al., 2002; McTernan et al., 2002 and Heilbronn, et al., 2004). Higher 
resistin levels were shown to be elevated in obese subjects as compared to non-obese subjects 
(Vendrell et al., 2004; Schaffler et al., 2004 and Degawa-Yamauchi et al., 2003). A study 
involving adult, nondiabetic, obese and Caucasian first-degree subjects showed that resistin 
levels were highly heritable and suggested that resistin might play a pathogenic role in insulin 
resistance associated with obesity (Menzaghi et al., 2006). However, in healthy young 
subjects, no correction was found between resistin levels and insulin resistance associated 
with obesity (Silha et al., 2003).  Other studies showed correlation between resistin levels and 
waist circumference and body fat mass but not with the BMI (De Luis et al., 2003). The 
differences between studies raised question of ethnic influence on resistin levels. Ethnic 
variability might influence the association between resistin, obesity and insulin resistance. 
24 
 
Therefore, studying these associations in an ethnically uniform population is of great 
importance. 
Moreover, positive correlation has been detected between serum resistin levels and body fat 
content (Rajala et al., 2004).  In obese Mice, it was observed that the levels of resistin drop 
during fasting and increase during re-feeding. It was suggested that resistin might be a 
hormone that works against the insulin and is considered as an independent factor for obesity. 
Some studies confirm that the resistin has been found at high concentrations in the high-fat-
induced obese Mice and diabetics (Steppan et al., 2001). 
    BMI =   m/ h2         m (weight) 
                                     h (height) 
                       Table 1.1 Body Mass Index 
BMI (kg/m2) Classification 
<18.50 underweight 
18.50-24.99 Normal weight 
25-29.99 overweight 
30-34.99 Class1 obesity 
35-39.99 Class11 obesity 
≥40 Class111 obesity 
 
  
Fig  1.8 Body Mass Index of men and women  




Fig 1.9 Body obesity: upper versus lower obesity. 
                                                 The diagram is provided from Kirschner et al., (1990) 
                                                        Apple –shaped                           Pear- shaped 
                                           Upper body obesity                  Lower body obesity             
1.6.4. Resistin, Insulin resistance and T2DM 
Insulin action at target tissue starts when insulin binds with its receptor and subsequently 
sends a signal cascade to produce glucose transport for decreasing glucose levels in the 
plasma. Disruption of the insulin pathway leads to hyperglycaemia and then development of 
T2DM. It was suggested that the resistin had significant effects on insulin action, and link 
obesity with insulin resistance (IR) (Banerjee et al., 2003). Injection of Mice with anti resistin 
antibody improved the action of insulin and glucose metabolism (Steppan, et al., 2001). As 
well as treatment of normal Mice with recombinant resistin disrupt glucose tolerance and 
insulin action (Steppan et al., 2001). Resistin gene knock-down led to a decrease in glucose 
by reducing gluconeogenesis, while giving resistin to these resistin-deficient Mice led to 
increases in sugar production in the liver (Banerjee et al., 2004). Moreover, increased 
production of resistin disrupts glucose transport in skeletal muscle in Rats, while injection 
with recombinant resistin decreases insulin mediated glucose transport in muscle cells 
(Pravenec et al., 2003). Furthermore, a study conducted by Rajala et al explored the 
physiological role of resistin in the development of insulin resistance in rodents (Rajala et al., 
2004). This study was explained that chronic hyperresistinemia impairs insulin signalling 
pathway in muscle, liver and adipose tissue, and indicated that resistin is considered one the 
factors which leads to insulin insensitivity and may participate to the development of insulin 
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resistance or diabetes in obese rodent. The role of resistin in the development of insulin 
resistance and T2DM was studied using Cell Cultures (Palanivel et al., 2006) and animal’s 
models but in human it remains controversial. Jenifer et al was found that there were 
association between resistin levels and obesity or insulin resistance in human and concluded  
that resistin hormone did  not play a role in insulin resistance in human (Jenifer et al., 2003). 
On the other hand, Silha et al reported that resistin was significantly associated with insulin 
resistance in obese individuals (Silha et al., 2003).  Hasegawa et al observed that resistin 
levels were higher with statically significant in patients with T2DM compared with healthy 
subjects, but this increase is not associated with obesity and insulin resistance (Hasegawa et 
al., 2005).  
1.6.5. Mechanism of action of Resistin  
For biological action, insulin binds to its receptor to form a complex that in turn results in 
insulin receptor phosphorylation. Following receptor phosphorylation at tyrosine residue, the 
insulin receptor substrate (IRS) proteins -1 and -2 are attracted and are subsequently 
phosphorylated. This starts a cascade of reactions involving phosphoinositide 3-kinase (PI3K) 
and protein Kinase B (PKB), which it known as AKT. Adding resistin to cultures was shown 
to reduce phosphorylation of Insulin receptor substrate (IRS) induced by insulin (Karmiris et 
al., 2005 & Kitagawa et al., 2004). Karmiris et al shown decreased IRS-2 phosphorylation 
and protein level in adipose tissue, skeletal muscle and liver of mice after exposed to resistin 
(Karmiris et al., 2005). In contrast, Moon and Palanivel have observed that there is no effect 
of resistin on IRS-2 and IRS-1 proteins in cultured L6 myoblasts and muscle liver and 
therefore lack effect of resistin on the PI3K activity or the subsequent phosphorylation of 
AKT (Moon et al., 2003 & Palanivel et al., 2006). Following activation of AKT, glycogen 
synthase kinase (GSK)-3 phosphorylates glycogen synthase converting it to an inactive form. 
It was found that resistin increases the production of the inhibitor protein SOCS3 (a protein 
known to have ability to disrupt insulin signal transductions) (Muse et al., 2007). SOCS3 
interacts with the insulin receptor preventing its phosphorylation, and therefore inhibiting 
activation of IRS-1, PI3K, and AKT. The end result is reduction in glycogenesis, increase in 






                       Fig 1.10 Action of resistin on the insulin signalling pathway:  
                       resistin participates in the insulin resistance by activate SOCs-3 protein which in turn 
                       disrupt the insulin signaling by    inhibiting Insulin receptor substrate 1 (IRS-1). The 
                       figure was reproduced from Song et al., (2013).  
1.7. Homocysteine 
1.7.1. Structure and Function of Homocysteine 
Homocysteine is an amino acid that is not present in the protein and contains sulfhydryl 
group (-SH) at the end (Hajjar, 2001).  Homocysteine is a 2-amino-4 butyric acid, Fig1.8 
(Finkelstein, 2003). Homocysteine was extracted for the first time from methionine after 




Normally homocysteine is not found in nature or in the diet, only as intermediate product in 
methionine metabolism, so it is considered as a main source of methionine production 
Fig1.12. Biologically, the homocysteine has three functions (i) a precursor of methionine 
formation Fig1.12. (ii) methyl group donor for the formation of choline (iii) metabolised to 
cystathionine and cysteine. (Finkelstein and Martin, 1986; Fig 1.12)  




Fig 1.12 Methionine, Homocysteine and Cysteine Structure 
1.7.2. Metabolism of the Homocysteine 
Homocysteine is an intermediate product during metabolism of methionine (Met). The 
reaction starts by removing the methyl group from methionine, a reaction that requires ATP 
and S-adenosylmethionine synthetase to produce S-adenosylmethionine (SAM), (Fig1.13 
reaction 1).  SAM (methyl donor) is then converted to S-adenosylhomocysteine (SAH) after 
the methyl group has been removed and donated it to an acceptor, such as Creatine, DNA, 
RNA and Neurotransmitters (Fig1.13, reaction 2&3) , SAH is hydrolyzed to L-homocysteine 
and adenosine by a reaction catalysed by S-adenosylhomocysteine hydrolase (Fig1.13 
reaction 4), (Fowler, 1997). Homocysteine can then be metabolized either to convert back to 
methionine via re-methylation pathway or by irreversible degradation to yield cystathionine 
and cysteine in the transsulfuration pathway (Mills et al., 1995; Selhub, 1999) (Fig1.13)  
1.7.2.1. Metabolism of homocysteine via re-methylation pathway  
The objective of the re-methylation pathway is the conversion of homocysteine to methionine.  
Homocysteine needs a methyl group that is obtained either from: 1) the conversion of 5-
methyltetrahydrofolate to tetrahydrofolate (the active form of folate) catalysed by methionine 
synthase enzyme using vitamin B12 as a cofactor (Fig1.13 reaction 7). This reaction occurs in 
all tissues. To regenerate the production 5-methyltetrahydrofolate from tetrahydrofolate, 
methylenetetrahydrofolate reductase (MTHFR) and riboflavin (B2) are required. This 
reaction occurs in two steps, first tetrahydrofolate is converted to 5, 10 
methylenetetrahydrofolate (Fig1.13 reaction 9), and then to 5-methyltetrahydrofolate 
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(Fig1.13 reaction 10). MTHFR is considered to be the key enzyme in the re-methylation 
pathway. The vitamins Folate, B2 (riboflavin), B6 (pyridoxal phosphate), and B12 
(cobalamin) are required to complete the re-methylation pathway (Mattson and Shea, 2003). 
2) The conversion of betaine to N, N-dimethylglycine catalysed by betaine-homocysteine 
methyltransferase enzyme (BHM) this pathway is considered a relatively minor pathway and 
vitamin B12 is not required as a cofactor. It found mainly in the liver. (Fig1.13 reaction 8; 
Perry, 1999). 
1.7.2.2. Metabolism of homocysteine via Transsulfuration pathway 
The main goal of the transsulfuration pathway is the production of cysteine from methionine 
via homocysteine as an intermediate (Medina et al., 2001). The first step in this pathway is 
the formation of cystathionine from the condensation of homocysteine and serine catalysed 
by pyridoxal-5'-phosphate–dependent-cystathionine ß-synthase (CßS) using vitamin B6 as a 
coenzyme (Fig1.13 reaction 5). Cystathionine is cleaved into cysteine and ketobutrate a 
reaction catalysed by pyridoxal-5'-phosphate–dependent- cystathionine β-lyase with 
Pyridoxal phosphate (vitamin B6) as a co-factor (Fig1.13 reaction 6), (Mangoni and Jackson, 
2002; Perry, 1999). Finally, cysteine is degraded into three compounds (sulfate, taurine and 
pyruvate) after removal CO2 and NH3. In addition to its main function, which is cysteine 
formation, this pathway also relieves the body from the excess homocysteine, mutations in 
transsulfuration pathway leads to homocystinuria (Medina et al., 2001). All these reactions 





Fig 1.13 Homocysteine metabolism:   
the toxicity of homocysteine can be removed either by re-methylation pathway where the homocysteine is 
converted to methionine or by transsu-lfuration pathway where the homocysteine is degraded to cysteine and α- 
ketobutyrate.  The figure was taken from Finkelstein and Martin, (1986). 
1.7.2.3. The roles vitamins in homocysteine metabolism 
Many of the water-soluble vitamins have important roles, as coenzymes, in homocysteine 
metabolism:-   
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Vitamin B2  
Flavin adenine dinucleotide (FAD) is considered the active form of vitamin B2 and it has an 
important role, as a coenzyme, in MTHFR. 0.6 mg intake daily from the diet was enough in 
modest reductions in homocysteine levels (Malinow et al., 1999).  
Vitamin B6  
The active form of this vitamin B2 is Pyridoxal-5-phosphate (PLP) which plays a role as a  
coenzyme for many enzymes like cystathionine-β-synthase (CßS), β-lyase, γ-cystathionase 
and serine hydroxymethyltransferase (SHMT). The absorption of the vitamin B6 occurs in 
the upper small intestine afterward becomes transported to the liver where phosphorylation 
takes place (Merill and Henderson, 1990). Albumin is the main carrier of the PLP in the 
circulation and exported to extrahepatic tissues (Leklem, 1990).  
Vitamin B12  
The active form of vitamin B12 is methylcobalamin. It acts as a coenzyme for methionine 
synthase (MS) enzyme. In the stomach, methylcobalamin binds with haptocorrin forming a 
complex. In the duodenum, Vitamin B12 is released by pancreatic proteases and subsequently 
gets bound to intrinsic factor (IF) (Russell-Jones and Alpers, 1999). In the ileum, the complex 
(vitamin B12/IF) binds with its receptor- cubulin (Seetharam et al., 1999) and is absorbed by 
receptor-mediated endocytosis. It is transported in the circulation by transcobalamin (TC). 
The complex (vitamin B12/TC) enters cells by endocytosis via the transcobalamin receptor 
(TC-R) which is expressed on the cell surface in many tissues. After entering cells, B12 is 
released from its carrier, TC,  and in metabolized in several steps before it becomes a methyl 
carrier in homocysteine metabolism (Seetharam and Li, 2000). 
Folic acid 
Folate is a biological carrier of the one-carbon unit; the active form is tetrahydrofolate when 
it binds with the methyl group becomes 5-methyltetrahydrofolate. It is a methyl donor in 
many reactions. It is formed upon reduction of 5, 10-methylenetetrahydrofolte by MTHFR. It 
is required by methionine synthase as a co-substrate (Castro et al., 2006; Fig1.13 reaction 9 
&10). 
1.7.2.4. The role of enzymes in homocysteine metabolism  
Three key enzymes play important roles in the metabolism of homocysteine:    
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Cystathionine β-Synthase (CβS) 
 Homocysteine can be converted to cysteine in the transsulfuration pathway, which requires 
the enzyme cystathionine- β-synthase (CβS). CβS requires vitamin B6 (pyridoxal 5-
phosphate) as coenzymes (Finkelstein and Martin, 2000).  
Methionine Synthase (MS) 
 Homocysteine binds with methyl group derived from 5- methyl-tetrahydrofolate (methyl 
donor) to become methionine. This reaction is catalysed by methionine synthase (MS), which 
requires vitamin B12 as coenzymes (Olteanu et al., 2001). 
Methyltetrahydrofolate reductase (MTHFR). 
 The enzyme 5, 10 methylenetatrahdrofolate reductase (MTHFR) catalyses the conversion of 
5, 10 methylenetatrahdrofolate into 5-methyl tetrahydrofolate. This is the major circulating 
form of folate. Folate in turn, is used in many biochemical pathways, including the 
methylation of homocysteine to methionine. Mutations in the MTHFR gene can be associated 
in reduction in the enzyme activity and can result hyperhomocysteinemia   that can 
precipitate coronary artery disease CAD (Kluijmans et al., 1997). 
1.7.3. Forms of the homocysteine in plasma  
In plasma, homocysteine was found in two forms (i) free homocysteine (it has a free 
sulfhydryl group) is present in trace amount (< 0.3 nmol/l, 1%). It is unstable and rapidly 
oxidized at neutral pH 7.3. (ii) The bound forms: are present in three forms: (a) 
Homocysteine (homocysteine-homocysteine). It is the second compound found in the plasma 
and is composed of two molecules linked together by a disulfide bridge. (b) Homocysteine 
binds with a cysteine molecule to form another large oxidized molecule (cysteine-
homocysteine) which accounts for around 20-30% of total homocysteine in the plasma. (c) A 
large amount of the homocysteine in plasma binds covalently with a cysteine residue in 
protein especially those found in albumin which represents about 70%-80% of the total 
homocysteine (Ueland et al., 1993).  
The total homocysteine in the plasma is calculated of the sum of free and bound 




Elevated levels of homocysteine in the plasma above the normal level (5-15 µmol/l) is a 
considered clinically a pathological state known as hyperhomocysteinemia (Dudman et al., 
1993). This elevation occurs due to defect in one of the enzymes in homocysteine metabolism 
or a deficiency in the vitamins which it contributes as cofactors to these enzymes in the 
homocysteine metabolism. According to this defects, hyperhomocysteinemia has been 
classified into three statuses depending on the level of homocysteine in plasma (i) mild (16-
30 µmol) this occur due to deficiency of the vitamins (ii) moderate (31-100 µmol) due to 
genetic polymorphism of the methionine synthase enzyme (iii) severe (>100 µmol) condition 
of hyperhomocysteinemia. It happens in case of CβS deficiency or MTHFR deficiency 
(Mangoni and Jackson, 2002; Perry, 1999; Table 1.2).   
        Table 1.2 Classification of hyperhomocysteinemia.                                
Aetiology Plasma total 
homocysteine 
Condition 
Cystathionine-β- synthase deficiency                                                                             
Methylenetetrahydrofolate reductase  deficiency                                                                           





methionine synthase deficiency                                                                                       
Compound heterozygosity of MTHFR                                                 
Interallelic combination of genetic defects                                                   
Nutritional deficiencies ± minor genetic defect 
31  - 100 mmol/l 
 
Moderate 
Interallelic combination of genetic defects                                               
Minor genetic defects                                                                                   
Nutritional deficiencies ± minor genetic defect 




Several factors participate in the elevation levels of homocysteine in plasma, which are 
summarized in either pathological or physiological condition.  
1.7.5. Physiological Factors 
1.7.5.1.  Age and sex 
Several authors have mentioned that homocysteine levels increases with age and found that 
men have a higher level of homocysteine compared with women (Dierkes et al, 2001; Hockly 
and Brown, 1999; Stein and McBride, 1998). Perry reported higher homocysteine in men by 
about 25% than premenopausal women (Perry, 1999). Previous studies showed that mean 
fasting homocysteine level in elderly patients (mean age 79±9 years) were 18.18 ±13.22 
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µmol/l) for men and 15.86 ± 12.14 µmol/l for women. The study concluded that the 
homocysteine levels in men were higher than in women (Ventura et al., 2001). Other studies 
reported similar findings (Powers et al., 2002). 
1.7.5.2. Pregnancy 
Normal levels of the homocysteine in non-pregnant women of childbearing age are 5.8-12.8 
µmol/l (Vilaseca et al., 1997). In pregnant women, lower levels of homocysteine (60% less 
than normal levels) were reported (Perry, (1999). Increased activity of the enzyme betaine 
homocysteine methyltransferase was shown to be associated with pregnancy, protecting 
pregnant women from developing hyperhomocysteinemia (Kang et al., 1987). Several other 
factors might contribute to the reduced levels of homocysteine associated with pregnancy that 
includes among others: increase in estrogen levels, a physiological response to the pregnancy, 
increasing the need for methionine by the mother and the fetus and dilution of blood from 
increased plasma volume (de la Calle et al., 2003). On the other hand, postmenopausal 
women have comparatively higher levels of homocysteine (11.5 µmol/l) than premenopausal 
women (10.7µmol/l), these findings support the hypothesis that estrogen reduces 
homocysteine levels (Hak et al., 2000) by stimulating cystathionine β-synthase (CβS) 
(Dimitrova et al., 2002). 
1.7.5.3.  Dietary factors 
McCully recommended consumption of food that contains adequate amounts of vitamin B6, 
vitamin B12 and folic acid. It is recommended to consume sufficient quantities of fresh 
vegetables, fruits, whole grains and legumes, and small amount of the fresh meat and dairy 
products, as well as very little amount of fats and sugars. These vitamins lead to reduction the 











Table 1.3: allele frequencies of MTHFR C677T mutation and homocysteine and folate levels among        
different ethnic group and gender 
Race and Gender  Main finding Reference 
12% of the Caucasian Caring TT genotype of C667T MTHFR gene  Kauwell et al., 2000 
African-Americans very low prevalence of this TT genotype Kauwell et al., 2000 
black in South Africa homocysteine was lower (11± 3.6 µmol/L) Ubbink et al., 1995) 
white in South Africa homocysteine was higher (18 ± 6.2 µmol/L) Ubbink et al., 1995) 
premenopausal Black females homocysteine was higher (8.32 µmol/L) (Gerhard et al., 1999) 
premenopausal whites females homocysteine was lower (7.6 µmol/L) (Gerhard et al., 1999) 
premenopausal whites females folate was higher (9.88 nmol/L) (Gerhard et al., 1999) 
premenopausal Black females  folate was lower (6.2 nmol/L) (Gerhard et al., 1999) 
Men in different population  Have high homocysteine levels 25% than women (Cappuccio et al., 2002) 
women in different population Have low homocysteine levels 25% than men  (Cappuccio et al., 2002) 
South Asian Have high homocysteine levels   (Cappuccio et al., 2002) 
whites Have low homocysteine levels   (Cappuccio et al., 2002) 
vegetarians and Hindus Have high homocysteine levels   (Cappuccio et al., 2002) 
non-vegetarians and other groups Have low homocysteine levels   (Cappuccio et al., 2002) 
Muslims and Whites No variation of   homocysteine levels  (Cappuccio et al., 2002) 
In Whites alleles frequencies of TT in MTHFR gene was 0.1 (Cappuccio et al., 2002) 
In African origin alleles frequencies of TT in MTHFR gene was 0.01 (Cappuccio et al., 2002) 
in South Asians alleles frequencies of TT in MTHFR gene was 0.02 (Cappuccio et al., 2002) 
in White Italians in Burkina Faso  High prevalence of coronary heart disease / high 
homocysteine levels  
(Simpore et al., 2002) 
Blacks population in Burkina 
Faso 
low prevalence of coronary heart disease / low 
homocysteine levels 





Table1.4: the role of pathological factors and vitamins B6 B12 and folate supplementation in  
            homocysteine levels  
Pathological factors   Main finding Reference 
Deficiency of vitamin B6, B12, folate  Hyperhomocysteinemia  (Samuels, 2003) 
supplementation of vitamin B6, B12, folate decrease homocysteine level in plasma (Samuels, 2003) 
daily requirement of vitamin B12 (0.5 mg) optimize homocysteine level in plasma (Clarke, 1998) 
daily requirement of vitamin B6 (16.5 mg) optimize homocysteine level in plasma (Malinow et al, 1999). 
daily requirement of folate (0.5 -5.0 mg) optimize homocysteine level in plasma (Malinow et al, 1999). 
intake of vitamins B6, B12, folate 30% reduced in  homocysteine levels in 
patients with recurrent venous thrombosis 
(den Heijer et al., 1998) 
vitamins B6, B12 and Folate Reduced homocysteine levels (Marcucci et al., 2005). 
renal disease Hyperhomocysteinemia (Wilcken & Guptar., 1979) 
85%-100% of end-stage renal disease(ESRD)  Hyperhomocysteinemia (Robinson et al., 1996) 
chronic renal failure High concentration of homocysteine  (Kang et al., 2002). 
 
Table1.5: association between life style, homocysteine and different vitamins levels  
Life style  Main finding Reference 
coffee consumption increased homocysteine levels in blood (Hainaut et al., 2002) 
alcohol consumption increased homocysteine levels in blood (Carvo and Camilo, 2000) 
smoking increased homocysteine levels in blood (O'Callaghan et al., 2002) 
alcohol abuse severe hyperhomocysteinemia (Carmel and James, 2002) 
moderate consumption of red wine Increase serum homocysteine levels (Van der Gaag et al., 2000) 
moderate consumption of beer No change in homocysteine levels (Van der Gaag et al., 2000) 
alcohol administration in Rats reduction in the methionine synthetase activity (Barak et al., 2002). 
80% of alcoholic liver disease Folic acid deficiency (Halsted et al., 2002). 
alcholics High levels of homocysteine / brain shrinkage (Bleich et al., 2003). 
caffeine (methyl xanthine) act as vitamin B6 antagonist  (Urgert et al., 2000) 
daily coffee consumption increases homocysteine concentration   Urgert et al., 2000 
polyphenol in coffee and Black tea raises total homocysteine concentrations  (Olthef et al., 2001). 
Smoking hyperhomocysteinemia and increased risk of 
vascular disease and  
(O'Callaghan et al., 2002) 
the smokers cardiovascular disease increased 12-fold with 
plasma homocysteine levels above 12 µmol/l 
(O'Callaghan et al., 2002)  
current smokers low levels of vitamins (B6, B12 and folic acid) (O'Callaghan et al., 2002)  
Smokers  positive association between elevated levels of 
plasma homocysteine and cardiovascular 
(Wilcken et al., 2002) 
in smokers low levels of folate/ higher levels of 
homocysteine  
(Christensen et al., 1999). 
 
1.7.6. Homocysteine and vasculers and heart diseases 
1.7.6.1. Pathogenic effect of homocysteine      
Although hyperhomocysteinemia was linked clinically to atherosclerosis, the mechanism of 
pathology induced by homocysteine on blood vessels is unclear. Several mechanisms were 
suggested to elucidate the pathogenic effects of homocysteine and these include;  
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(1) Homocysteine causes endothelial dysfunction and damage: the endothelium plays an 
active role in regulating blood flow, coagulation reactions, platelet activation, leukocyte 
adhesion and vascular muscle function. These effects are mediated by a variety of endothelial 
cell molecules, which include nitric oxide, prostacyclin, plasminogen activator and 
thrombomodulin. Impaired endothelial function was observed in experimental models of 
hyperhomocysteinemia and also in humans with acute hyperhomocysteinemia induced by 
oral methionine loading. The development of endothelial dysfunction in 
hyperhomocysteinemic animals was found to correlate with the degree of elevation of plasma 
homocysteine suggesting that the homocysteine is responsible for endothelial dysfunction 
(Lentz, 2005). (2) Acceleration of thrombin formation (Rodgers and Kane, 1986) by 
increasing the activity of the coagulation factors XII and V (Matthias et al., 1996), this is in 
addition to the reducing activity of Protein C and thrombomodulin (Thambyrajah and 
Townend, 2000). Hyperhomocysteinemia may also predispose to thrombosis via upregulation 
of tissue factor on endothelium or monocytes or hyperactivation of platelets (Lentz, 2005), (3) 
Induction of vascular smooth muscle proliferation (Upchurch et al., 1997), (4) Migration of 
monocytes (Upchurch et al., 1997), (5) Increase of lipid peroxidation and oxidized low-
density lipoprotein cholesterol (Thambyrajah and Townend, 2000) and (6) Inhibit 
thrombolysis by decreasing the effectiveness of tissue plasminogen activator (tPA) (Nappo  et 
al., 1999). 
1.7.6.2. Coronary Heart Disease    
Elevation of plasma homocysteine in cardiovascular disease in humans was reported from 
Australia in 1976 (Wilcken and Wilcken 1976). In that study, methionine metabolism was 
studied in 25 patients and 22 control subjects. Results suggested reduced ability to metabolize 
homocysteine in some patients with coronary artery disease (CAD). Nine years later, two 
studies investigated homocysteine metabolism in patients with CAD. The first study found 
that men with abnormal methionine intolerance had 7-fold increased risk for CAD (Murphy-
Chutorian et al., 1985). In the second study, the authors measured total plasma homocysteine 
levels in patients with CAD and in controls. The study showed a plasma homocysteine level 
of 5.41±1.62 nmol/ml in male patients, 4.37±1.09 nmol/ml in male healthy controls, 5.66±1.9 
nmol/ml in female patients with CAD and 4.16 ± 1.62 nmol/ml in female healthy controls 
(Kang et al., 1986). During the 1990’s several studies were performed on the role of 
homocysteine in CAD. Clarke et al detected hyperhomocysteinemia in 30% of coronary 
vascular disease patients, and they showed that hyperhomocysteinemia is an independent risk 
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factor for CAD (Clarke et al., 1991). Genest et al., 1990 found higher homocysteine 
concentrations in patients with premature coronary artery disease than did control subjects, 
and they concluded that elevated homocysteine level is an independent risk factor for 
development of early CAD in men. Similar findings were reported by Finish (Sadeghian et 
al., 2006) and Japanese research groups (Ogawa et al., 2003). Graham et al. showed that 
elevated homocysteine level is an independent risk of vascular disease similar to smoking or 
hyperlipidaemia (Graham et al., 1997). In addition to the elevated homocysteine levels, low 
levels of folic acid were identified as risk factors for myocardial infarction (Christensen et al., 
1999).  A limited number of studies on homocysteine came from the Arab world. A study 
from Syria showed that 61% of patients with CAD and 44% of controls were 
hyperhomocysteinemic (Hermann et al., 2003). Similar data was reported from an Egyptian 
population (El-Sammak et al., 2004). In addition to the above, large-sized studies from the 
US, Norway, France and UK investigated the association between elevated levels of plasma 
homocysteine and CAD. The US study concluded that moderately elevated levels of plasma 
homocysteine are associated with future risk of and myocardial infarction (MI), independent 
of other risk factors (Stampfer et al., 1992), while the study from Norway concluded that 
serum homocysteine is an independent risk factor for CAD in the general population 
(Arnesen et al., 1995). On the other hand, the British study showed that elevated serum 
homocysteine levels independently predict the risk for development of CAD in adults (Vasan 
et al., 2003), while the study from France concluded that elevated levels of homocysteine in 
healthy postmenipausal women increased the risk of future cardiac diseases (Ridker et al., 
1999).  Boushey et al (1995) performed a meta-analysis of 27 studies relating homocysteine 
to arteriosclerotic vascular disease. The conclusion of the meta-analysis   was that elevated 
homocysteine levels were independent risk factors for arteriosclerotic vascular diseases. In 
addition the study also showed that high folic acid intake (200µg/d) was associated reduction 
in homocysteine levels and higher folic acid intake (that reduces homocysteine levels) can 
play a role in preventing development of arteriosclerotic vascular disease (Boushey et al., 
1995). In Sudanese adults, homocysteine levels were higher with statistical signficance in 
patients with coronary heart disease (17.64; SD 11.68) and  also, in children with protein-
energy malnutrition (8.41; SD 1.61), as well as higher with statistical signficance in patients 
with recurrent venous thrombosis (5.06; SD 10.55) and recurrent malaria (13.61; SD 4.82) 
(Abdel, et al., 2009). 
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1.7.7. Homocysteine and T2DM and its complication 
Meigs et al. (2001) reported that there might be a link between increase levels of 
homocysteine and insulin resistance (Meigs et al., 2001). Abu-Amero et al. (2003) found that 
homocysteine levels are increased in patients with the T2DM and metabolic syndrome (Abu-
Amero et al., 2003). In addition, in vitro studies observed that insulin receptor tyrosine kinase 
activity, phosphorylation of phosphatidylinositol 3-kinase (PI3K) and glycogen synthase 
kinase-3 (GSK-3) are inhibited by homocysteine thiolactone in rat HTC-IR hepatoma cells 
(Najib & Sanchez-Margalet, 2005), which in turn leads to inhibition of the glycogen synthase 
enzyme (Liu et al., 2011). It has been shown that increase in the expression of 
phosphoenolpyruvate carboxykinase (PEPCK) gene and glucose output from the liver are 
associated with elevated levels of homocysteine (Yu et al., 2009).  Hoogeveen et al. (1998) 
found that hyperhomocysteinemia as a risk factor for cardiovascular disease in patients with 
T2DM but not in non-diabetic subjects (Hoogeveen et al., 1998). A 5 years follow-up study 
reported that hyperhomocysteinemia is an independent major risk factor for mortality in 
patients with  both cardiovascular and T2DM (Hoogeveen et al., 1998). Hyperglycemia of 
diabetes was shown to be associated with long-term damage, dysfunction of the various 
organs includes eyes, kidneys, and artery, (Shera et al., 2007). Diabetic retinopathy (DR) is 
one of the main complications of diabetes mellitus. Although several studies didn’t report any 
association between hyperhomocysteinemia and diabetic retinopathy, recent studies showed a 
strong association between them (Satyanarayana et al., 2011). A possible association between 
vitamin B12 deficiency and hyperhomocysteinemia in DR was suggested (Satyanarayana et 
al., 2011). Homocysteine was significantly elevated in diabetic nephropathy more than 
normoalbuminuric patients or control (Mtiraoui et al., 2007). Friedman et al. showed no 
association between the proteinuria and increased level of homocysteine in patients with type 
2 diabetic nephropathy (Friedman et al., 2002). In general, elevated homocysteine level can 
be contributed in the pathogenesis of several diseases; these include stroke, diabetes and its 
complications, cardiovascular disease CVD, coronary heart diseases CHD and ischemic heart 
disease (IHD) (Klerk et al., 2002).  
1.7.8. Genetic mutations in MTHFR gene and T2DM and its 
complication 
MTHFR is an important enzyme in methyl cycle and it catalyzes the conversion of 5, 10 
methyltetrahydrofolate into 5-methyltetrahydrofolate which participates in the vitamin-B12-
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dependent-remethylation of homocysteine to methionine (Strain et al., 2004). The MTHFR 
gene was found in the chromosome 1 (Goyette et al., 1995). Suppression of the enzyme 
MTHFR activity was attributed to either presence of a genetic defect, in the gene encoding 
MTHFR enzyme, or deficiencies of the enzyme itself, which leads to increase level of 
homocysteine in the blood (Kluijtmans et al., 1996). The activity of enzyme MTHFR was 
shown to be affected by presence of two genetic polymorphism,  C677T and A1298 C, in 
MTHFR gene (Castro et al., 2003). The most common MTHFR is a C to T transition at 
nucleotide 677 resulting in an alanine to valine substitution with 50% less activity (Engbersen 
et al., 1995). The A 1298 C MTHFR variant is an A to C transversion at nucleotide 1298  
resulting in a glutamate to alanine substitution, and the enzyme activity is decreased to 40% 
of the wild type enzyme (Weisberg et al, 1998).  Increased plasma homocysteine levels in 
human have been associated with the presence of a common C677T mutation in the MTHFR 
gene, which reduced MTHFR activity (Frost et al, 1995).   
There is a difference in frequency of the two mutations in the MTHFR gene (C677T and 
A1298C) among different geographical regions and ethnic populations (Esfahani et al., 2003; 
Yang et al., 2016). The prevalence of the C677T mutation polymorphism in the European 
populations from Norway, Ireland, Britain and Italy are was 22%, 32%, 37%, and 44%, 
respectively (Botto and Yang, 2000), while it ranged between 34% to 37% among whites 
from Australia, Brazil, Canada, and the United States (Botto & Yang., 2000). The prevalence 
of this polymorphism in other ethnic groups was 78%, 45.2%, 25.6%, and 44.4% in Mexicans, 
Hungarians, Thais, and Greek-Cypriots, respectively (Abu-Amero et al., 2003). The 
prevalence of the C677T polymorphism is higher in Japan (34%) compared with other Asian 
countries (Botto & Yang., 2000).  The frequency is 9% in two studies from Canada 
(Weisberg et al, 1998) and the Netherlands   (Van der Put et al., 1998).  Falik-Zaccai et al  
mentioned that the prevalence of CVD among the Muslim Circassians, which they have been 
lived in Israel, were not related to the mutation C677T MTHFR gene or mutations in 
prothrombin gene and factor V gene (Falik-Zaccai et al., 2003). Among healthy Blood donor 
group tested for C677T variant, the heterozygous C677T   prevalence was 25.8%, comparable 
to the prevalence rates observed in other ethnic groups (Abu-Amero et al, 2003). The genetic 
polymorphisms of the MTHFR gene, C677T and A1298C, were associated with reduced 
enzyme activity, decrease production of active folate and consequently elevate the blood 
levels of homocysteine (Weisberg et al, 1998).   
Increased levels of plasma homocysteine have been considered as an independent factor of 
CVD (Refsum et al., 1998). In spite of the elevated level of homocysteine has been 
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associated with atherosclerosis, but there is no clear mechanism to explain this association. 
However, there are several suggestions to elucidate homocysteine causes pathology in blood 
vessels. Lentz reported that homocysteine is an independent factor that causes damage and 
dysfunction in endothelial cells of the blood vessels. The blood flow, platelet activation, 
coagulation reactions and vascular muscle function are regulated by the endothelium. So any 
defect in the endothelium can lead to atherosclerosis. Experimental models demonstrated how 
homocysteine causes impairment in the endothelial cells after oral methionine loading given 
to animals. It was found that there is a correlation between  development of endothelial 
dysfunction and the degree of elevation of plasma total homocysteine in these animals (Lentz, 
2005),  Others reported that homocysteine decreases the concentration of HDL-cholesterol in 
plasma by suppressing the hepatic production of apoA1, the main apoprotein in HDL (Barter 
and Rye., 2006). Several studies have investigated the association between folic acid 
supplementation and cardiovascular disease. Li et al mentioned that folic acid 
supplementation may be effective for CVD prevention in patients with kidney disease, 
particularly in patients with end-stage renal disease (ESRD) or Advances in Chronic Kidney 
Disease (ACKD). In addition, they found that folic acid supplementation led to reduced (10%) 
risk of stroke, 4% lower risk of overall Cardiovascular disease (CVD) (Qin et al., 2013; Li, et 
al., 2016 & Zeng, et al., 2014). In this meta-analysis study, MTHFR 1298C allele was 
considered a risk factor for coronary heart disease (CHD), but the authors suggested  that 
further studies are needed to investigate the correlation of plasma homocysteine levels, 
enzyme activity, and folic acid supplementation with the risk of CHD (Yu, et al., 2017).  
To our knowledge, a few studies have been conducted in Africa and no reports are available 
on the prevalence of the C677T and A1298C MTHFR gene polymorphisms among Sudanese. 
1.7.9. Homocysteine and resistin 
Homocysteine is an amino acid (containing sulphur) which is formed during methionine 
metabolism. Elevated levels of homocysteine were proposed as a risk factor for coronary 
artery disease (Clarke et al., 1991). It is a potent proinflammatory factor that was shown to 
promote inflammation in both in vitro and in vivo models (Wang et al., 2000 and Wang et al., 
2002). Studies showed that elevated homocysteine can be associated with insulin resistance 
(Meigs et al., 2001 and Oron-Herman et al., 2003), this is in addition to an association 
between homocyteine and insulin levels in healthy subjects as well as in diabetic and obese 
subjects (Fonseca et al., 2003; Emoto et al., 2001 and Masaki et al., 2007). In in vitro models, 
homocysteine thiolactone was shown to induce oxidative stress that can lead to impaired 
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insulin signalling (Najib and Sanchez-Margalet, 2001; Najib and Sanchez-Margalet , 2005). 
However, whether Hcy can promote insulin resistance by directly regulating the expression 
and secretion of resistin— one of the adipokines that may link inflammation and obesity to 
insulin resistance. In a study using a murine model, homocysteine was shown to induce 
resistin expression in cultured adipocytes and to impair glucose transport (Steppan et al., 
2001). In obese children, they found that Resistin might be an independent factor contributing 
to cardiovascular disease (Codoñer-Franch, et al., 2014).  Esbah et al suggested that smoking 
might contribute to the elevated levels of resistin levels, and resistin led to insulin resistance 
in smokers. While, the BMI has no role in resistin levels in smokers or non-smokers and 
resistin. In addition, Resistin might not have a role in C-reactive protein, homocysteine and 
uric acid levels both in smokers and non-smokers (Esbah, et al., 2011). 
1.8. Vitamin D  
1.8.1. Vitamin D forms and sources 
Vitamin D is a generic term that includes more than one type that includes vitamin D3 and 
vitamin D2.  Vitamin D3 (cholecalciferol), the main type of Vitamin D, is derived from 7-
dehydrocholesterol after exposure to ultraviolet light (Lips, 2006; Fig1.14). 
The formation of vitamin D3 is affected by many factors among them is skin pigmentation 
(webb et al., 1989), clothing, sunscreen and UV intensity (Holick, 1995). In addition to 
sunlight, Vitamin D3 can be obtained from food items which include: fish or their liver oils, 
milk, egg yolk and other sources (Mathieu et al., 2005). On the other hand, Vitamin D2 
(ergocalciferol) is obtained from plant sources (plants and plant materials) (Galea and 
Blundell, 2011; Fig1.14). Only 30% of vitamin D is obtained from the diet while the majority 
is obtained via the skin after exposed it to the U V- sun light. Chemically, Vitamin D2 differ 
from vitamin D3 in having a double bond between C22 and C23 in addition to a CH3 in C24 
(Bikle, 2014). These differences are responsible for decreased affinity of Vitamin D2 for 
vitamin D binding protein (Galea and Blundell, 2011), increased clearance from the blood, 




Fig 1.14 Forms of vitamin 
 
1.8.2. Biological functions of Vitamin D and its Metabolism  
The main role of vitamin D is to facilitate the absorption of calcium and phosphate from the 
gut and increases calcium reabsorption by the kidney (Deluca and Cantorna, 2001). 
Accordingly, the main function of vitamin D is to keep plasma calcium and phosphate within 
normal levels and bone mineralization (Zittermann, 2003).  
For Vitamin D3 to get activated to 1, 25 (OH) 2 D3 (the active form) two hydroxylation steps 
are needed. In the liver, the initial hydroxylation takes place at carbon number 25 in vitamin 
D3 to produce 25-(OH) vitamin D3 (catalysed by 25-hydroxylase (CYP27A1) enzyme). 
Subsequently 25-(OH) D3 is transported to the proximal tubules in the kidney where a 2nd  
hydroxylation takes place at 1-carbon on 25-(OH) D3 to produce the active form (1, 25-
(OH)2 vitamin D3) (1,25-(OH)2D3) (catalysed by 1-hydroxylase enzyme (CYP27B1) 
(Passeri et al., 2008). Vitamin D2 is metabolized in the same manner. Several factors are 
involved in regulating the levels of the active vitamin D3 (1, 25 (OH) 2D3), including 
parathyroid hormone and directly via negative feedback inhibition. 1, 25(OH) 2D3 and 25-
vitamin D3 are degraded by the mitochondrial enzyme, 24-hydroxylase or CYP24A1, which 
is also involved in regulation of the levels of 1, 25(OH) 2D3 and 25-vitamin D3 (Tanaka et 
al., 1977). For the active form of vitamin D to do its biological function it has to bind to 
vitamin D receptor (VDR). Upon binding and signalling, this result in activation of more than 
200 genes, among them are genes for proteins involved in facilitating absorption of calcium 
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and phosphate from the intestine to blood circulation (Bronner and  Pansu, 1999; Deluca and 
Cantorna, 2001; Fig 1.15 ). 
The extra-renal production of the active form of vitamin D (1, 25 dihydroxyvitamin D) seems 
important for paracrine regulation of cell differentiation and function (Peterlik and Cross, 
2005). Vitamin D deficiency plays an important role in the pathogenesis of autoimmune 
disease and exposure of children aged 6-15 to sunlight prevents them from developing 
multiple sclerosis. Chiu et al, 2004 found that vitamin D affects the function of  
β-cells of the pancrease and serum 25(OH) D were positively associated with insulin 
sensitivity to the target tissues (Chiu et al., 2004; Fig 1.15).  
 
Fig 1.15 Sources and action of the active form of vitamin D 
Sources of vitamin D3 (ultraviolet light UV and diet), transported in the circulation (by vitamin D 
binding protein DBP), formation of 25-hydroxyvitamin D3 in the liver (activated by 25-hydroxylase), 
formation of the active form of vitamin D (1,25 dihydroxyvitamin D3) in kidney (activated by 1-
hydroxylase), metabolic activation form have , classical role (increasing calcium and phosphate level 
in plasma)   and non-classical role of vitamin D3 (molecular action of the activeform). The diagram is 
reproduced from Hewison et al. (2004). 
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1.8.3.  Vitamin D, β-cell function and T2DM 
Vitamin D deficiency is a global problem, affecting more than one million people worldwide 
(Cavalier et al., 2011). Vitamin D Receptor (VDR) was shown to be expressed on β-cells of 
the pancreas, and a role for vitamin D in insulin secretion was suggested (Johnson et al., 
1994). Several in vivo (in animal models) and in vitro studies showed that vitamin D is 
essential for normal insulin release and for glucose Homeostasis. Furthermore, Vitamin D 
deficiency was shown to contribute to impairment in glucose homeostasis and decreased 
insulin secretion (Nyomba et al., 1984; Alvarez and Ashraf, 2010); Norman et al., 1980).  
A link between deficiency of vitamin D and type 1 Diabetes (T1D) was extensively studied 
(Mathieu et al., 2005). Helper T (Th) 1 cell (Th1) secrete many cytokines includes, 
interferon-γ (IFN-γ), interleukin-2 (IL-2), and tumour necrosis factor-α. These cytokines 
participate in cell-mediated immune responses including host responses to tumors and 
intracellular pathogens (such as viruses). In autoimmune diseases, Th1 cells play an 
important role in pathogenesis of autoimmune diseases, like multiple sclerosis and T1DM 
(Cantorna and Mahon, 2004). It was found that vitamin D is involved in downregulating Th1 
responses and suppressing the antigen-presenting capacity of macrophages (Lips, 2006). It 
was suggested that vitamin D supplementation can play an important role in preventing type 
1 diabetes (Stene et al., 2000; Gregori et al., 2002; Mathieu et al., 2005). On the other hand, 
subgroup analysis revealed that the effects of vitamin D supplementation on different 
glycemic measures were influenced by age, calcium coadministration, vitamin D deficiency, 
serum 25(OH)D level after supplementation, and duration of supplementation. Vitamin D 
supplementation and improved vitamin D status improved glycemic measures and insulin 
sensitivity and may be useful as part of a preventive strategy for T2DM. (Mirhosseini, et al., 
2018). Insulin secretion was shown to be decreased as a result of deficiency of vitamin D, and 
vitamin D supplementation could improve β-cell function and glucose tolerance (Boucher et 
al., 1995). In addition, it was shown that vitamin D deficiency was associated with increased 
risk of T2DM and supplementation of vitamin D and calcium might have a beneficial effect 
in preventing T2DM (Pittas et al., 2007A). Vitamin D might affect glucose metabolism in 
two ways: either directly by increasing insulin receptor expression therefore stimulating 
insulin response to glucose (Boucher et al., 1995), or indirectly by affecting calcium influx to 
ensure adequate calcium amount in the cell cytoplasm. In the tissues that expresses insulin 
receptors (skeletal muscles and adipose tissues) Ca+2 acts as a 2nd messenger for the insulin 
signal inside the cell (Pittas et al., 2007B).  
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It is generally believed that T2DM is associated with systemic inflammation which might 
play a role in insulin resistance (Hu et al., 2004). It was suggested also that elevated levels of 
cytokines might have a role in the β-cell dysfunction by enhancing beta cell apoptosis. 
Vitamin D might have a fundamental role in improving insulin sensitivity to its receptor and 
enhance β-cell survival (Pittas, 2007A). Kedari and Hareesh (2014) have reported that there 
is substantial evidence to indicate that deficiency of vitamin D is associated with progression 
of T2DM and also, they suggested that there was an inverse association between blood 
glucose and insulin resistance and Vitamin D levels. Furthermore, it found that genetic 
polymorphism (allelic variations) in the vitamin D receptor (VDR) and Vitamin D-binding 
protein (DBP) might influence insulin secretion and glucose homeostasis (Ortlepp et al., 
2003), and therefore participating to genetic risk for T2DM. Accordingly, a possible role for 
vitamin D in regulation of insulin receptor gene expression and insulin secretion was 
suggested. In addition, a fundamental role for VDR in the pathogenesis and development of 
T2DM was also suggested. In beta cells, genetic polymorphisms in a VDR gene inhibit its 
association with an active form of vitamin D, leading to the decrease in insulin secretion and 
subsequent T2DM (Ortlepp et al., 2003). 
1.8.4. Vitamin D receptor gene and type 2 diabetes Mellitus 
Measurement of the vitamin D levels and its relation to T2DM development does not give a 
complete picture of vitamin D and its role in diseases. Sometimes individuals with normal or 
high levels of vitamin D may have suboptimal biological functions associated with vitamin D. 
Metabolising enzymes are needed for the formation of the biologically active form of vitamin 
D which binds with vitamin D receptor (VDR). Any defective of the metabolising enzymes 
might lead to failure of the body to produce the active form of the vitamin D. Furthermore, 
even when the active form of the vitamin D is produced normally, if there is a defect in the 
vitamin D receptor, the active form cannot bind with the receptor, thus leading to failure of 
function (DeLuca, 2004) as shown in Fig 1.16. 
McCullough et al observed that the VDR gene have several allelic variations (McCullough et 
al., 2007). Several polymorphisms in VDR gene were found to be associated with diabetes 
mellitus (Györffy et al., 2002; Hitman et al., 1998). Mayer et al (2018) found that decreased 
vitamin D levels were associated with reduction of insulin sensitivity, especially in those with 
GG genotype of rs2228570 VDR (Mayer et al., 2018).  Among VDR polymorphisms which 
are shown to be associated with diabetes are rs1544410 (BsmI), rs10735810 (Fok1).rs731236 
(TaqI) and rs7975232 (ApaI). The single nucleotide polymorphisms (SNP) for Taq1 and 
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Bsml were T 65058 C and G 63980 A, respectively. Several studies showed associations 
between the two polymorphisms rs731236 and rs7975232 of VDR gene and elevated  levels 
of fasting blood glucose (Li et al., 2013), while others found no associations (Ye et al., 2001; 
Malecki et al., 2003; Cyganek et al., 2006).  
1.8.5. Vitamin D and resistin 
Vitamin D deficiency has been shown to contribute to the development of T2DM (Bland et 
al., 2004). Vitamin D may have similar fuction to resistin on insulin secretion, insulin action 
or both (van Etten, 2005), and also it was shown that viamin D inhibits production of several 
cytokines in in vitro studies (Khoo et al., 2011). Furthermore, vitamin D was shown to be 
protective against several diseases like cancer and cardiovascular disease and autoimmune 
disease (Dusso et al., 2005). The role of vitamin D deficiency in insulin resistance and the 
use of vitamin D in treatment of hyperglycaemia are still unclear. Resistin was shown to be a 
link between insulin resistances with obesity. Additionally, several studies reported a positive 
association between resisitin levels and pro-inflammation cytokines in diabetes (Osawa et al., 
2005). Vilarrasa et al reported no association between the levels of vitamin D and resistin. 
However, the findings showed a negative association between vitamin D and BMI waist and 





Fig 1.16 The role of vitamin D in the regulation of blood glucose and on β- Islet cells.   
The active form of vitamin D (1, 25(OH) vitamin D) binds with VDR to activate several genes among 
them insulin gene which it led to increase insulin synthesis. The vitamin D regulates intracellular 
calcium levels by increasing ATP/ADP ratio, which in turn leads to insulin secretion and glucose 
tolerance. Insulin receptors and signalling transduction were produced after vitamin D activated to 
these genes, resulting translocation of GLUT4 to the membrane and glucose transport in peripheral 
tissues.  
1.9. Rationale for the study 
The role of homocysteine, resistin and vitamin D in type 2 diabetes mellitus (T2DM) has 
been studied in different populations and ethnic groups in Asia and Europe but limited 
numbers of studies have been conducted in African populations. To our knowledge, there is 
no reported study that has investigated the possible association of resistin, homocysteine and 
vitamin D with T2DM in Sudanese population. In addition, previous studies that have 
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investigated the role of vitamin D in T2DM were performed in populations from non-
equatorial/tropical regions where sunlight exposure is seasonally variable and/or less intense. 
Thus, studying a Sudanese population, where sunlight intensity is less variable and more 
intense, provides the possibility of gaining a deeper insight into the role of vitamin D in the 
development of T2DM.  The purpose of this study was to investigate the possible 
associations between levels of resistin and homocysteine, and levels of vitamin D with T2DM 
and in a representative population from Sudan. 
1.10. General objectives  
The primary aim of the current study is to investigate the association between levels 
homocysteine, resistin and vitamin D and T2DM in Sudanese study population. In addition, 
their associations with several demographic, clinical and metabolic parameters will be 
investigated. 
1.11. Specific Objectives 
a. To compare plasma levels of vitamin D (D2/D3), resistin and homocysteine levels 
between patients with T2DM and their healthy controls.   
b. To investigate possible associations between resistin, Vitamin D and 
homocysteine levels with demographic, clinical and metabolic variables in female 
patients with T2DM compared to male patients with T2DM. 
c. To compare plasma resistin and homocysteine levels between female and male 
patients with T2DM.  
d. To compare plasma resistin levels between obese and non-obese subjects. 
e. To investigate possible association between homocysteine, vitamin D levels and 
resistin in patients with T2DM. 
f. To compare the prevalence of the MTHFR gene polymorphisms (C677T and 
A1298C) among patients with T2DM and their healthy controls.  
g. To investigate possible associations between genetic polymorphisms of MTHFR 
gene (MTHFR C677T and A1298C) and plasma levels of homocysteine in 
patients with T2DM. 
h. To investigate possible association between vitamin D receptor (VDR) gene 





2. Materials & Methods 
2.1. Study design and population 
A case-control hospital-based study was conducted with a study population of 395 Sudanese 
individuals: 200 patients with type 2 diabetes (T2DM) and 195 healthy controls. Ethical 
approval was obtained for the study from the Health Ministry in Khartoum (Sudan) and 
Middlesex University (UK).  Written consent was obtained from each participant. The 
identities of the participants were anonymised. Confidentiality of each subject was assured by 
the research team members, and personal information of the participants was not shared with 
other parties. 
2.1.1. Patient group 
The patients had been previously diagnosed with type 2 diabetes (T2DM) and underwent 
regular follow-up at the diabetes clinic at the Military Hospital in Omdurman, Sudan. 
Although they all live in Omdurman, they belong to different tribes in Sudan. They were 
consecutively recruited from the diabetes clinic between September 2013 and December 
2014.  The patient group consisted of 200 participants (71 males and 129 females). Their age 
ranged between 37 and 70 years with a mean age of 52.3 ± 7.3 years and their mean of BMI 
was 27.2 ± 2.5 Kg/m2. Patients with type 1 diabetes and those who did not give consent to 
participate in the study were excluded. 
2.1.2. Control group    
The participants in the control group were selected after confirmation they were not diabetic, 
are not known patients with chronic illness (especially heart and kidneys problems) with no 
family history of diabetes and all of them live in Omdurman, Sudan. The control group 
consisted of 195 individuals (130 males and 65 females). Their age ranged between 19 years 
and 82 years with a mean of 42.7 ± 14.4 years and their mean of BMI was 25.6 ± 3.9 Kg/m2.  
2.2. Blood sample collection, storage and plasma separation 
Following 8-12 hours of fasting, blood samples of 3 ~ 4 ml were collected from the study 
population by venepuncture using disposable plastic syringes. Blood samples were dispensed 
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into tubes containing EDTA, heparin and fluoride oxalate, followed by separation of the 
plasma by centrifugation at 3000 x g for 10 minutes at room temperature. HbA1c was 
measured in whole blood, and part of the plasma was used to measure blood glucose, lipid 
profiles, urea and creatinine. For the analysis of resistin, homocysteine and vitamin D, part of 
the plasma was stored at -20 OC and later shipped from Sudan in a box containing dry ice to a 
laboratory at Middlesex University (UK). 
2.3. Clinical history, base line parameters, anthropometric, and 
drug history    
Baseline data recorded for the study participants included baseline parameters (Age, sex, 
Body Mass Index (BMI), Waist Circumference (W),  Fasting Blood Glucose (FBG), 2-hour 
blood glucose (2hBG), Glycated Hemoglobin (HbA1c), cholesterol (CHOL), Triacylglycerol 
(TAG) , Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Systolic Blood 
Pressure (SBP), Diastolic Blood Pressure(DBP) and anthropometric measurements (Body 
Weight and Height) and (BMI) (calculated as weight (kg) divided by height (m2)). Subjects 
were regarded as normal, obese or overweight based on their BMI. Normal weight 
individuals have BMI between 18.5-24.9 (Kg/m2), Obese have BMI > 30 (Kg/m2) and 
overweight having a BMI ranging between 25-29.99 (Kg/m2) (Flegal et al., 2002: Read et al., 
2017). Data on medications were also collected including anti-diabetes drugs, Vitamin D, 
Folate, B12, Statins and Niacin. The data sheet used to collect the data is as in Appendix 
1.       
2.4. Study criteria and diabetes diagnosis 
The diagnosis of diabetes was based on the definition of the American Diabetes Association 
and World Health Organization (WHO) (ADA, 2009; WHO, 1985). A doctor with special 
expertise in Diabetes was recruited during the sample collection period. An individual is 
considered to be diabetic when fasting blood sugar (FBG) level is ≥ 7.0 mmol/l (126 mg/dl) 
or had an oral glucose tolerance test (OGTT) samples taken within two hours of consuming 
75g oral glucose dose) results of  ≥ 11.1 mmol/l (200 mg/dl). In addition, HbA1c level ≥ 48 
mmol/mol (≥ 6.5 %) is indicative of T2DM. Patients with type 1 diabetes and other types of 
diabetes were excluded from this study. 
52 
 
2.5. Quantification of resistin using sandwich ELISA assay     
Manufacturer’s instructions were followed to measure resistin in human plasma by using a 
Quantikine Human-Resistin Immunoassay (R&D system, Abingdon, Oxon, UK, Catalog 
Number SRSN00).  
2.5.1.  Reagents  
 The ELISA Kits were purchased from R&D Systems, Abingdon, UK.  The assay kit contains: 
Resistin polystyrene microplate (96 wells coated with a mouse monoclonal antibody against 
human resistin); Resistin Conjugate (21 ml/vial of monoclonal antibody against Resistin 
Conjugated to horseradish peroxidase with preservatives), Assay diluent RD1-19 (11 ml/vial 
of a buffered protein base with preservatives), Resistin Standard (100 ng/vial of recombinant 
human resistin in a buffered protein base with preservatives; lyophilized), Calibrator Diluent 
RD5K (21 ml/vial of a buffered protein base with preservatives), Wash buffer concentrate (21 
ml/vial of a 25-fold concentrated solution of buffered surfactant with preservatives), Colour 
Reagent A (12.5 ml/vial of stabilized hydrogen peroxide), Colour Reagent B (12.5 ml/vial of 
stabilized chromogen (tetramethylbenzidine) and Stop Solution (6 ml/vial of 2 N sulphuric 
acid). All reagents were stored at 2-8OC. Before use, the reagents were left at room 
temperature for a period of half an hour for optimal conditions for the assay as recommended 
by the manufacturer.    
2.5.2.  Protocol for resistin analysis 
Plasma samples were diluted 5-fold by adding 60 µl sample + 240 µl of the Diluent.  
2.5.2.1. Reagent preparation 
Concentrated wash buffer (20 ml) was diluted in 500 ml deionized water to prepare the 
working wash buffer solution. Substrate solution was prepared by mixing equal amounts of 
colour reagents A and B 15 minutes before use. 200 µl of the mixture was used per well. 
Resistin standard was reconstituted with1.0 ml of deionised water to prepare a 100 ng/ml 
stock solution.  The Standard was incubated for 15 minutes and agitated prior to making 
serial dilutions. Seven tubes were prepared to be ready for dilutions. Calibrator Diluent 
RD5K (900 µl) was added into first tube containing resistin standard (100 ng/ml) to prepare a 
10 ng/ml solution. Calibrator Diluent RD5K (500 µl) was added to the rest of the tubes. 
Taking 500µl from the first tube to prepare the next dilution, the following dilution series was 
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prepared: 10, 5, 2.5, 1.25, 0.62, 0.31, and 0.15 ng/ml, each tube was mixed thoroughly before 
the next transfer.   
2.5.2.2. Procedure for the measurement of resistin   
All reagents and samples were brought to room temperature before the start of the experiment. 
The 96 well microplates used were coated with monoclonal antibody specific for human 
resistin. All samples and standards were assayed in duplicates. A volume of 100 µl of assay 
Diluent RD 1-19 was added to each well before adding 100 µl of the standards and samples. 
The standards and samples of participants (patients and healthy individuals; controls) were 
added to separate wells and the 96-well microplates were covered with adhesive strips and 
incubated at room temperature for 2 h. After incubation, each well was washed four times 
with 400 µl wash buffer.  At the final step, the plate was inverted and blotted against clean 
paper towels. Human Resistin conjugate (200 µl) was added to each well and covered by a 
new strip and incubated for 2 hours. After the incubation period, the same procedure in the 
previous step for washing was repeated. Substrate solution (200 µl; mixed in equal amounts 
of reagent A and reagent B) was added to each well and incubated for a further 30 minutes at 
room temperature. Finally, a stop solution (50 µl) was added to each well to stop the reaction 
and the colour changed from blue to yellow in all the wells. 
2.5.2.3.  Data analysis of the resistin results  
Plasma samples for patients, controls and standards were tested in duplicate. The 
concentration of human resistin in each sample was calculated from the standard curve. 
additional informations are shown in appendix 2.  
2.6. Measurement of Homocysteine using competitive EIA 
 Homocysteine concentrations in plasma were measured using Axis Homocysteine Enzyme 
immunoassay (EIA) (Axis-shield Diagnostics Ltd, Dundee, UK, Catalog Number FHC Y100). 
The experiment was carried out according to manufacturer’s instructions.    
2.6.1.  Reagents  
The homocysteine EIA Kits contained the following reagents: 
Reagent A (assay buffer 45ml), Reagent B (adenosine/DTT 3.5ml), Reagent C ( SAH 
hydrolase), Reagent D ( Enzyme inhibitor 3.5ml), Reagent E ( Adenosine deaminase 55ml), 
Reagent F (a-SAH antibody 25ml), Reagent G (enzyme conjugate 15ml), Reagent H 
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(substrate solution15ml), Reagent S (stop solution 20ml), washing buffer ( phosphate buffer, 
merthiolate,  Tween 20 ,  and  BSA  60ml), CAL1-CAL  (calibrators, S-adenosyl-
L.homocysteine (2, 4, 8, 15, 30, 50 µmol/l) in buffer with preservative 6x1.5ml) and 
microtitre strips (coated with S-adenosyl-L.homocysteine 12x8 wells). Controls were 
provided in a separate kit containing control L, (7.0 µmol/l L.homocysteine in diluted serum 
samples of human origin and phosphate buffer); control M (12.5 µmol/l L.homocysteine in 
diluted serum samples of human origin and phosphate buffer);  control H (25.0 µmol/l  
L.homocysteine in diluted serum samples of human origin and phosphate buffer).   
2.6.2.  Principle of the homocysteine measurement   
The level of total homocysteine in the plasma was determined by the EIA using the Axis-
Shield Enzymatic Homocysteine assay. All Homocysteine forms such as that bound with 
protein or dimerised with another homocysteine, were reduced to free homocysteine and 
enzymatically converted to S-adenosyl-L-homocysteine (SAH) in a separate procedure 
(section 2.6.2.1) prior to the immunoassay.  
2.6.2.1. Reduction process in samples and enzymatic conversion  
Dithiothreitol (DTT) was added to the samples for reducing either mixed disulfide bonds 
(homocystine or other thiol compound homocysteine) or protein bound forms and  
S-adenosyl- L-homocysteine was formed from homocysteine (Hcy) after addition SAH 
hydrolase and excess adenosine (Ad) in the test samples.      
Prot-ss-Hcy 
R1-ss-Hcy        DTT                                Hcy          + Adenosine        SAH + H2O 
Hcy-ss-Hcy                                                                        SAH hydrolase 
     Prot: protein  
      R1 is any other thiol-residue  
2.6.2.2. Competition assay for homocysteine 
After reduction and enzymatic conversion, the samples were transferred to wells of an ELISA 
plate for the competition assay. The solid-phase enzyme immunoassay is based on 
competition between SAH in the samples and SAH bound to the walls of the ELISA plate for 
binding sites on a monoclonal anti-SAH antibody (capture). Unbound anti-SAH antibodies 
were washed and secondary rabbit anti-mouse antibody labelled with the enzyme horse 
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radishperoxidase (HRP) was added. The bound HRP activity was measured by the 
absorbance at 450 nm (FLUOstar Omega Microplate Reader (BMG Labtech, Aylesbury, UK) 
after the addition of enzyme substrate and is inversely related to the concentration of total 
homocysteine in the sample. 
2.6.2.3. Preparation of the reagents and storage  
All the kits were stored at 2-8OC before use. All kit components were brought to room 
temperature and left over night before use. The samples, calibrators and controls were run in 
duplicate. Reagents A, B and C were mixed together to form sample pre-treatment solution, 
and this solution was valid for one hour after preparation. The wash buffer was diluted in 
ratio 1: 9 with deionized water before use. The diluted washing buffer was stable for 4 weeks 
when stored at room temperature (18-25OC). Reagents D and H were stored in dark bottles to 
avoid exposure to light. The microtitre plate was kept dry in a sealed bag with drying 
capsules and stored in the refrigerator for at least 2 hours before use.  
2.6.3.  Protocol of homocysteine  
2.6.3.1. Sample pre-treatment procedure  
Reagents A, B and C were mixed together to form sample pre-treatment solution. This 
solution was valid for one hour after preparation. Volumes required per 10 samples (no dead 
volume calculated) are as follows: 4.5 ml from Reagent A, 0.25 ml from Reagent B and 0.25 
ml from Reagent C (Mixing well using vortex).  
Samples, calibrators and controls were diluted in glass tubes as follows: 
Samples, calibrators and controls (25 µl) and sample pre-treatment solution (500 µl) were 
mixed well using vortex and covered by parafilm before incubating for 30 minutes at 37OC.  
Reagent D (500 µl) was added to the tubes (containing samples, calibrators and controls and 
sample pre-treatment solution prepared in the previous steps). The solutions were mixed well 
and incubated for 15 minutes at room temperature, followed by the addition of reagent E (500 
µl) and incubated for a further 5 minutes at room temperature.   
2.6.3.2. Procedure for the measurement of homocysteine 
After the sample pre-treatment was completed, diluted sample/control (25 µl) was added into 
the each well (coated with S-adenosyl-homocysteine), followed by an addition of reagent F 
(200 µl) to all the wells and incubated for 30 minutes at room temperature. The plate was 
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covered (with a lid provide with kits) for the incubation periods (30 minutes), then diluted 
washing buffer (350 µl) was added to each well for washing purposes. Subsequently, reagent 
G (100 µl) was added to each well and incubated for 20 minutes at room temperature. Each 
well was then washed with diluted washing buffer (350 µl) and after this, reagent H (100 µl) 
was added and the plate was incubated for a further 10 minutes at room temperature. Finally, 
reagent S (100 µl) was added and mixed into each well and the plate was read at 450 nm 
within 15 minutes using FLUOstar Omega Microplate Reader (BMG Labtech, Aylesbury, 
UK).   
2.6.3.3.  Data analysis of the homocysteine results 
All samples, controls and calibrators were tested in duplicate. A calibration curve was drawn 
by plotting optical density against the concentration of the standards. The concentration of 
human homocysteine in each test sample was calculated by using the calibration curve. Two 
examples are shown in Appendix 3. 
2.7. MTHFR C677T genotyping using real-time PCR 
2.7.1. Focus 3MTM integrated Cycler 
Genotyping for MTHFR C677T polymorphism was performed using a real-time PCR with 
this instrument extraction of the genetic material (DNA or RNA) from the blood sample was 
not required, and the instrument has the ability to do two processes: real-time PCR 
amplification and fluorescence for detection of target. The instrument has the capability to 
use one of two types of disc for processing the samples and reagents: the Universal Disc and 
Direct Amplification Disc. A fluorescent signal is generated after separation of the 
fluorophore from the quencher as a result of the binding of a probe element to the extended 
DNA fragment synthesized during amplification. The instrument is controlled by an external 
computer running the Integrated Cycler Studio Software. 
2.7.2.  Amplification protocol of MTHFR C677T Direct 
The PCR reactions contained master mix (4 µl), MTHFR C677T wild type primer (0.5µl), 
MTHFR C677T mutant type primer (0.5µl) (Oxford Biosystems Ltd, UK) and PCR grade 
water (3µl) (Life technologies, UK) and whole blood.   
 Blood (2 µl) diluted 1:4 in sterile PBS (30 µl PBS +10 µl whole blood). The 2.5 X Universal 
master Mix contains the enzyme DNA polymerase, buffers, deoxynucleoside triphosphates 
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(dNTP) and Mgcl2. The bifunctional fluorescent probe-primers are used together with the 
reverse primers to amplify the MTHFR gene and the internal control. A fluorophore labels 
was incorporated for the gene targets: wild type (FAM 520) and mutant type (CFR 610).  
The reagents and blood samples were pipetted into the appropriate test wells on the Universal 
Disc (96 wells). Briefly, 8 µl (master mix (4 µl), MTHFR 677 wild type primer (0.5), 
MTHFR 677 mutant type primer (0.5) and PCR grade water (3µl)) were pipetted into each 
test well in the universal disc, followed by added diluted blood sample (2µl) into appropriate 
test well.  Finally, PCR grade water (2µl) was added into last test well instead of a blood 
sample to form the Negative control (NC). 
The disc was covered with the adhesive disc cover and firmly smoothed with a blue plastic 
disc sealer to ensure the cover was secure. After placed the disc in the instrument and started 
running, the approximate run time was 55 minutes. PCR was performed under the following 
conditions: one cycle of 360 second at 97OC with ramp rate 10OC/second followed by 40 
cycles consisting of denaturation at 97OC for 10 seconds at ramp rate 10OC/second, annealing 
at 60OC for 30 seconds at ramp rate 10OC/second and no extend and final cycle were needed 
at all amplification steps.  The emitted fluorescence was measured at the end of the annealing 
phase in each cycle using Focus 3MTM integrated thermal cycler (3M-Focus Diagnostics). See 
Appendix 4 for raw data. 
2.8. MTHFR (A1298C) and VDR (T65058C) genotyping 
2.8.1.  DNA Extraction  
The DNA was extracted from the blood samples by using the PureLinkTM Genomic Mini Kit 
(Invitrogen, UK). 
Reagents required for DNA extraction (Invitrogen, UK): Proteinase K (20 mg/ml), RNase A 
(20 mg/ml, in 50 mM Tris-HCI, pH 8.0,10 mM EDTA), lysis/binding buffer, wash buffers 1 
& 2, elution buffer (10 mM Tris-HCI, pH 9.0, 0.1 mM EDTA), spin columns with collections 
tubes.  Extra material needed included 96-100% ethanol.  
2.8.2. Protocol for DNA Extraction 
To extract genomic DNA from a blood sample, proteinase K (20 µl) was added to the tube 
followed by transfer blood (200 µl) and then RNase (20 µl). The mixture of the reaction tube 
was vortexed and incubated at room temperature for 2 minutes. This was followed by the 
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addition of the lysis/binding buffer (200 µl). After vortexing, the mixture was incubated in a 
water bath (55 OC) for 10 minutes. Before transferring the lysate mix to the spin column, 
absolute ethanol (200 µl) was added. The lysate mix was centrifuged at 10,000 x g for 1 
minute; the spin column was removed from the collection tube and put into a clean collection 
tube. Wash buffer (500 µl) diluted with ethanol (96-100%) were added to the spin column 
and centrifuged at 10,000 x g for 1 minute (repeated twice using buffer 1 and 2).   Finally, the 
elution buffer (50 µl) was added to the spin column and centrifuged at maximum speed 
(16,000 x g) for 1 minute at room temperature. Then the eluted purified DNA was 
quantitatively and qualitatively assessed.  
2.8.3. DNA concentration and purity 
To assess the quantity and quality of DNA in the eluted DNA from each blood sample, a 
Nanodrop spectrophotometry (Thermo scientific, UK) was used. The eluted DNA was mixed 
well first and 1µl was used. Purity (quality) of DNA was obtained by Nanodrop spectrometer 
by measuring the ratio of the absorbance at 260 nm and 280 nm (OD260 /OD280), with an 
ideal range between 1.6 to 2.0. All the DNA extraction gave DNA of acceptable quality and 
none of the samples gave abnormal purity result above range (contaminated with protein) or 
below it (contamination by RNA). 
2.8.4. Genotyping for genetic variants using TaqMan SNP assays 
The TaqMan Single nucleotide polymorphism (SNP) genotyping assays (Applied Systems, 
Foster City California) use TaqMan 5- nuclease chemistry for amplifying and detecting 
specific single nucleotide polymorphisms (SNP) (real-time) in the DNA extracted samples. 
The assays use TaqMan minor grove-binding (MGB) probes for allele discrimination. The 
two allele specific TaqMan MGB probes contain a pair of fluorescent dyes (FAM and VIC) 
and a pair of primers to detect the specific SNP targets. In addition, all MGB probes include a 
quencher (non-fluorescent) that attenuates the background fluorescence.  
Each of the two MGB Probes with report dye at the 5'-end of each probe (FAM dye for the 
wild type allele and VIC dye for the mutant allele; with quenchers at the at the 3'-end) binds 
specifically with the DNA template if it is complementary, according to the base-pairing 
phenomena. During the extension phase of the amplification, the 5'-nuclease activity of the 
Taq polymerase degrades the hydrolysis probe leading to fluorescence. For illustration, 




                          Fig 2.1 Method of genotyping by using TaqMan 
                            the complementary TaqMan probe template and after cleavage  
                            by AmpliTaq DNA polymerase, Ultra Pure (UP).   
2.8.5. Genotyping for the MTHFR gene (rs1801131) and VDR gene 
(rs731236) variants 
TaqMan predesigned SNP genotyping assays (Applied Biosystems, Foster City, California) 
were used to genotype two SNPs; T 65058 C (VDR gene) and A1298 C (MTHRF gene). The 
single nucleotide variation ATT ⇒ ATC is located at exon 9 of the VDR gene at position 
T65058C (rs731236) and is located at exon 9 in and it is a silent mutation. The alleles change 
(variation GAA ⇒ GCA), a result of a SNP in MTHFR gene, is located at exon 7 of the 
MTHRF gene at position A1298C (rs1801131).  
All real-time PCR reactions were performed on 96- well plates on a real time Lightcycler 96 
instrument (Roche, Munich, Germany) and the following reagents were provided by the 
manufacturer: Nuclease free water, 40X TaqMan primer/probe solution (Two primers 
(forward/reverse), two probes (VIC/FAM) and TE buffer (10 mM Tris–HCl, 1 mM EDTA, 
pH 8.0) and the TaqMan master mix (AmpliTaq Gold ® DNA Polymerase, Deoxy 
ribonucleotide triphosphates (dNTPs), Passive Reference dye- Rhodamine X (ROX) and 
Buffer). 
Nuclease free water was used to adjust the DNA quantity in the PCR reaction at a final 
concentration of 100-200 ng. The final PCR reaction volume in each well was 25μl diluted 
DNA (11.25μl) and primers/probes solution (1.25 μl) diluted in TE buffer (1:1) and TaqMan 
master-mix (12.5μl). Nuclease free water was put instead of diluted DNA in two wells to be 
Negative Template Control (NTC).  
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To prepare the PCR reaction on the 96-well plates, for each reaction TaqMan primers/probes 
(1.25 µl) and TaqMan master mix (12.5 µl) were added to each well. Then diluted DNA 
(11.25 µl) (or nuclease free water on the two negative control wells) were added. 
Plate was covered with adhesive optical cover and centrifuged at 1500 rmp for 1 minute to 
ensure that reagent settled to the bottom of the wells without air bubbles before analysis. 
Real-time PCR cycling on the LightCycler 96 (Roche, Germany) performed according the 
manufacturer’s recommendations: 95OC for 600s followed by 45 cycles at 92OC for 15s, and 
then 60OC for 60s). After the PCR run, the data transferred from the LightCycler 96 to the 
application software. The final results were reported as homozygous for VIC, heterozygous 
or homozygous for FAM (were translated to genotypes). See Appendix 5 and appendix 6 for 
some exmaples of raw data. 
2.9. Quantification levels of vitamin D3/D2 in plasma by using 
Ultra High Performance Liquid Chromatography with 
ultraviolet detector (UHPLC -UV Detector) 
2.9.1. General description of the analytical procedure  
Plasma levels of total 25-OH -vitamin D3/D2 was measured using an UHPLC system with 
UV-detector. Briefly, plasma, calibrator and two-level controls were prepared separately 
before injection into the system. Before the analysis of vitamin D3/D2 in plasma, the 
calibrator and the two controls, the blank sample (no vitamin D3/D2 but spiked with the 
internal standard) was used. All samples (calibrator, controls and patients) were analysed. 
Vitamin D3/D2 concentration was calculated by using a well-established equation.   
2.9.2. Reagents, sample preparation and instrument 
2.9.2.1. Materials   
Reagents required to measure total vitamin D3/D2 in 100 plasma samples were purchased 
from Waters Limited, UK. The kit components include: Mobile phase, Internal Standard (IS), 
serum Calibrator, serum control Level I, serum control Level II, test solution (blank), 
Precipitant P solution, sample preparation vials and the column (Waters ACQUITY UPLC 
BEH C18 1.7μm 2.1x50mm Col.). 
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2.9.2.2. Reagent preparation 
Lyophilized calibrators and lyophilized controls Level I and II were reconstituted by adding 2 
ml of the HPLC-grade water to each vial and mixed for 15 minutes. To prepare the Blank, 2 
ml of the IS solution was added to the lyophilized blank and mixed well. 
2.9.2.3. Sample, calibrator and control I/II pre-treatment  
For sample pre-treatment, the following laboratory equipment was required: pipettes/pipette 
tips, table top centrifuge, HPLC-grade water and Vortex-mixer. Protein precipitation was 
used for pre-treatment of samples. Of the Precipitant P, 500 µl were added into sample 
preparation vials followed by addition of 400 µl of the plasma and equal volume (400 µl) of 
the Internal Standard. The contents were vortexed for 30 second and subsequently 
centrifuged for 5 minutes at 1000xg, 5 µl of the supernatant were injected into the UHPLC 
instrument. The same applies to the calibrator and the controls. Many exmaples are shown in 
Appendix 7. 
Table 2.1 Chromatographic condition  
UHPLC pump Flow rate: 0.75 ml/minute 
Mobile phase 1000 mL/L Methanol 
Column ACQUITY  UPLC  BEH  C18  1.7 µm  2.1x50mm Col 
Column temperature 40 OC 
Detection wavelength 264 nm 
Injection volume 5 µl 
 




25-OH-vitamin D3     approx 1.3 min 
25-OH-vitamin D2     approx 1.5 min 
Internal standard        approx 1.3 min 
 
2.9.2.4. Calculation method  
The concentration of the unknown (vitamin D3/D2) was calculated by using the 
following: 1) Peak area patient. 2) Peak area internal standard (IS) patient. 3) Peak area 
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IS of the calibrator. 4) Peak area analyte of the calibrator. The calculation was done in 
two steps: 




Calculation of  the analytes (vitamin D3/D2) concentration 
 
Assay performance: 
2.9.2.5. Recovery (REC) 
The recovery is 99-104% referred to a directly injected external standard solution 
2.9.2.6. Precision (inter and intra assay Coefficient of variation) 
 Four samples with different concentration were used to evaluate intra - and inter assay 






2.9.2.7. Detection limit and quantitation limit 
                                    Table 2.3 Detection limit and quantitation limit of vitamin D   
 25-OH-Vitamin  D2 25-OH-Vitamin D3 
 µg/l µg/l 
LLOD 2.8 2.2 
LLOQ 4.6 3.7 
LLOD: Lower  limit  of detection , LLOQ: Lower  limit  of quantitation  




Sample 1 10.0 10.0 
Sample 2 20.7 21.0 
Sample 3 53.2 53.2 
Sample 4 88.4 87.1 
REC  =        Area IS (sample) 
                          Area IS (calibrator) 
        
 
C [(Analytes, sample) (µg/l)]    =   Area (Analyte, sample) X C (Analyte, calibrator ) [µg/l]   




2.10. Statistical Analysis  
Data are presented as median and interquartile range (IQR) or mean±standard error (SE).  
P-Value <0.05 was considered as statistically significant. Normality tests were performed 
before the analysis of difference (between resistin and homocysteine in patients with type 2 
diabetes and healthy control, as well as between resistin and homocysteine in the males and 
females; also between resistin and homocysteine in difference BMI), normality tests were 
performed for each group, The results inferred that the data do not follow a normal 
distribution pattern, so non-parametric, Mann Whitney test (MW) was used to determine the 
association between them. A correlation test was performed to study possible association 
between the resistin or homocysteine and the demographic, clinical and metabolic variables 
(Age, Duration of DM, BMI, waist, FBG 2hBG, HbA1c%, CHOL, TAG, LDL, HDL, SBP 
and DBP) in all participants. A chi-square test was used to analyse the association between 




3. Results  
3.1. Resistin study  
3.1.1. General feature of the participants  
In this study, 200 patients with type 2 diabetes (T2DM) and 195 healthy controls were 
recruited. The characteristics of the study population are summarised in the Table 3.1. 
Demographic and clinical variables (Age, sex, 2 hour Blood Glucose (2hBG), Fasting Blood 
Glucose (FBG), Glycosylated Hamoglobin (HbA1c), Body Mass Index (BMI), Cholesterol 
(CHOL), Triglycerides (TAG), Low-Density Lipoprotein (LDL) and High-Density 
Lipoprotein (HDL) Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), 
creatinine, Waist circumference (waist) and plasma levels of resistin, vitamin D and 
Homocysteine (Hcy) are also presented in Table 3.1. 
In patients with T2DM, the median (range) age is 50.0 (47.0-58.0) years, while it is 42.5 
(31.0-50.0) years in the control group. The average BMI is higher, with statistically 
significant difference in patients with T2DM compared to the control group {26.8 (25.6-28.4) 
(kg/m2) vs 24.9 (23.0 - 28.0) (kg/m2); p<0.001}. There was no statistically significant 
difference in levels of CHOL, LDL and HDL in patients as compared to controls. TAG levels 
are higher with statistical significance in controls compared with patients {153.5 (96.0 - 
224.0) (mg/dl) vs 131.0 (84.3-164.0) (mg/dl); p< 0.0001)}. Also the waist circumference was 
lower with statistical significance in T2DM patients compared to the healthy control group 
{78.0 (74.0, 86.0) (cm) vs 86.0 (73.0, 94.0) (cm); p= 0.0079}.    
All variables (clinical and metabolic) remaining (median values and ranges) are summarised 









Table 3.1 General characteristic of the study participants  
Variable    Patient (T2DM ) 
Median   (IQR) 
Control 
Median   (IQR) 




Number (n) 200 195 N/A N/A 
Age (y) 50.0  (47.0-58.0) 42.5 (31.0-50.0) 10.0 (8.0,12.9) < 0.0001  
Males [n (%)] 71 (35.5) 130 (66.7) N/A N/A  
Females [n (%)] 129 (64.5) 65   (33,3) N/A N/A 
2hBG (mg/dl) 215.0  (156.5 -284.0) 100.0 (88.0-116.8) 108.0 (91.0, 126.0) < 0.0001 
FBG (mg/dl 132.0 (98.5, 196.5) N/A N/A N/A 
HbA1c    (%) 8.0   (7.0-9.0) 5.0 (5.0-6.0) 3.0  (2.4, 3.0) < 0.0001 
BMI   (kg/m2)   26.8  (25.6-28.4) 24.9  (23.0-28.0) 1.8 (1.2, 2.4) < 0.0001 
CHOL    (mg/dl) 172.0  (144.0 -201.0) 176.0 (150.0,203.3) -5.0 (-14.0, 4.0) 0.2405 
TAG  (mg/dl) 131.0 (84.3-164.0) 153.5  (96.0-224.0) -13.0 (-48.0, -16.0) < 0.0001 
LDL        (mg/dl) 102.5 (86.0-123.0) 103.0 (79.1-121.0) 1.0 (-6.0, 8.0) 0.7481  
HDL       (mg/dl) 42.0   (36.0-48.0) 44.1  (37.8-49.2) -1.7 (-4.0, 0.40) 0.1256 
 SBP (mmHg) 130.0  (120.0-140.0) 120.0  (110.0-120.0) 10.0 (10.0, 10.0) < 0.0001 
DBP (mmHg) 90.0  (85.0-100.0) 80.0  (80.0- 85.0) 10.0 (10.0, 10.0) < 0.0001 
Creatinine (mg/l) 0.70   (0.50,  0.90) 0.70   (0.80,  0.90) -0.10 (-0.20,0.00) 0.002  
Waist  (cm)    78.0 (74.0, 86.0) 86.0 (73.0,  94.0) -4.0 (-7.0, -1.0) 0.0079 
SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, BMI: Body Mass Index, BG: Blood Glucose, CHOL: 
Cholesterol, TAG: Triglycerides, LDL: Low Density Lipoprotein and HDL: High Density Lipoprotein N/A: not applicable 
Hypertension known as SBP Systolic Blood Pressure/ DBP Diastolic Blood Pressure , Point Estimates (95% confidence 
Interval) and p-value < 0.05 for patients with T2DM vs control group.  
 
3.1.2. Plasma resistin levels between patients with T2DM and healthy   
controls 
Comparing resistin levels between patients with T2DM and healthy controls in representative 
group of Sudanese population. Plasma resistin levels were investigated in patients with 
T2DM (n=200) and healthy controls (n=195). The results showed that plasma resistin levels 
were higher with statistical significance in control group compared with patients with T2DM, 






  Table 3.2 Difference of the plasma resistin concentration in patients with T2DM and control 
Variable    Patient (T2DM ) 
Median   (IQR) 
Control 
Median   (IQR) 




Number (n) 200 195 N/A N/A 
Resistin ng/mL 2.70  (2.00   4.28) 3.80   (1.80, 7.40) -0.90 (-1.50, -0.30) p< 0.000. 
   Data were presented as mean ± standard deviation (SD) 95 % CI.  
  Mann Whitney test. p-value is signification at < 0.05. 
  Point Estimates (95% confidence Interval)  
3.1.3. Correlation between plasma resistin levels in patients with T2DM 
and Healthy control and the different variables. 
One of the objectives of this study was to evaluate the correlation between the plasma resistin 
levels in patients with T2DM and clinical and metabolic variables, such as age, waist, FBG, 
2hBG, HbA1c %, CHOL, TAG, LDL, HDL, SBP, DBP. The correlation between plasma 
resistin levels in all participants, patients, and controls were summarized in Tables 3.3. There 
is a positive but a weak correlation between resistin levels and 2hBG and HbA1c % in all 
participants (r = 0.121; p= 0.035 and r = 0.237; p<0.001), respectively), as well as weak 
positive correlation between resistin levels and FBG, log BMI in patients with T2DM (r = 
0.188; p= 0.008 and r = 0.140; p=0.048, respectively). In addition, the results also showed a 
negative correlation between resistin levels and vitamin D (r = 0.261; p<0.0001) and positive 
correlation between resistin and homocysteine (r = 0.335; p<0.0001) in patients with T2DM. 
There was no correlation between resistin levels and the remaining variables (demographic, 
clinical and metabolic) in all participants and in patients.  Results also showed that there is no 
correlation between resistin and all variable in the control group. It worth mentioning that, the 
number of females exceeded the number of male in individuals with diabetes, while in the 













Table 3.3 Correlation between plasma resistin values and subject characteristic variables  
                 listed for combined, patients with T2DM and healthy control groups. 
Variable    All  Patient (T2DM) Control 
Number (n) 395  200 195 
 r p r p r p 
Age (y) 0.005 0.921 0.098 0.172 0.112   0.120 
2hBG (mg/dl) 0.121 0.035 0.069  0.368  0.065 0.456 
FBG (mg/dl 0.188 0.008  0.188   0.008 N/A N/A 
HbA1c    (%) 0.237   0.000 -0.018 0.806  0.111 0.271 
BMI   (kg/m2)   -0.047 0.351 0.133  0.060 -0.040 0.585 
CHOL    (mg/dl) -0.018   0.751      0.081 0.261 -0.170   0.051  
TAG  ( mg/dl) 0.008 0.887 -0.018    0.798 -0.098 0.266 
LDL        (mg/dl) -0.076 0.170 -0.200 0.005 0.063 0.471     
HDL       (mg/dl) -0.006   0.919 -0.006 0.933  -0.069 0.436    
 SBP (mmHg) -0.031 0.570 0.091 0.199  0.036 0.681 
DBP (mmHg) -0.060 0.281 0.033 0.646   0.082 0.355 
Creatinine (mg/l) 0.036 0.556 0.095 0.269 -0.012 0.890   
Waist  (cm)    0.055 0.318 -0.031 0.664     0.058 0.507   
   
Vitamin D (µg/l) -0.119 0.018  -0.261 0.000  0.108 0.134 
Hcy   (µmol/l) -0.025 0.615 0.335 0.000 0.011 0.879 
Log BMI  (kg/m2)   -0.059 0.243 0.140 0.048 -0.045 0.536 
  (r) Person correlation coefficient 
3.1.4. Difference of resistin levels in patients with T2DM and healthy 
controls according to the gender: 
Resistin levels in T2DM patients (n=200) were comparable to levels in healthy controls 
(n=195), (Fig. 3.1). However, there was a statistically significant increase in plasma resistin 
levels in males compared to females in both the All and control groups; (4.4±0.2 ng/ml vs 
3.8±0.2 ng/ml; p= 0.002) and (5.1±0.3ng/ml vs 4.2±0.49 ng/ml; p= 0.007), respectively. The 
same applies to male patients with T2DM versus female patients with T2DM, where there 
was no statistical significantly difference in plasma resistin levels between them 




              Fig 3.1 Comparison of human plasma resistin levels between males and females in all  
            participants, patients with T2DM and healthy controls group Data were expressed as  
            mean ± standard error and, *p < 0.05, **p <0.01 and ***p <0.001). 
3.1.5. Difference between resistin levels in patients with type 2 diabetes 
and healthy controls according to the BMI 
To investigate the levels of resistin according to BMI, participants were classified into two 
groups: those with BMI >25 (kg/m2) and those with BMI <25(kg/m2) and the data are 
summarised in Fig 3.2. Among each group, levels of resistin were compared between patients 
with T2DM and healthy controls, between male patients and male healthy controls and 
between female patients and female healthy controls. The results showed that levels of 
resistin were statistically significantly higher in healthy controls compared to patients in both 
BMI groups (4.7±0.33 ng/ml vs 3.5±0.16 ng/ml, p=0.03 for those with BMI >25(kg/m2); 
4.9±0.37ng/ml vs 2.9±0.27ng/ml, p=0.03 for those with BMI <25) (kg/m2). The results 
showed that the resistin levels were statistically significantly higher in male healthy controls 
as compared to male patients with T2DM in both BMI groups (4.9±0.36 ng/ml vs 3.1±0.21 
ng/ml, p<0.001, for males with BMI >25(kg/m2); 5.4±0.44 ng/ml vs 2.5±0.50 ng/ml; p=0.007 
for males with BMI <25) (kg/m2). There was no statistical difference between the levels of 
resistin between female healthy controls and their female patients with T2DM in both BMI 
groups ((4.2±0.76 ng/ml vs 3.7±0.21 ng/ml; p=0.16 for females with BMI <25(kg/m2); 




  Fig 3.2 Comparison of plasma resistin levels between patients with T2DM and 
                      healthy control according to BMI group. Data were expressed according to  
                      the mean ± SEM. (*p < 0.05, **p <0.001 and ***p <0.0001) 
3.1.6. Difference between resistin levels in patients with type 2 diabetes 
and healthy controls according to the waist circumference  
To verify the levels of Resistin according to waist circumference, participants were classified 
into two groups according to the gender (female group and male group) and the data were 
summarised in fig 3.4. Among each group, levels of resistin were compared between patients 
with T2DM and healthy controls, between female patients and female control have WC >80, 
also between female patients and female control have WC <80 cm, as well as, between male 
patients and male control have WC >94 cm, also between male patients and male control 
have WC <94 cm. The result showed that there were no statistically significant of resistin 
levels between female patients and female control which have WC > 80 cm (4.0±0.35 ng/ml 
vs 2.7±1.7 ng/ml, p=0.1024); , but the results showed that the resistin levels were higher with  
statistically significant in diabetic female compared with female control which have WC<80 
cm (3.5±0.22 ng/ml vs 2.5±0.47 ng/ml, p=0.0070). while as in two male groups, the results 
showed that levels of resistin were statistically significant higher in patients with T2DM 
compared to health controls in both WC groups (2.5±0.22 ng/ml vs 4.9±0.49 ng/ml, p=0.0018 





Fig 3.3  comparison of human plasma resistin levels between female and males in all patients  
with T2DM and all control group  according to waist circumference (WC) group. Data were 







3.1.7.   Resistin levels in patients with T2DM and their healthy controls    
according to the HDL 
Levels of Resistin were compared between patients and healthy control according to HDL. 
Participants (patients with T2DM and control) were divided in two groups, those with HDL > 
50 (mg/dl) and those with HDL > 50 (mg/dl) and the data are summarised in fig 3.5. Among 
each group, levels of resistin were compared between patients with T2DM and healthy 
controls. The results showed that there was no statistically significant between patients with 
T2DM and healthy controls in those with HDL>50 mg/dl (3.4 ±0.34 ng/ml vs 5.1 ±0.62 
ng/ml, p=0.08). Those with HDL<50 mg/dl, levels of resistin were statistically significant 
higher in healthy controls compared to patients in HDL<50 mg/dl (3.1±0.14 ng/ml vs 
4.7±0.29 ng/ml, p<0.0000). 
 
 
Fig 3.4 Comparison of human plasma resistin levels between patients with T2DM and  
healthy controls group according to HDL. Data were expressed as  mean ± standard error  
and, *p < 0.05, **p <0.01 and ***p <0.001). 
3.1.8. Resistin levels in the study population (patients with T2DM and   
Healthy controls) according to triglycerides 
The levels of resistin were compared between patients with T2DM and healthy controls 
according to triglyceride (TAG). the participants were classified into two groups: those with 




were higher with statistically significant difference in healthy control compared with diabetic 
patients in both TAG groups (4.6±0.37ng/ml vs 3.4±0.22 ng/m; p=01 for those with 
TAG >150 mg/dl; 4.8±0.37ng/ml vs 3.5±0.19 ng/m; p=002 for those with TAG <150 mg/dl).  
 
Fig 3.5 Comparison of human plasma resistin levels between patients with T2DM and  
healthy controls group according to TAG. Data were expressed as mean ± standard error  
and, *p < 0.05, **p <0.01 and ***p <0.001). 
3.2. Homocysteine study  
3.2.1. Plasma homocysteine levels between patients with T2DM and 
healthy controls 
The hypothesis: to compare between the levels of homocysteine in patients with T2DM and 
healthy controls. Homocysteine levels were tested in 200 patients and 195 healthy controls. 
Our finding showed that homocysteine were significantly higher in patients with T2DM 
compared to controls (17.3 (13.2, 22.1) µmol/l vs 5.2 (2.2, 13.3) µmol/l, p< 0.0001). 
   Table 3.4 Difference of the plasma homocysteine concentration in patients with T2DM and control 
Variable    Patient (T2DM ) 
Median   (IQR) 
Control 
Median   (IQR) 




Number (n) 200 195 N/A N/A 
Hcy (µmol/l) 17.3 (13.2, 22.1) 5.2 (2.2, 13.3) 10.3 (9.00, 11.6) p< 0.0001 
     Data were presented as mean ± standard deviation (SD) 95 % CI.  
     Mann Whitney test. p-value is signification at < 0.05. 







3.2.2. Correlation between plasma homocysteine levels in patients with 
T2DM and Healthy control and the different variables 
The association between homocysteine (Hcy) and demographic and metabolic variables (Age, 
2hBG, FBG, HbA1c %, BMI, CHOL, TAG, LDL, HDL, SBP, DBP, creatinine and Waist) 
were investigated in the studied population and the results are summarised in Table 3.5. 
Homocysteine levels positively correlated with Age, 2hBG, HbA1c, BMI, SBP and DBP, (r = 
0.231; p<0.001, r = 0.361; p< 0.001, r = 0.298; p< 0.001, r = 0.126; p= 0.013, r = 0.213; 
p<0.001 and r = 0.269; p< 0.001, respectively), however, the correlations were weak. 
Homocysteine also had a negative correlation with TAG, r= -0.234; p< 0.001, waist, r= -
0.165; p<0.001in all participants. In patients with T2DM, homocysteine levels had a weak 
positive correlation with Age (r = 0.212; p= 0.003), BMI (r=0.186; p= 0.008) and SBP (r= 
0.181; p= 0.011).  The results showed that there was a weak negative correlation between 
homocysteine levels and Log-vitamin D (µg/l) in patients with T2DM and all participants, r= 
-0.138; p= 0.052 and  r = -0.100; p= 0.050, respectively. In addition, in the healthy control 
group, there was only a negative correlation between homocysteine levels and LDL levels 


















Table 3.5 Correlation between plasma homocysteine values and subject characteristic  
         variables listed   for combined, patients with T2DM and healthy control groups. 
Variable    All  Patient (T2DM) Control 
Number (n) 395  200 195 
 r p r p r p 
Age (y) 0.231 < 0.001 0.212 0.003 -0.047 0.516 
2hBG (mg/dl) 0.361 < 0.001 0.087   0.253  -0.211 0.015 
FBG (mg/dl 0.083  0.247 0.083   0.247  N/A N/A 
HbA1c    (%) 0.298 0.000  0.022    0.762    -0.151 0.133 
BMI   (kg/m2)   0.126 0.013 0.186 0.008  -0.107 0.139 
CHOL    (mg/dl) -0.094 0.088  0.002 0.973 -0.126 0.151 
TAG  ( mg/dl) -0.234 0.000   -0.022 0.764 -0.150 0.086 
LDL        (mg/dl) -0.048 0.390 0.011 0.876 -0.189 0.030 
HDL       (mg/dl) -0.010 0.861 0.051   0.492  0.066  0.459 
 SBP (mmHg) 0.213 0.000 0.181 0.011  -0.134 0.127 
DBP (mmHg) 0.269 0.000 0.092 0.195 -0.015   0.862 
Creatinine (mg/l) -0.030 0.626 0.010 0.903 -0.072 0.414 
Waist  (cm)    -0.165 0.002 0.094 0.184 -0.321 0.000 
   
Vitamin D (µg/l) 0.078   0.122 -0.064 0.365 -0.002 0.980 
Resistin ng/l -0.025 0.615 0.335 0.000 0.011   0.879    
Log-vitamin D (µg/l) -0.100 0.050  -0.138 0.052 -0.061 0.409 
  (r) Person correlation coefficient 
3.2.3. Distribution of MTHFR 677 C> T gene polymorphism in patients 
with T2DM and their healthy controls 
The allele frequency and genotype distribution of the MTHFR gene (677 C>T) were 
investigated in 200 Sudanese patients with T2DM and 195 healthy controls. As shown in 
Table 3.6, the percentage of patients carrying the CC (wild type homozygotes), TT (mutant 
type homozygotes) and CT (Heterozygotes)  genotypes is 85.5%, 0.5% and 14.0%, 
respectively; while among healthy controls it is 88.7%, 11.3 % and 0.0%. There is no 
statistically significant difference in the genotype CT distribution between patients and 
healthy control (χ2=0.660, p= 0.417) and the same applies to the “C” and “T” allele 





Table 3.6 Distribution of MTHFR C677T genotypes and allelic frequencies among patients  
              with T2DM and their healthy controls 
 Patient (T2DM) 
(n =200) (400 alleles ) 
Control 
( n = 195) (390 alleles) 
 χ2
  /  p. value 
CC   n (%) 171 (85.5) 173 (88.7) 0.909 / 0.340 
CT n (%) 28 (14.0) 22 (11.3) 0.660 / 0.417 
TT n (%) 1   (0.5)  0    (0.0) N/A 
Allele C (%) 370 (92.5) 368 (94.4)  
1.110 / 0.292 Allele T (%) 30 (7.5) 22  (5.6) 
P-values obtained for the χ2-test for the CT genotypes distribution of allele T frequencies l between patients  
and healthy control.  N/A = χ 2 Not calculated due to zero TT genotype. CC (wild type homozygotes),  
TT (mutant type homozygotes) and CT (Heterozygotes) 
3.2.4. Distribution of MTHFR A1298 C gene polymorphism in patients 
with T2DM and their healthy controls  
The genotype distribution of the MTHFR gene (1298 A>C) and allele frequency were 
investigated in 200 Sudanese patients with T2DM and 195 healthy controls. As summarized 
in Table 3.7. The distribution of genotypes of the MTHFR gene   (1298 A> C) in patients was 
as follows: AA (65.0%), AC (29.0%) and CC (6.0%): while among the control group was as 
follows: AA (65.1%), AC (29.8%) and CC (5.1%). There is no statistically significant 
difference in frequencies of AA (χ2= 0.001 / p = 0.098), AC (χ2= 0.026 / p = 0.87) and CC 
(χ2= 0.143 / p = 0.71) genotypes of the MTHFR gene between patients with T2DM and 
healthy controls.  The same applied  for  alleles "A" and "C" frequencies of the MTHFR gene, 
where results showed that there is no statistically significant difference between, alleles "A" 













Table 3.7 Distribution of MTHFR A1298 C genotypes and allelic frequencies among patients with 
                  T2DM and their healthy controls 
 Patients (T2DM) 
(n =200, 400 alleles) 
Control 
( n = 195, 395 alleles) 
χ2 / p. values 
AA   n (%) 130 (65.0) 127 (65.1) 0.001 / 0.098 
AC n (%) 58  (29.0) 58   (29.8) 0.026 / 0.87 
CC n (%) 12  (6.0) 10  (5.1) 0.143 / 0.71 
Allele A (%) 318 312  
0.031 / 0.86 Allele C (%) 82 78 
 P-values obtained for the χ2-test for the AA/AC /CC genotypes distribution of allele A and C frequencies 
between patients and healthy control. AA (wild type homozygotes), CC (mutant type homozygotes) and AC 
(Heterozygotes) 
3.2.5. Association between plasma homocysteine levels and MTHFR 
gene polymorphisms, C677T and A1298C, in patients with T2DM and 
control group.    
Here we investigated possible association between the genetic polymorphisms in MTHFR 
gene (C677T and A1298C), and levels of Hcy in plasma. Results showed that the levels of  
Hcy were significantly higher in patients with T2DM carrying genotypes C677T ( 18.6  
(14.4,21.9) µmol/l) , A1298C (16. 3  (12.3, 21.3)  µmol/l)  and  C1298C  ( 20.9   (15.3, 25.9) 
µmol/L) compared with the control group carrying the same genotype polymorphisms C677T 
( 3.6  (1.0, 16.3) µmol/l , A1298C (4.7  (1.6, 13.3) µmol/l)  and  C1298 C  ( 4.7  (2.9, 13.3) 
µmol/l;  p<0.001 (Table 3.8). 
As shown in table 3.6, it was observed that the heterozygosity at both alleles (C677T/ 
A1298C) are statistically significantly associated with elevated level of homocysteine in 












         Table 3.8 Homocysteine levels in MTHFR 677C>T and 1298 A>C carries 
Genotype  Patients (T2DM) 
Median   (IQR) 
Control 





C 677 C     17.1  (12.9,22.1) 5.6 (2.5, 13.30) 10.0  (8.5, 11.4) p<0.001 
C 677 T    18.6  (14.4,21.9)      3.6  (1.0, 16.3) 12.5   (7.7, 15.9) p<0.001 
A 1298 A   17.4   (13.8, 21.9) 5.9  (2.1, 14.1) 10.2   (8.5, 11.8) p<0.001 
A 1298 C   16. 3  (12.3, 21.3)     4.7  (1.6, 13.3)     9.8    (7.1, 12.3) p<0.001 
C 1298 C   20.9   (15.3, 25.9) 4.7  (2.9, 13.3)   13.5   (7.4, 20.8) p=0.001 
C 677 T/ A 1298 C  14.1   (11.1, 25.0) 1.6  (0.9, 3.9)   12.1    (6.3, 26.8) p=0.03 
          P-values obtained for the Mann-Whitney test for the AA/AC /CC and CC/CT/genotypes distribution  
           between patients and healthy control. 
3.2.6. Homocysteine levels in the study population (patients and healthy 
Controls) according to Gender: 
The levels of Hcy were compared between males and females. In all participants, the results 
showed that the plasma Hcy levels were higher with statistically significant difference in 
females compared with males (15.56±0.56 µmol/l vs 11.09±0.71 µmol/l; p<0001). In 
addition, in the healthy controls, plasma Hcy levels were higher with statistically significant 
differences in females compared with the males (11.47±1.16 µmol/l vs 6.75±0.63 µmol/l; 
p<0001). However, in the patients group, the plasma Hcy levels were not statistically 
significant different between males and females (19.03±1.15 µmol/l vs 17.63±0.53 µmol/l; 
p= 4498). All data are summarised in Fig 3.3. 
 
                Fig 3.6 Comparison of plasma homocysteine (Hcy) levels between females with males  
                in all participants, patients with type 2 diabetes and healthy controls. Data is expressed  
                as mean ± SEM 
78 
 
3.2.7. Investigation of the relationship between homocysteine and resistin 
hormone levels in patients with T2DM. 
The possible association between levels of Hcy and resistin in patients with T2DM was 
investigated. Table 3.2 showed that resistin levels were significantly higher in control group 
than in patients with T2DM (3.8 (1.80, 7.40) ng/ml   vs 2.7 (2.00   4.28) ng/ml; p= 0.002). In 
addition, Table.3.4 showed that Homocysteine levels were a significantly higher in patients 
with T2DM than in control group (17.3 (13.2 - 22.1 µmol/L vs 5.2 (2.2 - 13.3µmol/L; p< 
0.0001). As shown in Fig 3.4 and 3.5 there is a positive Pearson correlation between Hcy 
levels and resistin levels in patients with T2DM (r = 0.335; p<0.001) and no correlation 


























































3.3. Vitamin D study 
3.3.1. Plasma vitamin D levels patients with T2DM and healthy controls 
One of the objectives of this study was investigate any association between vitamin D 
deficiency in individuals with T2DM. Total vitamin D levels were measured on 200 patients 
with T2DM and 195 healthy controls. The results showed vitamin D levels were higher with 
statistical significance in patients with T2DM compared with control groups.  The median 
(range) for total vitamin D is 51.0 (35.3 - 116.3) µg/l in T2DM patients and 21.8 (6.9 - 79.9) 
µg/l in control groups (p< 0.0001; Table 3.9). 
 
Table 3.9 Difference of the plasma vitamin D concentration in patients with T2DM and control 
Variable    Patient (T2DM ) 
Median   (IQR) 
Control 
Median   (IQR) 




Number (n) 200 195 N/A N/A 
Vitamin D (µg/l)  51.0 (35.3 -116.3) 21.8 (6.9 - 79.9) 27.7 (20.6, 34.1) < 0.0001 
Data were presented as mean ± standard deviation (SD) 95 % CI.  
Mann Whitney test. p-value is signification at < 0.05. 
Point Estimates (95% confidence Interval)   
3.3.2. Vitamin D supplementation based analysis of clinical and 
laboratory characteristics of patients with type 2 diabetes (T2DM) 
Clinical and metabolic features of patients with T2DM are summarized in Table 3.10. The 
characteristics of the patients were presented according to vitamin D supplementation. 
Among patients with T2DM, 58 were using vitamin D supplementation, while 142 were not 
using a vitamin D supplementation. The median age of those not taking vitamin D was higher 
with statistically significant difference than those taking vitamin D supplementation (52.0 
(48.0, 59.8) years vs 49.0 (46.0, 51.0) years; p= 0.0008). The BMI is significantly higher in  
patients not using vitamin D supplementation as compared to patients using vitamin D 
supplementation (27.0 (25.9, 28.8) Kg/m2 vs 26.1  (25.4,  28.2) Kg/m2; p< 0.05). The fasting 
Blood glucose (FBG) was higher with statistical significant in the patients not taking vitamin 
D compared with patients taking vitamin D (143.5 (102.3, 207.5) mg/dl vs 114.0   (91.0, 
171.0) mg/dl; p = 0.04).  No significant difference in HA1c % between the patients not taking 
vitamin D compared with patients taking vitamin D (8.0 (7.0, 9.0) vs 8.0 (7.0, 9.0); p= 0.870). 
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Plasma vitamin D levels are higher with a statistically significant difference in patients taking 
vitamin D compared with patients not taking vitamin D (106.8 (50.7, 327.2) vs 43.2 (32.2, 
73.6); p< 0.0001. In addition, the results showed that resistin levels were higher with 
statistical significantly difference in patients not taking vitamin D compared with patients 
taking vitamin D (2.85 (2.18, 4.80) vs 2.45  (1.70, 3.43); P= 0.0039. 
 
Table 3.10 General characteristics of patients with and without vitamin D supplementation   
Variable    Patient (T2DM ) with 
Vitamin  D 
Median   (IQR) 
Patients (T2DM) 
without vitamin D 





Number (n) 58 142 N/A N/A 
Age (y) 49.0 (46.0, 51.0) 52.0 (48.0, 59.8) 4.0 (1.0, 6.0) 0.0008 
Males [n (%)] 16 (27.6) 55 (38.7) N/A N/A 
Females [n (%)] 42 (72.4) 87 (61.3) N/A N/A  
2hBG (mg/dl) 177.0   (143.0, 274.0) 228.5  (162.3, 291.3)  28.0  (-2.0, 56.0) 0.0697 
FBG (mg/dl 114.0   (91.0, 171.0) 143.5   (102.3, 207.5) -18.0  (-37.0, -1.0) 0.0391 
HbA1c    (%) 8.0    (7.0,  9.0)    8.0    (7.0,  9.0) 0.0  (-0.8, 1.0) 0.8695  
BMI   (kg/m2)   26.1   (25.4,  28.2) 27.0 (25.9, 28.8) 0.70  (-0.0, 1.3) 0.0465 
CHOL    (mg/dl) 169.0  (143.8, 205.0) 175.0   (143.5, 200.0) -0.0   (-14.0, 13.0) 0.9635 
TAG  ( mg/dl) 140.00  (87.5, 168.8) 125.0  (84.0, 164.0) -7.0  (-23.0, 8.0) 0.3525  
LDL        (mg/dl) 111.50  ( 88.50, 129.7)  99.8   (84.5, 120.00 -10.0 (-19.0, -0.2) 0.0432  
HDL       (mg/dl) 43.0    (37.0, 49.5)  42.0    (36.0, 48.0) -2.0 (-4.0, 1.0) 0.2516 
 SBP (mmHg) 130.0  (120.0, 140.0) 130.0  (120.0, 140.0) -0.0 (-0.0,-0.0)  0.4421 
DBP (mmHg) 90.0 (83.8, 100.0) 90.0 (85.0, 100.0) -0.0  (0.0, 5.0) 0.2871 
Creatinine (mg/l) 0.70   (0.54, 0.81)   0.60   (0.50, 0.90) 0.0 (-0.1,  0.1) 0.9443 
Waist  (cm)      76.0   (72.0, 83.0) 80.0  (76.0, 86.0) 3.0 (1.0, 6.0) 0.0114 
 
 
Resistin ng/ml 2.45  (1.70, 3.43) 2.85 (2.18, 4.80) 0.6   (0.2, 1.0) 0.0039 
Vitamin D (µg/l) 106.8    (50.7, 327.2) 43.2   (32.2, 73.6) -55.2 (-94.2,-30.2) < 0.0001 








3.3.3. Correlation test was done between vitamin D levels and different 
variables in all participants, patients and control groups 
Correlation between Vitamin D levels and clinical metabolic and analytical variables were 
shown in table 3.11. The results showed that there is a strong negative correlation between 
vitamin D and resistin in all participants (r = -0.172; p<0.001), and in patients with T2DM (r 
= -0.261; p<0.001), but not in control group (r = 0.017; p< 0.827).  In addition, no correlation 
between vitamin D and homocysteine levels in all groups (all participants, patients and 
control subjects, (- r =0.054; p=0.331), (r = -0.064; p=0.366) and (r= -0.001; p= 0.994, 
respectively). There is a negative correlation between the vitamin D and both (FBG & SBP) 
in patients (r = -0.177; p=0.013) & (r= -0.242; p= 0.001), respectively. As shown in table 3.9, 
there is no correlation between vitamin D levels and the other clinical and metabolic 
parameters.  
 
   Table 3.11 Pearson correlation (r) between vitamin D and all other variables 
Variable    All  Patient (T2DM)  Control 
Number (n) 395  200 195 
 r p r p r p 
Age (y) 0.056 0.266 -0.036 0.615 -0.034 0.636 
2hBG (mg/dl) 0.058 0.316 -0.023  0.762  -0.186 0.032 
FBG (mg/dl -0.177 0.013 -0.177 0.013 N/A N/A 
HbA1c    (%) 0.058 0.317 -0.050 0.486 0.163 0.104 
BMI   (kg/m2)   -0.004  0.938 -0.082 0.250 -0.041 0.570  
CHOL    (mg/dl) -0.044 0.424  -0.042 0.562   -0.016 0.855 
TAG  ( mg/dl) -0.019 0.727 0.086 0.232 -0.058 0.512 
LDL        (mg/dl) 0.062 0.262 0.127 0.076 -0.121 0.167  
HDL       (mg/dl) 0.030 0.597 0.130 0.079 -0.120 0.178 
 SBP (mmHg) -0.067 0.224 -0.242 0.001 0.103 0.241  
DBP (mmHg) 0.025 0.645  -0.107 0.131 0.152 0.082  
Creatinine (mg/l) -0.029 0.638  -0.062 0.471 0.020 0.824  
Waist  (cm)    -0.054 0.331   -0.112   0.116 0.076 0.389 
   
Resistin ng/ml  -0.119 0.018  -0.261   0.000 0.108 0.134 
Hcy   (µmol/l) 0.078 0.122 -0.064 0.365    -0.002 0.980 
  (r) Person correlation coefficient 
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3.3.4. Distribution of VDR (T 56058 C) gene polymorphism (TaqI) in 
patients with T2DM and their healthy controls  
The distribution of VDR gene polymorphisms (65058 TC) in patients with T2DM is CC 
(36.5%), TC (46%), TT (17.5%), while it is CC (28.7%), TC (52.8%) and TT (18.5 %) for the 
healthy controls; while the allele frequency is C (238) and allele T (162) for patients with 
T2DM and C (215) and allele T (175) in the healthy controls.  The results showed that there 
are no statistically significant differences in genotype frequencies, CC (χ2 = 2.719, p = 0.099) 
TC (χ2 = 1.838, p= 0.175) and TT (χ2 = 0.062, p = 0.803), between patients with T2DM and 
their healthy controls and also that there is no statistically significant difference in alleles 
frequencies "T” and "C" (χ2 = 2.084, p = 0.149) between patients and control group. (Table 
3.12). 
 
       Table 3.12 Distribution of VDR genotypes and allelic frequencies among patients with T2DM 
                           and their healthy controls 
 Patient (T2DM) 
(n =200, 400 alleles) 
Control 
( n = 195, 395 alleles) 
χ2 / p. values 
CC   n (%) 73 (36.5) 56    (28.7) 2.719 / 0.099 
TC n (%) 92  (46) 103 (52.8) 1.838 / 0.175 
TT n (%) 35 (17.5) 36   (18.5) 0.062 / 0.803 
Allele C (%) 238 215  
2.084 / 0.149 Allele T (%) 162 175 
        p-values obtained for the χ2-test for the CC, TC AND TT genotypes distribution of allele C 
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3.3.5. Association between vitamin D levels and elevated levels of 
resistin in patients   with T2DM in representative group of the 
Sudanese population. 
The hypothesis: There is an association between vitamin D deficiency and elevated levels of 
resistin in patients with T2DM. Results showed that vitamin D levels were statistically 
significantly higher in patients with T2DM compared with control group (51.0 (35.3 - 116.3) 
µg/L vs 21.8 (6.9 - 79.9) µg/L; p< 0.0001) Table 3.9.  In contrast, resistin levels were 
statistically significant higher in healthy controls than in patients with T2DM (3.8 (1.80, 7.40) 
ng/ml   vs 2.7 (2.00   4.28) ng/ml; p= 0.002). Table 3. 2.  Pearson correlation test is presented 
in Fig 3.6 and Fig 3.7.   
Fig 3.6 shows that there is a negative correlation between vitamin D levels and resistin levels 
in patients with T2DM. Whereas Fig 3.7 revealed that there is no correlation between vitamin 























































4. Discussion  
In this case-control study I investigated the association between resistin, homocysteine and 
vitamin D, and T2DM in a Sudanese population, this is in addition to investigating possible 
associations between them and T2DM. Firstly, the levels of resistin, homocysteine and 
vitamin D were measured in patients with T2DM and healthy controls. Secondly, a 
correlation test was done to show the association between resistin, homocysteine and vitamin 
D and demographic, metabolic and clinical variables. Thirdly, we have tested the genetic 
polymorphisms in the MTHFR gene (C677T and A1298C) and the VDR gene (T 56058 C) 
and association of the former with homocysteine levels and the latter with vitamin D levels in 
patients with T2DM.    
Our findings suggested possible associations between resistin, homocysteine and vitamin D, 
individually and together in the development of the T2DM. Our study was not limited to 
investigating the role of resistin in T2DM but it was extended to investigate possible 
association (in patients with T2DM) between resistin and vitamin D on one hand, and 
between resistin and homocysteine on the other hand.  
Resistin is a hormone which is secreted from adipocytes and inflammatory cells, especially 
macrophages (Osawa et al., 2005). Obesity was shown to be associated with decreased levels 
of vitamin D due to trapping of vitamin D in the adipose tissue and further increased risk of 
vitamin D deficiency (El-Tahir et al., 2016). Subsequently, it is possible that vitamin D 
deficiency may contribute to insulin resistance and the development of metabolic syndrome 
secondary to inflammation aggravated by the increased resistin levels in diabetics. (El-Tahir 
et al., 2016).  
Several studies suggested an association between homocysteine and insulin resistance (Meigs 
et al., 2001; and Oron-Herman et al., 2003). An in vitro study using a hepatoma cell line 
suggested that the oxidative stress resulting from homocysteine thiolactone led to disruption 
of the insulin signalling pathway (Najib et al., 2001). In addition, homocysteine may promote 
insulin resistance by inducing resistin secretion, which links inflammation and obesity with 
insulin resistance. Homocysteine was shown to induce resistin expression in cultured 
hepatocytes in mice but not in humans (Li et al., 2004). 
Previous studies showed that resistin is synthesized during adipogenesis and is secreted by fat 
cells and it contributes to insulin resistance in both humans and animals. There is a 
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controversy about the association between obesity in T2DM and levels of human resistin 
(Steppan et al., 2001).  In this study, levels of resistin in Sudanese patients with T2DM and 
their possible association with demographic, clinical and metabolic parameters were 
investigated. Our findings showed that the plasma resistin levels were higher in healthy 
controls in comparison with the patients with T2DM. Similarly, others have reported no 
association between resistin levels and T2DM (Stejskal et al., 2003 and Lee et al., 2003). 
However, in contrast, findings are not consistent with previous studies that demonstrated that 
resistin levels were elevated in patients with T2DM (Hasegawa et al., 2005 and McTernan et 
al., 2003). In the current study, we found that BMI was lower in the healthy controls 
compared with patients with T2DM, while there were higher levels of blood glucose (2hBG) 
and HbA1c in the diabetic patients. In addition, results from this study showed a positive 
correlation between resistin levels and FBG, 2hBG, HbA1c, log BMI and homocysteine 
levels.  
Plasma resistin levels were higher in males compared with females in all the study population 
and also among the healthy controls. Findings from Fujinami et al., (2003) reported that 
resistin concentration in diabetic patients was higher in females than in males (Fujinami et al., 
2003). Differences in resistin levels according to gender were also observed by Silha et al., 
(2003), where plasma resistin levels were higher in females compared to males. Chen et al., 
(2005) reported no significant difference in levels of resistin between males and females, 
which is in contrast with our study findings. 
In overweight and obese individuals, our findings showed that plasma resistin levels were 
higher in healthy controls and in male controls compared with patients and males patients. 
Steppan et al., (2002) demonstrated that plasma resistin levels were significantly associated 
with obesity and insulin resistance. I showed that resistin was lower in patients with T2DM 
and obese individuals and in contrast to our findings, El-Shal et al., (2013) reported that 
resistin levels are increased in obese patients with T2DM in an Egyptian population. Most of 
studies on role of resistin in T2DM were from Europe and Japan. Limited numbers of studies 
were conducted in Africa. In addition to the study by El-Shal et al., Azab et al., demonstrated 
that serum resistin was higher in patients with T2DM compared with healthy controls (Azab 
et al., 2012). This study is the first to be done in the Sudanese population.    
In this study, a negative correlation was found between vitamin D levels and resistin levels in 
patients with T2DM. This finding is consistent with the El-Tahir et al., who reported a 
negative correlation with resistin levels and vitamin D in a Saudi population (El-Tahir et al., 
2016). In addition, our studies showed increased levels of resistin in patients not taking 
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vitamin D supplementation compared with those who are not indicating that lower plasma 
resistin levels in patients with T2DM can be due to vitamin D supplementation. 
The association between the increased levels of homocysteine and T2DM was reported by 
Hoogeveen et al., (2000) and Shaikh et al., (2008). Most of the studies were conducted in 
Europe and Asia but very few studies were conducted in Africa, whereas, one study in Sudan 
showed high level of homocysteine in patients with ischemic hemi disease but not in 
individuals with diabetes (Adbel et al., 2009).  Our results showed that plasma homocysteine 
levels were higher in patients with T2DM compared with the healthy controls. The findings 
are consistent with previous studies that that showed that homocysteine was elevated in 
patients with T2DM compared with healthy controls (Huang et al., 2006 and Shaikh et al., 
2012). Our results showed a positive correlation between the 2hBG and HbA1c% and the 
levels of homocysteine in plasma. This was considered as evidence for the association 
between the homocysteine and T2DM. In vitro studies observed that insulin receptor tyrosine 
kinase activity, phosphorylation of phosphatidylinositol 3-kinase (PI3K) and glycogen 
synthase kinase-3 (GSK-3) are inhibited by homocysteine thiolactone in rat HTC-IR 
hepatoma cells (Najib and Sanchez-Margalet, 2005), which in turn leads to inhibition of the 
glycogen synthase enzyme (Liu et al., 2011). It was also shown that increased expression of 
the phosphoenolpyruvate carboxykinase (PEPCK) gene and glucose output from the liver are 
associated with elevated levels of homocysteine (Yu et al., 2009). 
A study by Dominguez et al., (2010) observed that homocysteine levels increase with age. 
Our study found a positive correlation between levels of homocysteine and age in patients 
with T2DM but not in healthy controls. This is in addition to the positive correlation between 
homocysteine and Blood pressure, DBP and SBP, in all participants and in patients with 
T2DM but not in control subjects. Our findings are in agreement with a previous study that 
reported elevated levels of homocysteine in hypertensive compared with normotensive 
subjects (Sutton-Tyrrell et al., 1997 and van Guldener et al., 2003).   
Several studies investigated the possible association between MTHFR gene polymorphism, 
levels of homocysteine and T2DM (Kluijtmans et al., 1996; Abu-Amero et al., 2003 and 
Mtiraoui, et al., 2007). There is no report on the prevalence of the MTHFR genotype and 
T2DM was documented for the Sudanese population. Differences in the ethnicities and 
population genetics might contribute to differences in allele frequencies and hence disease 
susceptibility. The association between MTHFR gene polymorphism and complications 
associated with T2DM was suggested by several studies: cardiovascular disease (Clarke et 
al., 1991), occlusive arterial disease and thrombosis (Kang et al., 1992; Malinow 1994; Den 
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Heijer et al., 1995) and diabetic nephropathy (Miraoui, et al., 2007). Here we investigated the 
association of the MTHFR gene polymorphism and T2DM among Sudanese population in a 
case-control hospital based study. Our findings showed that there was no association between 
the MTHFR C677T polymorphisms and T2DM among Sudanese population, which is 
consistent with the study by Schneider et al., 1998 and Sarah et al., 2016. The later study 
showed that the frequency of the TT genotype in sub-Saharan population was zero 
percentage. Previous studies indicated that the prevalence of the MTHFR C677T depend on 
the geographical location and ethnicity (Liew et al., 2012). Others reported that T allele 
frequency to be higher in the Italian and the Hispanics population (Botto et al., 2000), and 
lowest in the Germans (Girelli et al., 1998 and Abbate et al., 1998) and American Blacks and  
the frequency of T homozygosity allele was shown to be zero percentage in the sub-Saharan 
African (Pepe et al., 1998). Our results showed that the percentage of the TT genotype among 
the Sudanese population to be 6%, which is comparable with the prevalence observed in 
other ethnic group (Abu-Amero et al., 2003). The MTHFR gene polymorphism was shown to 
be associated with increased level of the homocysteine in the plasma which has negative 
effects on the diabetes complication (Santos et al., 2010). Hence, T2DM patients with 
MTHFR polymorphism may be at greater risk of Diabetic nephropathy, and atherosclerosis. 
Therefore, we investigated the relationship between the MTHFR C677T polymorphism and 
homocysteine levels in 200 patients with type 2 diabetes and 195 healthy controls. The results 
show that homocysteine levels were higher with statistical significance in patients with 
T2DM that carrying MTHFR C677T compared with the healthy controls carrying the same 
alleles.  
With regard to the polymorphism, A1298C, in the MTHFR gene, Yan et al., observed a 
significant association between T2DM and MTHFR A1298C gene polymorphism in an Asian 
population (Yan et al., 2014). Conversely, our finding showed no significant association 
between MTHFR A1298C gene polymorphism and T2DM. Our result is consistent with a 
study conducted on the Caucasian population which found no association between T2DM and 
MTHFR A1298C gene polymorphism (Yan et al., 2014). The frequencies of the 1298 CC 
genotype were 6% among patients with T2DM and it was 5.1% among the healthy controls. 
Differences in results can be related to differences in ethnicities. The frequencies of the 
MTHFR gene A1298C alleles and genotype was lower compared to other ethnic groups: 
Canada (9%), Netherlands (9%), Germany (13.8), China (17%) and Brazil (41.1%) (Abu-
Amero et al., 2003).  
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The findings also showed that the levels of homocysteine were higher in patients with T2DM 
carrying C1298C and A1298C alleles compared with control group carrying C1298C and 
A1298C and also homocysteine levels were higher in patients with T2DM who are 
heterozygosity for both alleles (C677T/ A1298C) than in healthy control.  Van der Put et al., 
1998 and Moczulski et al., 2003) reported that heterozygosity at both alleles decreases the 
MTHFR enzyme activity and elevated plasma homocysteine levels. A study from Tunisia 
showed that double heterozygosity (C677T/ A1298C) in patients with T2DM had not effect 
on the plasma homocysteine levels (Mtiraoui et al, 2007).  
In addition, we compared the levels of homocysteine between the females and males. In all 
participants and control group, the results were higher in females compared with the males. 
Other studies were not in agreement with our findings, where they reported that males in 
general have higher homocysteine levels compared with females (Powers et al., 2002). 
However, a study suggested that homocysteine levels increase in the females after menopause 
due to deficiency or completely lost of the estrogen hormone (Powers et al, 2002). Estrogen 
has been shown to affect plasma homocysteine levels (Kim et al, 1997 & Giri et al, 1998). In 
our study the age of female patients and healthy controls was (51.2±7.2) and (39.9±17.7), 
respectively. 
In this study, has been explained for the first time the relation between levels of the 
homocysteine and the resistin in human plasma of the patients with T2DM. These findings 
revealed that the resistin levels were lower in patients compared with control, and 
homocysteine levels were higher in patients than in control. However, our results showed that 
there is a positive correlation between homocysteine and resistin levels in patients with 
T2DM. 
Several in vitro and experimental studies have demonstrated that hyperhomocysteinemia can 
induce the ROS-PKC-NF-kB pathway to produce resistin from adipocytes (Li et al., 2008).  
Homocysteine was considered a strong proinflammatory factor which boosts inflammation 
both in vitro (Wang et al., 2000) and in rat (Wang et al., 2002). Zeng et al., mentioned that 
homocysteine induces synthesis and secretion of proinflammatory cytokines from 
macrophage, by the mediation of oxidative stress in human monocytes (Zeng et al., 2003). 
Previous studies investigated the associate between insulin resistance and increase levels of 
homocysteine (hyperhomocysteinemia) (Golbahar et al., 2007). In contrast, others found no 
association between insulin resistance and hyperhomocysteinemia (Goldsland et al., 2001). 
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Recently, Li et al., suggested that homocysteine can contribute to insulin resistance by 
inducing the production of adipokines (Li et al., 2008).  
The discovery of the association between resistin and insulin resistance has drawn the 
attention of many researchers and scientists to pursue further studies in this field. In mice, the 
association between obesity, resistin and insulin resistance appears strong, but in humans, 
still unclear (de Luis, 2011). In humans, Patel et al., reported that resistin is mainly secreted 
from the macrophages (Patel et al., 2003), although, fat cells secrete a huge amount of 
resistin (Pagano et al., 2005). Recently, a link between insulin resistance and inflammatory 
condition was suggested (Vgontzas et al., 2004). The association between diabetes and 
inflammation was supported by studies that used bacterial endotoxin (inflammation inducing 
substance) which led to insulin resistance (Cani et al., 2007). The effects of inflammation on 
the insulin signalling attenuated by the use of aspirin as an anti-inflammatory medicine and 
subsequently, improve insulin resistance (Yuan et al., 2001). In vitro study showed increased 
expression of resistin following exposure to pro-inflammatory factors. This study supported 
that resistin is the link between inflammation and obesity associated with insulin resistance 
(Kaser et al., 2003). Najib et al observed that thiolactone (part of homocysteine) has the 
ability to induce oxidative stress which in-turn lead to disruption of insulin signalling 
pathway in rat hepatoma cell line (Najib et al., 2005). In vitro and in experimental studies by 
Li et al., was showed that homocysteine (thiolactone) enhances insulin resistance via up-
regulation of resistin expression and secretion from the adipocytes (Li et al., 2008). 
Although insulin resistance and change in insulin secretion are considered as main factors 
contributing to T2DM, the precise pathogenesis of T2DM remains unclear. Recently, it has 
been suggested that environmental factors and genetic factors might play important roles 
(accelerating or protective effect) in the development or protection from T2DM by affecting 
insulin secretion and its action or both. Among the environmental factors is “hypovitaminosis 
D” that is due to deficiency which has been suspected to be a risk factor for glucose 
intolerance.  
In this study I investigated possible association between vitamin D levels and T2DM in a 
study population from Sudan, where there is no seasonal variation in sunlight. Our hypothesis 
is that our results might be different from that from other populations due to differences in 
lifestyle, ethnicity and genetic factors. My first findings note that vitamin D levels were 
higher remarkably in patients with T2DM compared with healthy controls group.  Among 
patients with T2DM, some used vitamin D supplementation while others not. This can be 
attributed to the fact that some of the individuals with T2DM are already on vitamin D 
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supplement. Also, these results showed a marked decrease of FBG and 2hBG in patients who 
took vitamin D compared to those who didn’t. Furthermore, in patients with T2DM, a 
negative correlation was found between vitamin D and several variables including fasting 
blood glucose (FBG), Systolic blood pressure (SBP) and resistin levels. In addition, I found 
that resistin levels were higher in healthy controls compared to their patients with T2DM as 
well as lower in patients who took vitamin D compared with patients who did not. these 
results indicate that vitamin D supplementation improves glucose levels and reduces resistin 
levels. It is worth mentioning that resistin was considered as one of the main factors that 
contribute to insulin resistance and subsequently T2DM and its complication (El-Tahir et al., 
2016). 
Scragg et al (2004) observed that there is an inverse association between vitamin D status and 
diabetes in Mexican American and non-Hispanic white but not in non-Hispanic Black (Sragg 
et al., 2004). Authors questioned the lack of association between vitamin D status and 
diabetes in non-Hispanic Black, particularly taking into account that their low serum vitamin 
D levels. An explanation for this lack of association could be the existence of variable 
threshold effect among different ethnic groups (Scragg et al., 2004). A study from New 
Zealand found that vitamin D levels were lower in newly diagnosed patients with T2DM and 
impaired glucose compared with matched healthy control (Scragg et al., 1995). Kedari and 
Hareesh (2014) have reported that deficiency of vitamin D is associated with the progression 
of T2DM. On the other hand, a Bangladeshi group at high risk for T2DM was shown to have 
low  vitamin D levels compared with those with no and low risk of T2DM (Boucher et al., 
1995). This study indicated also that T2DM was more prevalent among Bangladeshis than 
British Caucasians, concluding that vitamin D plays an important role in the pathogenesis of 
the T2DM. Overall, long term studies revealed that there is a negative relation between the 
vitamin D and development of T2DM (Mitri et al., 2011).   
Boucher et al showed that Vitamin D deficiency led to reduction in insulin secretion and 
Vitamin D supplementation led to improvement in the function of β- cell and glucose 
tolerance (Boucher et al., 1995). These results showed reduced glucose levels in Sudanese 
patients with T2DM who took Vitamin D supplementation. Several studies showed that 
treatment of osteomalacia for long time led to improve glucose tolerance (Norman et al., 
1980 and Boucher et al., 1995).  
On the other hand, Boucher et al (1998) reported that vitamin D supplementation does not 
improve glucose tolerance in peoples without hypovitaminosis D (Boucher et al., 1998), 
indicating that the effect depends on the vitamin D status in the diabetic patients. 
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Cavalier et al. (2011) observed an increase in the levels of fasting blood glucose and HbA1c 
in patients with T2DM in the winter and a subsequent decrease in the summer. The seasonal 
variation in glycaemic parameters in Europe indicates the importance of exposure to sunlight. 
In Sudan, there is no seasonal variation in sunlight.  
The association between Obesity and metabolic syndrome or T2DM is very well established. 
Obesity was shown to be associated with a depletion of vitamin D (Palomer et al., 2008). Our 
results showed higher waist circumference (W) and lower vitamin D levels in the healthy 
controls compared with patients with T2DM. In addition, these results showed lower waist 
circumference and BMI in patients who took vitamin D supplementation compared with 
those who did not. Accordingly, there is an inverse correlation between obesity and vitamin 
D levels. Holick reported that vitamin D is stored in adipocytes, and obesity individuals are 
chronically vitamin D deficient (Holick, 2004) i.e. fat cells trap vitamin D leading to 
reduction in its bioavailability and therefore increase risk of vitamin D deficiency. Zittermann 
found that the vitamin D deficiency associated with obesity is associated with increased 
levels of parathyroid hormone (PTH) (Zittermann, 2003), which in turn lead to 
overproduction of glucose (glucose intolerance) (Ivarsson, 2014).  It was shown also that 
vitamin D can suppress PTH and stimulates insulin secretion by β- cells (Bikle, 1992). It was 
suggested that PTH and insulin stimulate synthesis of vitamin D, and deficiency of insulin (in 
case of diabetes) may reduce vitamin D production (Bikle, 1992). In addition, it was shown 
that patients with hyperparathyroidism are at high risk of developing T2DM and insulin 
resistance (Ivarsson, 2014). 
Here I also studied the association between vitamin D and resistin levels in Sudanese patients 
with T2DM. I showed that vitamin D levels was lower in the healthy controls compared with 
patients, and lower in patients with T2DM who took Vitamin D supplementation compared 
with those who did not. In both controls and patients, taking vitamin D supplementation was 
associated with lower resistin levels. In addition, there was a negative correlation between 
vitamin D and resistin levels in patients with T2DM but not in the healthy controls. These 
results are not in agreement with the study by Vilarrasa et. al. that reported no significant 
association between plasma vitamin D and resistin levels (Vilarrasa et al., 2010), but these 
results were in agreement with the study by EL-Tahir et al that showed a significant negative 
correlation between vitamin D and resistin levels in patients with T2DM (El-Tahir et al., 
2016). Therefore, the negative correlation between vitamin D and resistin levels observed in 
our study can be attributed to vitamin D supplementation. 
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VDR gene polymorphism was studied among different ethnic populations. It was reported 
that VDR is expressed in different tissues in the body among them pancreatic β- cells and fat 
cells (Reis et al., 2005 and Howard et al., 1995), and it was suggested that VDR 
polymorphisms might influence glucose metabolism and insulin secretion (Oh and Barrett, 
2002). Several studies investigated the possible association of VDR polymorphisms and 
T2DM, and it is generally believed that there is an association between VDR polymorphisms 
and clinical variables (glucose levels, obesity and insulin levels) of T2DM, but the other 
studies reported no association between VDR polymorphism and T2DM (osman et al,2016). 
Polymorphism in the Taq-I (rs731236) was found to be lower in Africans compared with 
Caucasians (Smolders et al., 2009). In the present study, we investigated the possible 
association of the VDR polymorphism Taq-I (rs731236) with T2DM in a Sudanese study 
population. Our results showed that there is no association between TT/TC/CC genotype nor 
T/C allele frequencies.  Studies by Malecki et al and Cyganek et al were in agreement with 
our findings, where they found no association between Taq (rs731236) and Bsm (rs1544410) 
VDR gene polymorphisms and T2DM (Malecki et al., 2003; Cyganek et al., 2006).  In 
addition, our results showed that allele and genotype distribution of the Taq (rs731236) in the 
Sudanese population is similar to that in the Emirati population (Osman et al., 2015). In 
contrast, several studies showed an association between the two SNPs Taq (rs731236) & Bsm 
(rs1544410) and T2DM (Ortlepp et al., 2003). A study from Greece by Panierakis et al found 
a strong association between the genetic polymorphisms in VDR gene, rs 731236 (Taq-I) and 
T2DM) (Panierakis et al., 2009). Taneja et al reported that the Taq-I polymorphism in VDR 
gene is prevalence in Indians and is associated with T2DM (Taneja et al., 2016).  
4.1. Conclusion  
Previous studies suggested a role for Vitamin D deficiency and elevated levels of plasma 
resistin and homocysteine levels in the pathogenesis of insulin resistance and T2DM. Our 
results are in agreement with previously reported high levels of homocysteine in patients with 
T2DM. In addition, a positive correlation was observed between levels of homocysteine, 
resistin, FBG, HbA1c, as well as a positive correlation between resistin and FBG and HbA1c, 
and a negative correlation between vitamin D and resistin, homocysteine and FBG levels in 
patients with T2DM. The negative association between vitamin D and resistin/blood glucose 
levels suggest that vitamin D might have an impact on resistin levels in patients with T2DM 
and improved insulin action/blood glucose levels and T2DM. Taken together, our results 
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suggest a possible role for vitamin D, resistin and homocysteine in the development of insulin 
resistance and T2DM. 
4.2. Recommendation for further study 
Further Sudanese population studies are needed to investigate the following: 
1. The role of resistin in Obesity   
2. The mechanism of expression of resistin gene by vitamin D deficiency or 
hyperhomocysteinemia or both.  
3. In vivo studies (animal experiments) to explore how Vitamin D deficiency 
induces/modifies expression of resistin gene.  
4. In vitro studies to explore the effect of hyperhomocysteinemia on the expression of 
resistin gene. 
5. The role of Vitamin D in glycaemic status in patients with T2DM and its role in 
keeping normal blood glucose levels. 
6. Develop sensitive techniques to assess insulin sensitivity and develop markers 
associated with obesity. 
7. Large samples size studies are needed to investigate the allele and genotype 
frequencies of two MTHFR gene variants (C677T and A1298) in the Sudanese 
population. It is worth mentioning that limited studies were conducted in African 
populations investigating these gene variants in the MTHFR gene. 
8. Large samples size studies are needed to investigate the allele and genotype 
frequencies of VDR T56058C/rs731236 (Taq) mutation and other gene variant in 
VDR: rs 544410 (Bsml), rs7975232 (Apal) and rs 10735810 (Fok1)) among different 
Sudanese tribes and ethnic groups living in Sudan.  
4.3. Study limitations 
Although the sample size was adequate for most of the association studies, a larger sample 
size (based on the VDR and MTHFR allele frequencies) would be required to improve the 
power of the statistical analysis. This is in addition to the financial constraints that aborted 
our plans to investigate the following: 
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1.      Associations between genetic variants of vitamin D metabolism associated with vitamin D 
deficiency and T2DM e.g. vitamin D 25-hydroxylase (CYP2R1), sterol 27-hydroxylase 
(CYP27A1), 25-Hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1), 1,25-
dihydroxyvitamin D3 24-hydroxylase (CYP24) and GC gene (encoding the Vitamin D 
binding protein). 
2.      The effect of resistin on insulin resistance and glucose output, via the expression of 
phosphoenolpyruvate carboxykinase (PEPCK) and glycogen synthase genes (GS) using a 
hepatocyte cell line for in vitro culture mod 
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Appendix:1 Questionnaire  
Homocysteine, resistin and vitamin D  level in type 2 diabetic patients  
 
 
Code :  Name :  
 









 Drug history  B12       Folate            
 
   Statins     Vitamin D           
 
   Niacin      anti-diabetes drugs            
 
Peripheral neuropathy                                        
  
 SBP :         DBP :       Height :    Weight :       BMI :   
 
 Fasting blood sugar :        Cholesterol :        Triglyceride :         
 
 LDL :          HDL :         HbA1C :   
 
 Albumin  :          Serum creatinine :        
   
 Homocysteine level  :        
 
 Vit. B12  level    :            
 






   











Appendix 2 Measurement of human resistin  
The blank, standards and samples (patients and healthy controls) in the Layout of ELISA 
plate were duplicated 
Table 1 A2 Layout for ELISA (Assay -1/resistin)   
B B C1 C1 C9 C9 C17 C17 P5 P5 P13 P13 
S1 S1 C2 C2 C10 C10 C18 C18 P6 P6 P14 P14 
S2 S2 C3 C3 C11 C11 C19 C19 P7 P7 P15 P15 
S3 S3 C4 C4 C12 12 C20 C20 P8 P8 P16 P16 
S4 S4 C5 C5 C13 113 P1 P1 P9 P9 P17 P17 
S5 S5 C6 C6 C14 C14 P2 P2 P10 P10 P18 P18 
S6 S6 C7 C7 C15 C15 P3 P3 P11 P11 P19 P19 
S7 S7 C8 C8 C16 C16 P4 P4 P12 P12 P20 P20 
 
Table 2.A2 Raw data of resistin absorbance (Assay -1/resistin)   
1 2 3 4 5 6 7 8 9 10 11 12
A 0.047 0.046 1.848 2.009 0.803 0.831 1.196 1.357 0.633 0.62 1.979 1.941
B 2.525 2.522 2.356 2.405 1.369 1.334 1.006 1.056 0.851 0.837 0.743 0.762
C 1.278 1.29 1.237 1.295 1.282 1.32 0.422 0.434 1.216 1.212 1.373 1.398
D 0.609 0.62 1.876 1.914 1.202 1.24 0.928 0.942 0.603 0.565 1.829 2.118
E 0.318 0.285 1.677 1.654 0.641 0.619 0.999 1.006 0.564 0.553 0.921 0.955
F 0.161 0.155 1.394 1.335 1.133 1.107 1.211 1.266 1.119 1.072 0.557 0.538
G 0.092 0.088 0.929 0.97 1.116 1.05 0.453 0.426 0.647 0.673 0.618 0.66
H 0.063 0.058 0.601 0.557 0.688 0.704 0.641 0.671 0.634 0.654 1.405 1.373  
Table 3. A2 Raw data of resistin concentration (Assay -1/resistin)  
1 2 3 4 5 6 7 8 9 10 11 12
A 7.312 7.948 3.169 3.279 4.728 5.365 2.495 2.444 7.831 7.681
B 9.995 9.984 9.327 9.518 5.414 5.275 3.972 4.17 3.358 3.304 2.93 3.004
C 5.051 5.101 4.89 5.118 5.066 5.22 1.656 1.704 4.807 4.792 5.427 5.528
D 2.398 2.441 7.424 7.572 4.749 4.903 3.663 3.72 2.374 2.225 7.236 8.384
E 1.244 1.115 6.632 6.544 2.526 2.438 3.946 3.973 2.221 2.179 3.638 3.772
F 0.622 0.6 5.513 5.278 4.475 4.374 4.787 5.003 4.419 4.233 2.194 2.117
G 0.348 0.335 3.669 3.83 4.408 4.148 1.781 1.674 2.551 2.651 2.437 2.602
H 0.235 0.216 2.369 2.192 2.711 2.776 2.524 2.643 2.5 2.579 5.555 5.427  
 
 





Table 4. A.2 Layout for ELISA (Assay -6/ resistin) 
B B P132 P132 P142 P142 P150 P150 C45 C45 C53 C53 
S1 S1 P134 P134 P143 P143 P153 P153 C46 C46 C54 C54 
S2 S2 P135 P135 P144 P144 P154 P154 C47 C47 C55 C55 
S3 S3 P136 P136 P145 P145 P155 P155 C48 C48 C56 C56 
S4 S4 P137 P137 P146 P146 C41 C41 C49 C49 C57 C57 
S5 S5 P139 P139 P147 P147 C42 C42 C50 C50 C58 C58 
S6 S6 P140 P140 P148 P148 C43 C43 C51 C51 C59 C59 
S7 S7 P141 P141 P149 P149 C44 C44 C52 C52 C60 C560 
Table 5.A2 Raw data of resistin absorbance (Assay -6/resistin)   
1 2 3 4 5 6 7 8 9 10 11 12
A 5.113 5.357 2.502 3.41 7.874 7.784 12.518 13.754 4.163 4.288
B 9.621 10.306 2.501 2.626 6.31 6.583 7.308 7.312 14.254 14.352 7.603 7.813
C 4.901 5.263 2.581 3.062 10.162 11.03 7.912 7.892 8.502 8.713 9.081 9.137
D 2.388 2.67 2.56 2.73 5.43 5.6 7.174 7.165 8.897 8.245 8.158 8.516
E 1.287 1.072 3.708 4.797 7.101 7.45 7.893 7.472 7.913 7.635 5.062 4.943
F 0.527 0.598 2.805 3.26 8.823 8.636 14.653 14.763 6.905 6.615 7.351 7.751
G 0.258 0.388 5.685 5.368 2.681 2.792 7.626 7.697 8.142 8.466 5.085 4.766
H 0.209 0.199 5.199 4.291 4.904 5.358 7.941 9.061 9.186 9.498 7.687 7.806  
Table 6. A2 Raw data of resistin concentration (Assay -6/resistin)   
1 2 3 4 5 6 7 8 9 10 11 12
A 0.059 0.052 0.986 1.031 0.503 0.671 1.497 1.48 2.356 2.585 0.81 0.833
B 1.82 1.947 0.503 0.526 1.207 1.258 1.392 1.393 2.677 2.695 1.447 1.485
C 0.947 1.014 0.517 0.607 1.92 2.081 1.504 1.5 1.613 1.652 1.72 1.731
D 0.482 0.534 0.514 0.545 1.045 1.076 1.367 1.366 1.686 1.565 1.549 1.616
E 0.278 0.238 0.726 0.928 1.354 1.418 1.5 1.422 1.504 1.453 0.976 0.955
F 0.137 0.151 0.559 0.643 1.672 1.638 2.751 2.771 1.317 1.264 1.4 1.474
G 0.088 0.112 1.092 1.033 0.536 0.557 1.451 1.464 1.546 1.606 0.981 0.922
H 0.079 0.077 1.002 0.834 0.947 1.031 1.509 1.716 1.74 1.797 1.462 1.484  
 
 







Appendix 3 Measurement of the homocysteine  
The standards, controls and samples (patients and healthy controls) in the Layout of ELISA 
plate were duplicated 
Table 1A3 Layout for ELISA (Assay -5/homocysteine)   
S1 S1 CH CH P108 P108 P116 P116 C64 C64 C72 C73 
S2 S2 P101 P101 P109 P109 P117 P117 C65 C65 C73 C73 
S3 S3 P102 P102 P110 P110 P118 P118 C66 C66 C74 C74 
S4 S4 P103 P103 P111 P111 P119 P119 C67 C67 C75 C75 
S5 S5 P104 P104 P112 P112 P120 P120 C68 C68 C76 C76 
S6 S6 P105 P105 P113 P113 C61 C61 C69 C69 C77 C77 
CL CL P106 P106 P114 P114 C62 C62 C70 C70 C78 C78 
CM CM P107 P107 P115 P115 C63 C63 C71 C71 C79 C79 
 
Table 2.A3Raw data of homocysteine absorbance (Assay -5/homocysteine)   
1 2 3 4 5 6 7 8 9 10 11 12
A 2.803 2.835 2.203 2.271 2.764 2.739 2.545 2.603 2.602 2.708 2.471 2.546
B 2.877 2.877 2.674 2.652 2.646 2.634 2.108 2.143 2.499 2.451 2.255 2.283
C 2.748 2.744 2.335 2.285 2.56 2.637 2.382 2.494 2.577 2.567 2.428 2.492
D 2.658 2.651 2.584 2.679 2.647 2.616 2.692 2.696 2.329 2.186 2.163 2.32
E 2.107 1.984 2.611 2.567 2.69 2.625 2.74 2.722 2.603 2.684 2.57 2.662
F 1.649 1.524 2.405 2.529 2.689 2.542 2.361 2.478 2.329 2.393 2.514 2.475
G 2.796 2.788 2.556 2.476 2.568 2.547 2.623 2.516 2.433 2.469 2.318 2.252
H 2.753 2.755 2.716 2.662 2.739 2.75 2.683 2.647 2.67 2.604 2.586 2.594  
Table 3.A3 Raw data of homocysteine concentration (Assay -5/homocysteine)   
1 2 3 4 5 6 7 8 9 10 11 12
A 4.231 3.886 20.706 17.269 4.693 5.005 8.362 7.17 7.189 5.435 10.189 8.346
B 3.475 3.475 5.944 6.31 6.404 6.611 26.566 24.268 9.451 10.731 18.011 16.751
C 4.896 4.947 14.575 16.654 8.043 6.559 12.867 9.575 7.685 7.895 11.408 9.626
D 6.212 6.317 7.54 5.87 6.389 6.926 5.669 5.608 14.836 21.652 23.011 15.177
E 26.644 36.873 7.031 7.901 5.703 6.776 4.995 5.242 7.17 5.789 7.829 6.145
F 89.653 124.796 12.127 8.737 5.713 8.444 13.617 9.989 14.812 12.525 9.081 10.079
G 4.31 4.402 8.122 10.044 7.874 8.322 6.817 9.026 11.246 10.23 15.257 18.164
H 4.833 4.804 5.329 6.149 5.01 4.86 5.805 6.382 6.01 7.157 7.512 7.359  
 




Table 4A3 Layout for ELISA (Assay -5/homocysteine)   
S1 S1 CH CH P88 P88 P96 P96 C45 C45 C53 C53 
S2 S2 P81 P81 P89 P89 P97 P97 C46 C46 C54 C54 
S3 S3 P82 P82 P90 P90 P98 P98 C47 C47 C55 C55 
S4 S4 P83 P83 P91 P91 P99 P99 C48 C48 C56 C56 
S5 S5 P84 P84 P92 P92 P100 P100 C49 C49 C57 C57 
S6 S6 P85 P85 P93 P93 C42 C42 C50 C50 C58 C58 
CL CL P86 P86 P94 P94 C43 C43 C51 C51 C59 C59 
CM CM P87 P87 P95 P95 C44 C44 C52 C52 C60 C60 
 
Table 5.A3 Raw data of homocysteine absorbance (Assay -5/homocysteine)   
1 2 3 4 5 6 7 8 9 10 11 12
A 2.68 2.71 1.647 1.716 2.333 2.363 1.9 1.967 1.813 1.762 1.912 2.014
B 2.563 2.539 2.26 2.33 1.969 1.889 2.437 2.49 2.144 1.976 2.339 2.345
C 2.455 2.395 2.201 2.293 1.891 1.809 2.024 2.124 2.171 1.901 2.045 2.073
D 1.919 1.889 2.126 2.105 1.813 1.846 2.154 2.27 1.88 1.912 2.284 2.288
E 1.399 1.33 2.355 2.402 1.983 1.939 1.992 2.191 2.105 2.078 1.965 2.124
F 1.103 1.136 2.26 2.308 2.54 2.502 2.047 2.157 1.241 1.246 2.18 2.206
G 2.457 2.456 2.194 2.328 2.258 2.219 1.871 1.965 1.86 1.617 2.046 2.026
H 2.207 2.203 1.623 1.677 2.073 2.168 2.217 2.342 2.302 2.198 2.172 2.251  
Table 6.A3 Raw data of homocysteine concentration (Assay -5/homocysteine)   
1 2 3 4 5 6 7 8 9 10 11 12
A 0.455 -0.141 25.896 23.751 7.689 7.033 18.429 16.62 20.882 22.377 18.1 15.39
B 2.779 3.275 9.37 7.759 16.577 18.724 5.412 4.287 12.117 16.392 7.555 7.421
C 5.025 6.323 10.75 8.591 18.666 20.992 15.113 12.607 11.461 18.415 14.579 13.86
D 17.922 18.735 12.561 13.075 20.885 19.936 11.869 9.134 18.988 18.094 8.801 8.71
E 34.416 37.091 7.214 6.174 16.204 17.364 15.965 10.984 13.075 13.757 16.673 12.593
F 46.882 45.299 9.349 8.257 3.252 4.036 14.535 11.789 40.708 40.498 11.249 10.629
G 4.997 5.004 10.91 7.815 9.407 10.322 19.23 16.681 19.555 26.876 14.553 15.08
H 10.603 10.701 26.663 24.949 13.868 11.523 10.365 7.493 8.398 10.815 11.439 9.557  
 







Appendix 4 Method of genotyping (C677T) using 3MTM   
integrated Cycler 
All samples were placed in the disc below, which it contains 12 column (numbered 1, 2, 3, 4 
etc. …12) and each column have 8 wells (numbered and then covered and placed into the 
machine (3MTM integrated Cycler's). all samples and NTC were duplicated  
 




MTHFR 677 Direct_1 Segment Report 
 
Assay Name MTHFR 677 Direct Run Name abdelrouf4 9-2-2015 C677T 02-09-2015 At 1207 
Test By ICS Administrator Report By ICS Administrator 
Lot Number 26075 Lot 
Expiration 
08/2015 
Instrument 200057 Software 5.0.0.17 




































































Unknown 0 0 
 
MTHFR 677 Direct_1 Segment Report 
 
Assay Name MTHFR 677 Direct Run Name abdelrouf4 9-2-2015 C677T 02-09-2015 At 1207 
Test By ICS Administrator Report By ICS Administrator 
Lot Number 26075 Lot 
Expiration 
08/2015 
Instrument 200057 Software 5.0.0.17 



















































Cycling Parameters: MTHFR 677 Direct 
 
Cycle Count: 40 
 
Estimated Run Time: 59 Minutes 
 
Actual Run Time: 50 Minutes 
 
Hold 1 Cycle 360.0 97.0 10.0 
Hold 2 Not Used   
 
Denaturation 10.0 97.0 10.0  
Anneal 30.0 60.0 10.0 Yes 
Extend 1 Not Used    












Final Cycles Time(s) Temperature(C) Ramp Rate(C/s) Capture 





Final 2                                                               Not Used                                                                     
No 
 
Initial Cycles Time(s) Temperature(C) Ramp Rate(C/s) Capture 
 


















Appendix 5 Method of genotyping (A1298C) using 
TaqMan  
The reagents (master mix and TaqMan), DNA samples (patients and controls) and Negative 
template control all were duplicate 
Table 1A5 Layout of real time PCR plate  
 1 2 3 4 5 6 7 8 9 10 11 12 
A P46 P47 P48 P49 P50 P51 P52 P53 P54 P55  NTC 
B P46 P47 P48 P49 P50 P51 P52 P53 P54 P55  NTC 
C P56 P57 P58 P59 P60 P61 P62 P63 P64 P65  NTC 
D P56 P57 P58 P59 P60 P61 P62 P63 P64 P65  NTC 
E C137 C141 C145 C150 C151 C152 C153 C155 C157 C159   
F C137 C141 C145 C150 C151 C152 C153 C155 C157 C159   
G C160 C163 C168 C171 C181 C182 C183 C185 C1 C2   




MTHFR gene polymorphism (A1298C) according to the Layout of real time Lightcycler 96 plate 
 
Fig 1A5 MTHFR gene polymorphism (A1298C) were obtained by real time Lightcycler 96 
instrument (amplification) and LightCycler 96 application software, 
 
Fig 2A5 scatter plot for genetic polymorphisms separation 
 























Appendix 6 Method of genotyping (T65058C) using 
TaqMan  
The reagents (master mix and TaqMan), DNA samples (patients and controls) and Negative 
template control all were duplicate 
 
Table 1A6 Layout of real time PCR plate  
 1 2 3 4 5 6 7 8 9 10 11 12 
A P1 P1 P9 P9 P17 P17 C6 C6 C16 C16   
B P2 P2 P10 P10 P18 P18 C7 C7 C17 C17   
C P3 P3 P11 P11 P19 P19 C9 C9 C18 C18   
D P4 P4 P12 P12 P20 P20 C10 C10 C19 C19   
E P5 P5 P13 P13 C1 C1 C11 C11 C20 C20 NTC NTC 
F P6 P6 P14 P14 C2 C2 C12 C12 C21 C21 NTC  
G P7 P7 P15 P15 C4 C4 C13 C13 C22 C22   
H P8 P8 P16 P16 C5 C5 C14 C14 C24 C24   




  Fig 1A6VDR gene polymorphism (T65058C) were obtained by real time Lightcycler 96 
  instrument (amplification) and LightCycler 96 application software, 
 
        Fig 2A6 scatter plot for genetic polymorphisms separation 
 

























Appendix 7 Measurement of total vitamin D (D3/D2) using 
UHPLC  
clinCal and clinTest (level I and level II) and samples were injected in UHPLC using 
conditions set ( in the protocol) in section (2.9.2.3). The instrument was used in scan mode to 
identify all the possible molecules (vitamin D2/D3). The results for vitamin D3, vitamin D2 
and internal standard are shown in Fig 1A7 and the concentration of vitamin D3 and D2 were 






















































































































































ClinTest 1 28 06 2016 Smooth(Mn,1x2)

















      Fig 6A7 ClinTest Level 1 : at 0.62 peak (vitamin D3), 0.71 (vitamin D2) and 1.42 (IS) 
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ClinTest  Run Smooth(Mn,1x2)

















































      Fig 8 A7 ClinCal: at 0.62 peak (vitamin D3), 0.71 (vitamin D2) and 1.42 (IS) 
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Fig 20 A7 sample patients (P79): at 0.60 peaks (vitamin D3) and 1.40 (IS) 
 
